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Abstract 
Development and implementation of effective marketing strategies during various stages 
of product life cycle in the pharmaceutical industry are critical to an organization’s 
successful performance in the marketplace in the 21st century. Guided by the general 
systems theory developed by Bertalanffy and the evolutionary systems theory developed 
by Laszlo and Laszlo, the purpose of this single case study was to explore best practices 
among marketing managers within pharmaceutical companies related to marketing 
strategies during various stages of product life cycle. Data were gathered via 
semistructured interviews with 3 purposefully selected managers who have successfully 
developed marketing strategies in a central Ohio pharmaceutical company in business for 
more than 10 years. A review of secondary data included company documents, such as 
annual reports, news releases, and websites, in addition to government databases. 
Member checking was conducted to ensure accuracy of the interpreted data and 
trustworthiness of the research findings. Yin’s 5-step process and thematic analysis were 
used to analyze the data. Four themes emerged from data analysis: marketing function, 
product life cycle phases, factors influencing the decision-making process, and strategic 
activities in executing business strategies. Findings may have implications for positive 
social change such as assisting organizational leaders to understand the challenges and 
business practices in implementing marketing strategies to successfully deliver products 
that improve patients’ health. 
  
 
 
Marketing Strategies During the Product Life Cycle in the Pharmaceutical Industry 
by 
Natasa Naneva 
 
MBA, Ashland University, 2008 
BS, Sv. Kliment Ohridski - Bitola, 2005 
 
 
Doctoral Study Submitted in Partial Fulfillment 
of the Requirements for the Degree of 
Doctor of Business Administration 
 
 
 
Walden University 
November 2018 
  
Dedication 
I dedicate this doctoral study to my husband, Toni; my parents, Pavlina and 
Ljupce; my sister, Daniela; and my nephews, Marko and Dragan. 
I would like to thank my husband, Toni Kostrevski, for your support, 
encouragement, and patience throughout this journey. It would not have been possible 
without your support and love. You mean the world to me, and I love you. 
I would also like to thank my parents, my mother Pavlina Naneva and my father 
Ljupce Nanev, for your unconditional love, support, guidance, and wisdom. Without you 
I would not have been able to accomplish the program. I am grateful for having you in 
my life, and proud to be called your daughter. 
Lastly, I would like to thank my sister, Daniela Tosev, for your support and faith 
in me during this journey. Without you, Deni, and the smiles of my dear nephews, Marko 
Tosev and Dragan Tosev, I would not have been able to accomplish the degree. I am 
grateful for having you as my sister. 
 
  
Acknowledgments 
I would like to thank my Chair, Dr. Matthew Knight (Dr. Matt), for his 
continuous support and guidance through the process that helped me make it this far. I 
would like to also thank my Second Committee Member, Dr. David Moody, and my 
URR, Dr. Judy Blando, for their valued feedback and reviews of my doctoral study. 
 
 
 i 
 
Table of Contents 
List of Tables ..................................................................................................................... iv 
List of Figures ......................................................................................................................v 
Section 1: Foundation of the Study ......................................................................................1 
Background of the Problem ...........................................................................................1 
Problem Statement .........................................................................................................3 
Purpose Statement ..........................................................................................................3 
Nature of the Study ........................................................................................................4 
Research Question .........................................................................................................5 
Interview Questions .......................................................................................................6 
Conceptual Framework ..................................................................................................7 
Operational Definitions ..................................................................................................8 
Assumptions, Limitations, and Delimitations ..............................................................10 
Assumptions .......................................................................................................... 10 
Limitations ............................................................................................................ 10 
Delimitations ......................................................................................................... 12 
Significance of the Study .............................................................................................13 
Contribution to Business Practice ......................................................................... 13 
Implications for Social Change ............................................................................. 15 
A Review of the Professional and Academic Literature ..............................................17 
Conceptual Framework ......................................................................................... 19 
Potential Themes ................................................................................................... 22 
 ii 
 
Transition and Summary ..............................................................................................77 
Section 2: The Project ........................................................................................................79 
Purpose Statement ........................................................................................................79 
Role of the Researcher .................................................................................................79 
Participants ...................................................................................................................82 
Research Method and Design ......................................................................................89 
Research Method .................................................................................................. 89 
Research Design.................................................................................................... 91 
Population and Sampling .............................................................................................93 
Ethical Research...........................................................................................................98 
Data Collection Instruments ......................................................................................100 
Data Collection Technique ........................................................................................105 
Pilot Study ..................................................................................................................112 
Data Organization Technique ....................................................................................113 
Data Analysis .............................................................................................................115 
Reliability and Validity ..............................................................................................125 
Reliability or Data Dependability ....................................................................... 127 
Validity ............................................................................................................... 128 
Transition and Summary ............................................................................................133 
Section 3: Application to Professional Practice and Implications for Change ................134 
Introduction ................................................................................................................134 
Presentation of Findings ............................................................................................135 
 iii 
 
Marketing Function ............................................................................................. 140 
Product Life Cycle Phases .................................................................................. 146 
Factors Influencing the Decision-Making Process ............................................. 169 
Strategic Activities in Executing Business Strategies ........................................ 184 
Conceptual Framework and Research Findings ................................................. 189 
Summary ............................................................................................................. 208 
Application to Professional Practice ..........................................................................208 
Implications for Social Change ..................................................................................210 
Recommendations for Action ....................................................................................211 
Recommendations for Further Research ....................................................................213 
Reflections .................................................................................................................214 
Conclusion .................................................................................................................216 
References ........................................................................................................................220 
Appendix A: Email Invitation to Participants ..................................................................254 
Appendix B: Qualitative Interview Questions .................................................................255 
Appendix C: Interview Protocol ......................................................................................257 
 
 iv 
 
List of Tables 
Table 1. A List of Initial Codes for Marketing Efforts During the Product Life 
Cycle in the Prescription Medicine Segment ...................................................... 120 
Table 2. A List of Initial Codes for Factors Influencing the Decision-Making 
Process ................................................................................................................ 121 
Table 3. A List of Emergent Codes for Marketing as a Function ................................... 141 
Table 4. A List of Emergent Codes for Marketing Efforts During the Premarket 
Phase in the Branded Prescription Medicine Segment ....................................... 150 
Table 5. A List of Emergent Codes for Marketing Efforts During the Introduction 
Phase in the Branded Prescription Medicine Segment ....................................... 158 
Table 6. A List of Emergent Codes for Marketing Efforts During the Growth 
Phase in the Branded Prescription Medicine Segment ....................................... 161 
Table 7. A List of Emergent Codes for Marketing Efforts During the Maturity 
Phase in the Branded Prescription Medicine Segment ....................................... 165 
Table 8. A List of Emergent Codes for Marketing Efforts During the Decline 
Phase in the Branded Prescription Medicine Segment ....................................... 168 
Table 9. A List of Emergent Codes for Factors Influencing the Decision-Making 
Processes ............................................................................................................. 170 
Table 10. A List of Emergent Codes for for Strategic Activities in Executing 
Business Strategies.............................................................................................. 185 
 
 v 
 
List of Figures 
 Figure 1. Research results .............................................................................................. 140 
Figure 2. Product life cycle phases ................................................................................. 147 
 
 
 
 
1 
 
 
Section 1: Foundation of the Study  
Marketing strategies are the activities relating to customer and competitor 
analysis, market segmentation, targeting markets, defining appropriate positioning 
through marketing mix elements (product, price, place, and promotion), and context 
analysis at macro and micro level (Stros & Lee, 2015). Marketing strategies positively 
relate to financial and organizational performance and promote profitability and growth 
(Stros & Lee, 2015). Organizational leaders employed in pharmaceutical companies 
experience challenges in creating and implementing effective product life cycle 
management programs and marketing strategies due to several factors (Prajapati, 
Tripathy, & Dureja, 2013; Schramm & Hu, 2013; Song & Han, 2016). The strategic 
aspects of marketing strategy development and implementation and the challenges 
associated with marketing strategy execution require further research. The marketing 
efforts were explored by understanding how business professionals who develop and 
implement marketing strategies view marketing activities.  
In Section 1 of this study, the background of the problem, the problem statement, 
the purpose statement, the nature of the study, the research question, and the conceptual 
framework are presented and discussed. The significance of the study, including 
contributions to business practice and positive social change, and a review of professional 
and academic literature are also presented.  
Background of the Problem 
Organizational leaders develop competitive advantage and synergies through 
marketing mix elements (product, price, place, and promotion) tailored to the needs and 
2 
 
 
wants of potential customers in the target market (Liao, Rice, & Lu, 2015). The concept 
of product life cycle management, viewed as a strategic approach for managing a 
company’s product-related intellectual capital, originated in the electronics and 
automotive sectors, and existed for many years (Prajapati et al., 2013). In the 
pharmaceutical industry, while product decisions are most visible at the time of new 
product introductions to the market, what happens after launch has a substantial influence 
on the product’s profitability over its lifetime (Duflos & Lichtenberg, 2012). Visiongain 
(2018a) reported organizational leaders spend approximately 19% of their total revenues 
on product life cycle management activities as a marketing tool annually, and over 35% 
of the organizations’ performance in product life cycle management was average to poor. 
Company leaders need to develop marketing strategies during various stages of the 
product life cycle to effectively allocate and coordinate marketing resources and activities 
to accomplish the company’s objectives within a specific product-market (Mullins, 
Walker, Boyd, & Jamieson, 2010). 
The focus of this study was to explore two aspects of the topic under study. The 
first aspect was exploring the marketing efforts and practices related to marketing 
strategy development and implementation, while the second aspect was associated with 
the actors within the marketing system. From that perspective, I explored the marketing 
efforts by understanding how business professionals, involved in the decision-making 
process for marketing strategy development and implementation view the marketing 
activities.  
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Problem Statement 
In 2014, 76% of brand prescription medicines experienced first generic entry 
(Grabowski, Long, Mortimer, & Boyo, 2016). Brand drugs with $100 billion in sales are 
expected to lose patent protection in the coming years (Song & Han, 2016) causing 
increasingly competitive environment, revenue losses, and increased strategic importance 
for product life cycle management activities. Martin, Hartman, Benson, and Catlin (2016) 
published that generic medicines accounted for 82% of prescriptions dispensed in the 
United States in 2014. The general business problem was leaders of pharmaceutical 
companies experience challenges in creating and implementing effective marketing 
strategies during various stages of the product life cycle (Kakkar, 2015) that can lead to a 
loss of revenues, a loss of market shares, and reduced profitability. The specific business 
problem was determining the best practices among marketing managers within 
pharmaceutical companies on how to pursue marketing strategies during various stages of 
product life cycle. 
Purpose Statement 
The purpose of this qualitative case study was to determine the best practices 
among marketing managers within pharmaceutical companies on how to pursue 
marketing strategies during various stages of product life cycle. I obtained data from a 
sample of business professionals, managers, who create and implement marketing 
strategies for branded prescription medicines within the pharmaceutical industry. 
Branded prescription medicines accounted for 70% of the health care expenditures in the 
United States in 2013 (Naci, Carter, & Mossialos, 2015). I identified the pharmaceutical 
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company and the molecules by using the FDA orange book. To explore the lived 
experiences of the participants, I collected data through in-depth, semistructured 
interviews (face-to-face interviews and telephone interviews), and then analyzed the data. 
The scope of the study was in central Ohio in the United States. The data from this study 
might impact social change by assisting organizational leaders to better understand the 
marketing practices and challenges related to the product life cycle management, to 
successfully deliver products in the marketplace, or maximize the profitability of a 
product over its life cycle.  
Nature of the Study 
I employed qualitative research to understand the views and experiences of 
business professionals involved in development and implementation of marketing 
strategies regarding marketing solutions. Marketing strategy development and 
implementation is social constructionism because it involves complex interactions among 
individuals and groups from different business units and levels within an organization 
(Mullins et al., 2010). Cleary, Horsfall, and Hayter (2014) and McKinley (2015) linked 
the socially constructed experiences to the theory of social constructivism. Darawsheh 
(2014) recommended the use of a qualitative research approach to best explore the theory 
of social constructivism and the socially constructed experiences. Hlady-Rispal and 
Jouison-Laffitte (2014) demonstrated that researchers use qualitative research method to 
explore and understand the meaning that individuals or groups ascribe to a specific 
problem, and obtain new information, and that the use of quantitative research through 
surveys or experiments does not help obtain new information.  
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I selected a case study research design within the qualitative research 
methodology. Researchers could explore a complex social constructivism through the 
participants’ views, and use the qualitative case study research design in which 
individuals describe their experiences (Khankeh, Ranjbar, Khorasani-Zavareh, 
Zargham-Boroujeni, & Johansson, 2015), and obtain data using multiple data sources 
(Hyett, Kenny, Virginia Dickson-Swift, 2014; Morse, 2015b; Wiggins, Hughes, 
Rodriguez, Potter, & Rios-Campos, 2014). The experiences occur in a real-life context 
(Tsang, 2014). Strategy researchers used quantitative and qualitative methods since the 
inception of the field, and although researchers employed both quantitative and 
qualitative approaches, the use of quantitative research designs dominates (Duggleby & 
Williams, 2016). The goal of the doctoral study was to construct the meaning of the topic 
under study using multiple data sources through the participants’ views regarding 
marketing solutions and discover new insights, rather than generalizing the meanings into 
few categories, which is the intent of quantitative studies. Qualitative case study research 
was the best fit of research design for the doctoral study. 
Research Question 
The focus of this study was on exploring marketing professionals’ views of 
marketing strategy implementation to address the central research question: How do 
marketing managers within pharmaceutical companies pursue marketing (product, price, 
place, and promotion) during various stages of the product life cycle? 
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Interview Questions 
1. How do you pursue marketing (product, price, place, and promotion) 
during various stages of the product life cycle? 
2. Briefly describe the premarket and postmarket strategies in terms of (a) 
marketing mix: product, price, place, and promotion, (b) sales goals, (c) 
customers, (d) competition/market, (e) targeted market shares, and (f) 
marketing goal, for each of the following stages: launch strategy, first year 
postlaunch, and post first year of product launch. 
3. How do these decisions relate to the company’s revenue generation, 
market share, and profitability?  
4. What factors (variables) are most strongly associated with revenue 
generation, market shares, and profitability? 
5. What factors influence the decision-making process? 
6. What factors influence the company’s product portfolio management? 
7. What are the marketing implications and the challenges in the current 
models of the company’s product portfolio management?  
8. What are the strategic activities that are essential in executing business 
strategies? 
9. How does your company align the strategic marketing programs with the 
corporate strategies, and business strategies?  
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10. What are the key success factors for a pharmaceutical drug manufacturer 
(generic drug manufacturer or brand drug manufacturer) in order to fight 
competition, and the challenges within the industry? 
Conceptual Framework 
The conceptual framework of the study derived from the general systems theory 
and the evolutionary systems theory. Bertalanffy (1972) developed the general systems 
theory in 1972. Bertalanffy used the theory to explain the interconnectivity between 
marketing and other units within an organization and its environment, based upon the 
premise that every system is composed of interrelated components. Laszlo (1997) 
developed the evolutionary systems theory in 1987. Laszlo and Laszlo (1997) used this 
theory to explain the evolution and the dynamics of complex systems and the product life 
cycle model, based upon the premise that an organization as a complex system interacts 
with its environment and coevolves. Key constructs/propositions underlying the theories 
were the participants’ views and experiences on marketing strategies and activities 
related to (a) product, (b) price, (c) distribution, (d) promotion, (e) sales, (f) customers, 
(g) competition, and (h) marketing goals during product life cycle management from 
premarket to postmarket stages. As applied to this study, I expected that the propositions 
advanced by the theorists allowed me to effectively explore the marketing managers’ 
views and experiences regarding their decision-making processes as it pertains to the 
development and implementation of marketing strategies. 
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Operational Definitions 
In this section, the operational definitions of key technical terms, or special words 
uses were provided. The definitions were derived from the academic literature and were 
conceptualized to accommodate the context of this study. 
Branded prescription medicine business: Brand prescription medicine businesses 
are innovation-based and discover novel treatments in form of new molecular entities 
(NMEs), new indications (NIs), new drug delivery systems, or new dosage forms (NDF) 
for existing and emerging diseases (Naci et al., 2015). 
Generic prescription medicine business: Generic prescription medicine business 
operates by introducing versions of innovator products by conducting a limited research 
and development (R&D) work to prove generic medicines’ clinical equivalence to 
respective brand medicines without performing any clinical trial (Xie, & O'Neill, 2014).  
Manufacturing strategy: Manufacturing strategy is set of capabilities that a 
manufacturing unit must have for the organization to compete given its business and 
marketing strategies, and critical to win customer orders (Thomas, Pham, Francis, & 
Fisher, 2015). 
Market orientation: Market orientation as an organization’s strategic orientation 
is a capability to deliver superior customer value, based on knowledge derived from 
customer and competitor analyses and the process by which this knowledge is gained and 
disseminated throughout the organization (Özturan, Özsomer, & Pieters, 2014).  
Market value: Market value is a term that describes an appraisal based on the 
market's perception of the flow of future profits, and dividends, that are partly driven by 
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organizations' tangible, and partly by their intangible assets (Chen, Shil, & Chang, 2014). 
Market value is generally estimated by the value that is the average stock price of a 
company in a given year multiplied by the number of its common stock shares 
outstanding (Chen et al., 2014). 
Marketing strategy: Marketing strategy is the organization's integrated pattern of 
decisions that specify its crucial choices concerning products, markets, marketing 
activities and marketing resources in the creation, communication and/or delivery of 
products that offer value to customers in exchanges with the organization and thereby 
enables the organization to achieve specific objectives (Olson, Slater, Hult, & Olson, 
2018). 
Product life cycle management: Product life cycle management is a strategic 
approach for managing a company’s product-related intellectual capital to maximize the 
profitability of a product over its life cycle, and increase its return of investment 
(Prajapati et al., 2013). 
Relationship marketing: Relationship marketing are all marketing activities 
directed towards establishing, developing, and maintaining successful relational 
exchanges, that involves suppliers, service providers, governments, competitors, 
customers, and internal organizational structures (Payne & Frow, 2017). 
Strategy implementation: Strategy implementation is the realization of strategic 
intentions through organizational activities and practices that are directed toward the 
achievement of strategic goals (Ahearne, Lam, & Kraus, 2014). 
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Assumptions, Limitations, and Delimitations 
Assumptions 
Assumptions are ideas or beliefs about what the agents know and believe about 
each other’s choices and information (Singaraju, Nguyen, Niininen, & Sullivan-Mort, 
2015). Researchers could make assumptions about the participants in the study, the 
results, the topic under investigation, the methodology employed in the study, the data 
collection instrument, the results, or the theory under investigation (Rambe & Nel, 2015). 
An assumption was that the selected participants would cooperate and be willing to share 
their views openly. The selected participants who gave consent to participate in the study 
cooperated and shared their views openly. 
Limitations 
Limitations are elements the researcher has no control over (Rambe & Nel, 2015), 
and are potential weaknesses of the study (Simon, Latreille, Matte, Desjardins, & 
Bergeron, 2014). The major limitation in the study was the selected research method. 
Qualitative research is interpretative, meaning the interpretation of the collected data is a 
representation of interactive processes between researcher and the participants in the 
research, and a reflection of the researcher’s own interpretation based on cultural, social, 
gender, class, and personal politics (Darawsheh, 2014; Denzin, 2017). In qualitative case 
study research, the researcher needs to describe the topic under study through the views 
of the participants and interpret and understand the participants’ perception pertaining to 
marketing solutions in the pharmaceutical industry. The engagement in the data 
collection and the interpretation of data might result in a potential bias. To eliminate 
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potential biases the researcher needs to establish validity and reliability in qualitative 
research and maintain self-awareness during the research. Khankeh et al. (2015) 
documented major weaknesses of qualitative studies, such as contextually embedded 
findings, vague standards for data analysis, presentation of voluminous amount of 
qualitative data and theoretical criteria for judging the quality of studies. To clarify the 
information, accuracy, and credibility of the findings, I followed-up with the participant, 
and used triangulation where I compared the study findings to company documents 
located on company websites. In triangulation, researchers use multiple sources, methods, 
theories, and investigators to support the findings (Morse, 2015a). To maintain self-
awareness and limit the subjectivity during the data collection, I avoided leading 
questions and asked open-ended questions to avoid influence on the participants’ 
answers. I asked all participants the same questions. 
Another limitation was associated with the study population. The selection of the 
participants in the study needed to be rigorous and careful, because people directly 
involved with marketing activities are not necessarily located in marketing or sales 
departments within an organization, and their placement depends on the organizations’ 
structure (Mullins et al., 2010). Potential participants outside marketing and sales 
departments within the organizations who might provide valuable insights to the study 
might have existed. Another limitation was the geographic area. The findings from this 
study may not apply to other geographical areas. 
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Delimitations 
Delimitations are the boundaries of the study (Nagasaka, 2016). Delimitations are 
things that the researcher can control and include information about the sample, the 
variables studied, the theoretical perspectives, or the instruments (BOLD Educational 
Software, 2018); or in other words, information about what researchers will include and 
what will exclude in a study. The objective of this research was to explore the marketing 
efforts in the pharmaceutical industry and the challenges associated with marketing 
strategy development and implementation through lived experiences of business 
professionals involved in the decision-making process. I employed a qualitative case 
study research through primary semistructured interviews with the participants in the 
study. While other methods, such as quantitative or mixed research methods, could be 
employed to approach the topic under study, which is marketing strategies during product 
life cycles in the pharmaceutical industry, I found qualitative case study research well 
suited to answer the problem under study because it provides the means to describe the 
meaning of the topic under study through the participants’ views regarding marketing 
solutions. I did not use other research methodologies in the study. 
Another delimitation in the study was the focus on the activities associated with 
marketing efforts in the pharmaceutical industry. I did not consider other organizational 
efforts, such as research and development, human resources, financial resources, and 
available technologies. I limited the scope to internal factors specific to pharmaceutical 
organizations and external factors, such as competition and market forces within the 
pharmaceutical industry. I did not examine other external factors, such as social and 
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economic conditions, customer and consumer behavior, the government and insurance 
payers, the health care system relating to reimbursement plans, and the physicians’ 
prescribing behavior. Drawing on the general systems theory and evolutionary systems 
theory as a conceptual framework in this research, the development and implementation 
of marketing strategies was examined as a social human activity. 
Significance of the Study 
Contribution to Business Practice  
Research in marketing strategy development and implementation is important to 
scholars and management in organizations within the pharmaceutical industry, given the 
established association between marketing strategies and the organizational financial 
performance (Schramm & Hu, 2013). This study may be significant to the business 
practice for numerous reasons. Research to examine strategic aspects of marketing efforts 
is needed to help organizations in increasing the understanding of marketing strategy 
development and implementation and in designing appropriate marketing intervention 
programs to develop competitiveness or remain competitive in the marketplace and 
extend the life of the molecule, revenue generation, increase market shares and increase 
profitability. This study might contribute to business practice by providing a valuable tool 
for optimal allocation of marketing expenditures over time, because marketing models 
and marketing-mix effectiveness change over time, given the market conditions. Business 
leaders could also use this research to evaluate previous marketing strategies and models 
and derive input for new models during the management of the product life cycle and 
marketing efforts.  
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Kakkar (2015), Schramm and Hu (2013), and Song and Han (2016) concentrated 
on the stage of the brand prescription medicine patent expiration when faced with generic 
prescription medicine substitution. Kakkar, Schramm and Hu, and Song and Han 
examined the effects of specific life cycle management strategies, such as product line 
extensions (reformulations, new combinations of drugs and expanded indication ranges) 
on the commercial product life, revenue generation and market share. These researchers 
focused on the competition, the timing of market entry, the exclusivity of line extensions 
and the effects on market shares and sales (Kakkar, 2015; Schramm & Hu, 2013; Song & 
Han, 2016). Kumar, Brianna, and Greene (2017) focused on marketing-mix optimization 
and resource allocation during various stages of a product life cycle, with emphasis on 
marketing effectiveness, product margins, and costs. Dunne and Dunne (2015) and 
Kanavos (2014) focused on examining the effects of the pricing strategies on the market, 
and compared, and contrasted generic, and brand prescription medicine strategies. 
Barrales-Molina, Martínez-López, and Gázquez-Abad (2014) examined the effects of 
organizational competence or capability as a source of strategic advantage in the context 
of pharmaceutical research. In response to the existing research, I focused on the 
competitive strategies, market entry and organizational competence and their relationship 
with companies’ revenue generation and market shares. One of the objectives of this 
study was to provide new insight of important business drivers in the branded 
prescription medicine sector related to product portfolio management.  
Employing qualitative research methods in exploring marketing strategy 
development and implementation might allow researchers to discover new information 
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about the topic under study previously not available or explored. Khankeh et al. (2015) 
documented major strengths of employing qualitative research, such as extended 
knowledge on the research topic, by proposing theoretical patterns emerged gradually 
from the inductive mode of thinking. Employing a case study design within the 
qualitative methodology helps researchers explore the topic under study through the lived 
experiences of the participants (Maguire, Stoddart, Flowers, McPhelim, & Kearney, 
2014), and could produce new insights into the field of marketing in the pharmaceutical 
industry. I did not find any existing research that examined the perspectives of marketing 
managers on marketing strategy development and implementation in the pharmaceutical 
industry. One of the objectives of this study was to reduce this gap in the literature by 
enhancing the understanding about managers’ experiences of the strategic activities 
related to the development and implementation of strategies. 
Implications for Social Change 
Gray, Siemsen, and Vasudeva (2015) and Song and Han (2016) documented that 
the pharmaceutical market is complex and highly regulated industry, and that Food and 
Drug Administration (FDA) officials evaluate medicines for (a) safety, efficacy, and 
manufacturing quality as a condition of market access; (b) promotion; and (c) medicine 
prices. The constantly changing environment (technology, regulatory, markets, and 
competitor offerings) and intensified competition led to the need for marketing managers 
to develop and implement sound marketing strategies during various stages of product 
life cycle while leveraging the product portfolio mix in order to remain competitive in the 
marketplace (Prajapati et al., 2013; Schramm & Hu, 2013; Song & Han, 2016). 
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Medications have complex life cycles with diverse actors, social systems, and institutions 
determining who uses what medications, how, when, and why (Anderson, Stowasser, 
Freeman, & Scott, 2014). Organizational leaders view the life cycles as systems that are 
part of other systems, such as social, cultural, and economic systems, that are constantly 
changing (Anderson et al., 2014). The data from this study might impact social change by 
assisting organizations to better understand the challenges and business practices in 
implementing strategies during various stages of product life cycle to successfully deliver 
products in the marketplace, obtain cost advantages and generate high levels of return on 
investment. Product life cycle management is a strategic approach for managing a 
company’s product-related intellectual capital to maximize the profitability of a product 
over its life cycle and increase its return of investment (Prajapati et al., 2013). The 
marketing concept further requires marketing managers to organize the organization’s 
resources into a total system aimed at meeting the customer needs, and to influence and 
direct the activities from the manufacturer to the patient (Thomas et al., 2015).  
The pharmaceutical industry develops cures for health conditions, improves the 
health of patients, boosts welfare and economic development (Meara et al., 2016), and 
reduces the total health care expenditures (Berger, Dunn, Johnson, Karst, & Shear, 2016; 
Grabowski, Long, & Mortimer, 2014). Smith (2012) documented that in both developed 
and emergent markets, it is increasingly difficult to gain market access unless the product 
provides not only clinical advantages but also significant and demonstrably superior 
health economic outcomes. This study may contribute to social change by encouraging 
marketing managers to improve the access to safe and efficient medicine. 
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A Review of the Professional and Academic Literature 
The literature review provides a history, synthesis, and critical analysis of 
previous work in areas related to the research question under investigation, to help 
researchers understand the emerging patterns and trends in previous research (Boell & 
Cecez-Kecmanovic, 2015). The literature review in this study is organized into eight 
categories: (a) research methods review, (b) application to the applied business problem, 
(c) conceptual framework, (d) organizational competencies-current theories, (e) 
marketing strategy, (f) marketing instruments, (g) market dynamics, (h) measuring 
marketing value, and (i) challenges in the business models and product life cycle 
management.  
The 226 references used in the research study included 215 online scholarly peer-
reviewed references representing 95.1% of the total, six books representing 2.7% of the 
total, and five websites representing 2.2% of the total. The total number of references 
from scholarly peer-reviewed sources published within the past 5 years was 196, or 
86.7% of the total number, and 202 references published within the past 5 years, 
representing 89.4%. The literature review contained 104 references, with 100 references 
from scholarly peer-reviewed sources, representing 96.2%, and 91 references published 
within the past 5 years, representing 87.5%. 
The literature search is limited to primarily peer-reviewed journal articles. I used 
the following databases in conducting literature review: Business Source 
Complete/Premiere, ABI/INFORM Complete, ProQuest Central, ProQuest Dissertations 
& Theses, LexisNexis Academic, Cochrane Database of Systematic Reviews, CINAHL 
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& MEDLINE Simultaneous Search, and Google Scholar. The existing literature cited in 
the articles, and the research methodologies and approaches to problem were reviewed. 
This literature review is organized thematically rather than chronologically. Touboulic 
and Walker (2015) documented that researchers could organize literature reviews 
thematically or chronologically.  
Research methods review. Duggleby and Williams (2016) documented that 
strategy researchers used quantitative and qualitative methods since the inception of the 
field, and that the use of quantitative research designs dominates. Researchers employ 
quantitative research at theory testing or verification, qualitative research allows for 
theory building or generation, while mixed methods research enables the researcher to 
simultaneously generate and verify theory in the same study (Duggleby & Williams, 
2016; Wiggins et al., 2014). Hlady-Rispal and Jouison-Laffitte (2014) noted that in 
qualitative research, researchers focus on review of the literature on the topic as opposed 
to establishing a foundation for the problem under study, which is common in 
quantitative studies.  
Barrales-Molina et al. (2014) and Kanavos (2014) used quantitative research 
through structured record reviews of medical and financial information to examine the 
relationships between variables to find answers to their questions. Herhausen (2016) and 
Matikainen, Rajalahti, Peltoniemi, Parvinen, and Juppo (2015) used quantitative research 
through surveys to examine the market access within the pharmaceutical industry. 
Obeidat, Al-Hadidi, Tarhini, and Masa’deh (2017) also used quantitative research 
through surveys to examine to examine the strategy implementation within the 
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pharmaceutical industry. Hlady-Rispal and Jouison-Laffitte (2014) and Khankeh et al. 
(2015) employed qualitative research designs to explore topics within the pharmaceutical 
industry. Schulz, Broekemier, and Burkink (2014) used both quantitative research 
through surveys and qualitative research using interviews to examine the impact of 
marketing efforts on product sales.  
Sabatier, Craig-Kennard, and Mangematin (2012) and Smith (2012) used 
qualitative case study research through interviews to explore business models and the 
competitive environment within pharmaceutical industry. Sabatier et al. used 
methodological triangulation through the use of internal documents (project descriptions, 
or annual reports) and scientific research to test validity and develop a comprehensive 
understanding of the topic under study.  
Application to the applied business problem. The objective of this qualitative 
case study was to explore the marketing efforts during various stages of product life cycle 
in the pharmaceutical industry through lived experiences of business professionals who 
develop and implement marketing strategies. In this subsection, a critical analysis and 
synthesis of literature pertaining to the conceptual framework, potential themes and topic 
under study was presented. Different points of views were compared and contrasted, and 
the relationship of the study to previous research and findings were presented. 
Conceptual Framework 
The conceptual frameworks I used in the study were the general systems theory 
and the evolutionary systems theory. Bertalanffy (1972) developed a general systems 
theory based on the assumption that all open systems have similar principles and the 
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principles could be applied to all complex systems. Bertalanffy documented that 
according to the general systems theory, the deterministic laws of nature govern the 
movement of the components or subsystems of every system, organizations inclusive. 
Complex systems, including organizations, focus on the relationships and the interactions 
between the subsystems (such as technological, organizational, and social) and 
individuals within an organization (Guiette & Matthyssens, 2014; Popa, Guillermin, & 
Dedeurwaerdere, 2015). Complexity leadership creates new managerial strategies, such 
as creation of adaptive change, and is concerned more on the relationships among the 
agents and the subsystems within an organization to achieve a specific goal (Guiette & 
Matthyssens, 2014).  
The objectives, strategies, and action plans for a specific product market is only 
one part of a hierarchy of strategies within an organization. Mullins et al. (2010) noted 
that marketing managers are primary participants and contributors to the planning process 
at a corporate level, and business unit level, because they occupy positions at the 
boundary between the company and its customers, distributors, and competitors, and are 
familiar with conditions and trends in the market environment. The interrelationship 
between the marketing unit and other units, such as research and development, finance, 
and operations includes providing management with timely information for making 
critical business decisions. Within a marketing unit, the interconnectivity of common 
business practices could promote standardization. 
Laszlo and Laszlo (1997) explained the evolutionary systems theory that derived 
from the principles of complexity and chaos, based on the assumption that systems can 
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exist in equilibrium and far off equilibrium, and that fluctuations or disequilibrium lead to 
new levels of organization, complexity, and entropy. The focus of this theory is on the 
interactions between the complex systems, such as the organization, and its likewise 
complex operating environment. The product life cycle model was drawn from the 
concept of the evolutionary systems theory, in which the system, product life cycle, goes 
through the life stages from the idea, to result, and then maintenance (Leitao, Colombo, 
& Karnouskos, 2016). In each phase, the primary focus of a marketing strategy is to 
effectively allocate and coordinate marketing resources and activities to accomplish the 
company’s objectives within a specific product-market (Mullins et al., 2010). Another 
characteristic of evolutionary system is change at an organizational level or industry level 
through an ongoing process of coevolution in which agents, the likewise complex 
systems, interact with each other (Popa et al., 2015). To respond to change, the 
organizational leaders need to be creative and accept uncertainty. The primary 
responsibility of a manager is to look outside the organization and to keep the business in 
step with changes in the environment (Mullins et al., 2010). In the marketplace, once a 
strategy becomes dominant, it may be invaded by another strategy (Abatecola, Belussi, 
Breslin, & Filatotchev, 2015). Organizational leaders need to monitor the competitor 
moves in the industry, respond to their strategies, and develop strategies that will 
differentiate themselves from competition. This is ongoing process and requires 
continuous learning by the organizations.  
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Potential Themes 
Organizational competencies-current theories. Sabatier et al. (2012) discussed 
the concept of dominant industry logic, where organizational leaders within an industry 
develop similar worldviews, make similar critical decisions about resource allocation, 
and create similar strategies and business models to create and capture value in the 
marketplace, and sustain profitability. Sabatier et al. identified the following three 
components of the dominant industry logic: (a) the value context-industry landscape, (b) 
value creation-organization capabilities (processes or business models) and competencies 
(knowledge-based components or technologies), and (c) value creation-business 
processes used to deliver products and services. Sabatier et al. defined the business model 
concept as a strategy that organizational leaders develop to compete in the marketplace. 
Sabatier et al. asserted that the managerial choices of business models reflect the 
managerial perceptions about the competitors, the environment, and the customer wants 
and needs, and how an organization could deliver and meet the customer needs. Sabatier 
et al. further noted a change in managerial perceptions influences the organization’s 
decision-making process. 
Sabatier et al. (2012) identified the following characteristics of the dominant 
industry logic within the pharmaceutical industry: (a) focus on product innovation (drug 
discovery, development, and commercialization), (b) value stability, and (c) use of 
strategic alliances and networks. Sabatier et al. discussed the pharmaceutical industry 
landscape and evolution and documented that the value creation and capture model is 
product-focused, the value chain is highly regulated and fragmented, allowing small and 
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medium actors to focus on innovation, and that actors within large pharmaceutical 
organizations control the market. Sabatier et al. documented that strategic alliances and 
networks are necessary for product innovation. 
Kozlenkova, Samaha, and Palmatier (2014) used the resource advantage theory to 
explain the competition as a process of gaining comparative advantages in resources 
among organizations to achieve competitive advantages in the marketplace. Using the 
industry-based theory, Hunt (2015) argued that organizations’ financial performance 
resulted primarily from the industry factors, by selecting cost leadership (for example, 
low cost position), differentiation (such as unique products and services offerings) or 
focus (for example, focus on a specific market segment) strategy. Hunt noted when 
formulating a strategy, organizational leaders examine the competition and the 
underlying factors within the industry. Porter (1985) provided a framework for 
competitive analysis by identifying five forces, such as- threats of new entrants, 
bargaining power of suppliers, bargaining power of buyers, threats of substitute products, 
and rivalry among competitive firms, to determine the industry profitability and growth. 
The value chain model is a useful tool to identify and manage organizations’ core 
competencies and activities to develop a competitive advantage (Muhammad & Torbjørn, 
2014; Porter, 1985; Sabatier et al., 2012).  
Kozlenkova et al. (2014) evaluated the contributions of the marketing discipline 
to the body of knowledge of business strategy. Kozlenkova et al. discussed the resource-
based, the competence-based theory, and the market orientation concept and noted in 
resource-based and competence-based theory, the focus is on the internal factors. 
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Examples of resources include distribution networks, manufacturing capabilities, research 
and development capabilities, and employees’ skills (Kozlenkova et al., 2014). The 
competence-based theory explains how the organizations’ leaders develop strategies to 
exploit resources and develop competitive advantage in target markets (Kozlenkova et 
al., 2014). Kozlenkova et al. argued that through competition, the organizations’ leaders 
learn about their resources, and their position in the marketplace.  
Vidal and Mitchell (2018) examined how the organization’s networks and 
divestitures within the pharmaceutical industry develop as the organizational internal 
resources grow. Using the resource-based theory, Vidal and Mitchell identified the 
attributes that link resource development to network content, structure, and management. 
Vidal and Mitchell found that the relationship between the resource growth and network 
development is strong, and maintaining strong relationships with suppliers, customers, or 
social contacts is critical success factor to the organization and highly affects the 
organization’s financial and market performance.  
Thomas et al. (2015) conducted quantitative research through surveys to examine 
the strategic view of manufacturing, focusing on competitive capabilities, business 
strategies, manufacturing strategy choices, and manufacturing performance measures. 
Thomas et al. listed these critical competitive capabilities: (a) quality, (b) cost, (c) 
efficiency, (d) delivery, (e) responsiveness, (f) flexibility, (g) innovation, and (h) 
customer service. Thomas et al. developed taxonomy of manufacturing strategies with 
standard methods of cluster analysis based on the importance of the competitive 
capabilities, identified three distinct types of manufacturers (such as caretakers, 
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marketers, and innovators), and described the method of mapping manufacturing 
strategies. Thomas et al. found that the differences between categories were related to 
market characteristics, such as the degree of market differentiation and market scope, and 
the strategies were related to the product life cycle. Thomas et al. documented that 
innovators are influenced by engineering, technology, new product introductions, and 
research and development, focusing on modifications in business models through 
decreased lead times for product development and reduced manufacturing time. Thomas 
et al. noted that marketers with well-established products and markets focus on mature 
phases of product life cycle, while improving product reliability, or increased efficiency; 
while caretakers focus on declined phases of product life cycle. Thomas et al. 
recommended the need for combinations in capabilities and manufacturing strategies for 
revenue and profit generation.  
Birkinshaw, Zimmermann, and Raisch (2016) discussed the integration of 
organizational dynamic capabilities to explain how organizations adopt to change. 
Birkinshaw at al. identified three types of capabilities that people within organizations 
need to possess to succeed in the marketplace: sensing (to be able to identify and assess 
threats and opportunities), seizing (to be able to mobilize resources to address threats and 
resources), and reconfiguring capabilities (needed to continuous renew tangible and 
intangible assets). Birkinshaw et al. showed that these three capabilities contribute to the 
organizations’ project and product portfolio management and performance, measured 
through optimal allocation of resources, business strategy alignment, goals, spending, 
value and timing.  
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Barrales-Molina et al. (2014) examined the dynamic marketing and R&D 
capabilities in organizations. Barrales-Molina et al. focused on the influence of the 
organizational leaders’ experience (such as chief executive officers’ experience) on the 
dynamic capabilities, and the extent of the environmental conditions influence (market 
turbulence, intensity of competition, or developments in technology) on the chief 
executive officers’ experience. Barrales-Molina et al. documented that dynamic 
marketing capabilities shape the markets and markets shape these capabilities, so that 
organizations and markets co-evolve. Barrales-Molina et al. noted dynamic marketing 
capabilities include adaptation and change. Barrales-Molina et al. documented that 
organizational leaders who foster the use of dynamic capabilities have the ability to react 
to changing environments by reconfiguring the portfolio of strategic competencies, 
respond to changing environments, and provide value to customers.  
Similarly, Diestre, Rajagopalan, and Dutta (2015) examined the effects of 
dynamic marketing strategy and on the influence of directors’ experience on new market 
entry, marketing capabilities, market performance, and competitiveness. Diestre focused 
on marketing learning focus, product innovation awareness, customer orientation, and 
technology utilization. Davcik, and Sharma (2016) examined the marketing capabilities 
and evaluated the relationship between marketing resources’ performance and brand 
environment, marketing as a function, and marketing resource deployment. Davcik, and 
Sharma documented that dynamic marketing capabilities include adaptation to changing 
environments, and organizational leaders who use these capabilities have the ability to 
sustain in the marketplace.  
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Chang, Franke, Butler, Musgrove, and Ellinger (2014) examined the effects of 
new product development team characteristics focusing on the following three measures: 
market success or effectiveness, efficiency or meeting budgets and schedules, and the 
speed to market. Chang et al. documented that organizational ability to successfully 
develop and introduce new products to the market is critical determinant of 
organizational performance. Chang et al. found that team leadership, ability, external 
communication, group cohesiveness, and goal clarity were determinants of new product 
development team performance.  
Eng and Ozdemir (2014) conducted qualitative research to explore the effects of 
research and development and marketing integration on the organizational performance 
focusing on technological and market competence exploitation during new product 
development stage. Eng and Ozdemir emphasized the need for high levels of integration 
between research and development and marketing to combine critical knowledge, such as 
technological and market, to achieve market success. Eng and Ozdemir indicated the 
necessity of different levels of integration based on the type of the competence that the 
new product development teams want to develop. Eng and Ozdemir found the market 
performance (such as sales and market shares) need to be distinguished from the process 
performance (such as meeting budgets, and time to market). Eng and Ozdemir proposed 
higher levels of integration between research and development and marketing if 
organizational leaders want to achieve higher market and technical performance in the 
marketplace during new product launch.  
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Herhausen (2016) conducted quantitative study through surveys to examine the 
integration between market orientation and research and development and its effect on 
organizational success in the marketplace in the pharmaceutical industry. Herhausen 
emphasized the need of high level of communication, information sharing, and 
collaboration between marketing and research and development during the new product 
development process. Herhausen found high level of synergy between marketing and 
research and development teams is developed when organizational leaders focus on 
future market needs, and that the higher the degree of integration, the higher the market 
performance and new product acceptance. Herhausen further indicated that the high level 
of collaboration between the two teams is needed to launch new products in a timely 
manner and achieve organizational goals in terms of sales and market shares. Herhausen 
documented that organizational leaders balance their product portfolio mix of existing 
and new products to remain competitive in the marketplace.  
Riggs, Widmier, and Plank (2016) conducted a study through interviews and 
surveys to explore the impact of regulations and laws on the sales process and sales 
behaviors within the pharmaceutical industry in the United States. Riggs et al. identified 
the following sales behaviors and skills: building and maintaining relationships with 
customers, communication and presentation skills, ability to differentiate product/service 
from competition, selling, getting to buy skills, market targeting, designing sales plans, 
and business planning. Riggs et al. documented that salespersons, and marketing and 
promotional materials offered directly to the physicians are impacted by pharmaceutical 
regulations and laws that affects compliance. 
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Marketing strategy. Olson et al. (2018) evaluated the evolution of the field of 
strategic marketing. Olson et al. documented that strategic marketing focuses on 
organizational, inter-organizational and environmental topics concerned with (a) the 
behavior of organizations in the marketplace in their interactions with consumers, 
customers, competitors and other external environment, in the context of creation, 
communication, and delivery of products that offer value to customers in exchanges with 
organizations, and (b) the management responsibilities associated with the marketing 
function in organizations. Olson et al. focused on the organizational behavior in the 
marketplace, and discussed fundamental issues in the field of marketing, such as: (a) the 
differences in the marketing behavior of competing businesses in the marketplace, and 
their financial performance of competing product lines or brands, and (b) the factors 
influencing the organizational behavior in the marketplace.  
Mullins et al. (2010) provided a thorough explanation of marketing strategy 
models that organizational leaders employ through various stages of the product life 
cycle. These models can be applied equally to services and physical products, single-
product start-ups, and multidivisional corporations, global and domestic. Mullins et al. 
examined the relationship between the organization’s competitive strategy and the 
strategic marketing program for each product during product life cycle, and the marketing 
implications of ethical standards. Mullins et al. found that an organization is likely to 
achieve superior revenue growth, market share and profitability when the competitive 
strategy is aligned with the strategic marketing program. 
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Integrated marketing. Paich, Peck, and Valant (2011) documented that cross 
functional teams develop marketing strategies in the pharmaceutical industry, based on 
their perceived expectations of marketing strategies’ effects on market penetration, sales, 
or quality. Paich et al. developed integrated framework for pharmaceutical markets, that 
consists of three components (such as patient flow, physician adoption/prescribing, and 
treatment attractiveness), emphasizing the link and the dynamic relationships between the 
knowledge of market dynamics and the resulting behavior, that is essential to effective 
strategic decision making, marketing initiatives, and resource allocation. Paich et al. 
addressed the need to look into the market segments by therapy, product, or patient 
segments, and identified and discussed the factors influencing the key components for 
treatment options of a specific indication, such as safety, efficacy, tolerability, side 
effects, and mode of administration. Paich et al. asserted when drug toxicity problems are 
associated with a specific treatment program, then safety might be a key product attribute 
of treatment attractiveness; or, for established products in terms of efficacy, side effects 
might be the key attribute of treatment attractiveness.  
Jasper, Leenders, and O’Shannassy (2017) examined the interaction between 
brand orientation and market orientation in the pharmaceutical industry. Jasper et al. 
discussed the two concepts and documented that brand orientation emphasizes the 
organizational brand identity and covers organizational culture, strategy, and behavior, 
while market orientation emphasizes the importance of the customer. Jasper et al. 
documented that these two strategies are complementary, and suggested organizational 
31 
 
 
leaders to combine the two approaches when developing a marketing strategy to gain 
competitive advantage in the marketplace. 
Relationship marketing. Payne and Frow (2017) examined the concept of 
relationship marketing and explored the factors for relationship marketing success. Payne 
and Frow documented that organizations engaged in relationships with other 
organizations and customers to develop and leverage resources (competences, 
information, or processes) to achieve competitive advantage and superior financial 
performance. Payne and Frow viewed the relationship marketing as an organization’s 
competence for developing relationship with others to allow organizational leaders to 
compete more efficiently and effectively by using their resources and competences. The 
use of market-sensing and customer-linking capabilities is a critical success factor to 
organizations.  
Nätti, Pekkarinen, Hartikka, and Holappa (2014) documented that the value for a 
customer in business-to-business relationships is not created from the use of one resource 
only, but from a mix of supplier-customer interactions that support the successful use of 
the product offerings (deliveries, invoicing, or customer training). The suppliers need to 
understand how they can deliver value beyond the product offerings. Daukseviciute and 
Simkin (2015) documented that different marketing programs differ in their effectiveness 
and recommended resource allocation model for optimal mix. Daukseviciute and Simkin 
recommended (a) strategic use of financial programs in attracting new customers or as a 
response to competitors, long-term; and (b) structural relationship marketing investments 
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by increasing interaction frequencies with customers of above the average to generate 
positive short-term economic returns.  
Resource allocation. Kumar et al. (2017) examined the model of dynamic 
marketing-mix optimization, and resource allocation focusing on time-varying marketing 
effectiveness, product margins, and costs. Kumar et al. found the following: (a) the 
optimal allocation in marketing activities are directly proportional to their effectiveness, 
and inversely proportional to their costs; (b) optimal spending is influenced by how costs 
change over time, and spending on a marketing activity should increase or decrease as its 
cost decreases or increases over time; and (c) shifts in spending from one marketing 
variable to another variable during product life cycle as a result of time-varying 
effectiveness of marketing efforts. Kumar et al. indicated companies spend on interactive 
activities, such as social media even when their effectiveness is unproven, because of the 
lower costs compared to TV advertising.  
Strategic management approaches. Song and Han (2016) discussed strategies 
that organizational leaders of innovator organizations that market brand name medicines 
could employ to extend the commercial life of a drug and retain market shares. Song and 
Han identified four strategic choices: (a) prevention strategy, where organizational 
leaders extend patent protection through legal measures (patent clusters, or secondary 
patents to cover multiple aspects of the drug) with the intent to temporarily prevent 
competition, (b) innovation strategy, where organizational leaders avoid competition 
through product innovations (product line extensions, introduction of new indications, 
introduction of follow-on drugs, or switches from prescription to over-the-counter drugs) 
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or business model innovation (adjusting business models to changing environment), (c) 
extraction strategy, where organizational leaders exploit current market position without 
investing in product innovation (through pricing strategies, marketing campaign, 
promotion, cost reduction initiatives, or selling or licensing the drug to a generic drug 
supplier prior to patent expiry) and (d) adoption strategy, where organizational leaders 
enter the generic market segment through a launch of authorized branded generics 
(launch of generic drugs or developing and launching a generic drug through a 
subsidiary). Song and Han documented that development of a patent extension strategy 
requires (a) understanding of the business environment and industry dynamics, (b) strong 
collaboration between marketing managers, scientists, and attorneys to optimize the use 
of product life cycle management concept, and (c) use of marketing mix instruments 
(combination of product attributes, pricing, and promotional strategies). 
Innovation. Sternitzke (2014) investigated different types of innovation, such as 
radical innovations, market breakthroughs, technological breakthroughs, and incremental 
innovations in the pharmaceutical industry focusing on time-to-market aspects, 
knowledge sources, and protection strategies. Sternitzke provided an overview of the 
studies investigating lag structures between research, development, and product 
introduction, and commercialization, and discussed the product life cycle management. 
Sternitzke documented that once a drug is developed, organizational leaders apply 
different product life cycle management strategies to further develop and protect the 
product innovation by patenting new formulations, combinations, uses, molecules, or 
manufacturing processes. Sternitzke asserted these strategies provide opportunities to the 
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manufacturers to reduce the manufacturing costs, improve the product quality, reduce the 
drug development costs, and introduce the new product variations to the market faster 
since clinical studies already exist. Sternitzke also discussed the benefits for both the 
patients, and the organizations. Sternitzke noted pharmaceutical organizations consider 
the speed of filing new patents in order to gain or sustain competitive advantage in the 
marketplace, not only the amount of patent filings.  
Spieth and Schneider (2016) examined business models focusing on 
innovativeness. Spieth and Schneider documented that business models reflect 
organizational leaders’ beliefs about market needs, and describe the way organizations 
function. Spieth and Schneider described the business model innovation as a search for 
finding new ways to create value for its stakeholders, define value propositions for 
customers, suppliers, and partners, and generate revenues, to sustain competitive 
advantage in the marketplace. Spieth and Schneider documented that organizations’ 
leaders compete with different business models, profitability is adversely affected by 
competition, and that a business model could be adopted by a competition. Spieth and 
Schneider showed a positive correlation between innovation and profitability, and 
suggested that organizational leaders need to implement innovations in their business 
models to differentiate in the marketplace. 
Park, Srivastava, and Gnyawali (2014) examined the relationships among product 
innovation, competition, and profit generation. Park et al. found that sustained 
profitability results when an organization introduces innovations repeatedly over time, 
and that even though the return on investment in innovation might erode over time, the 
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innovation ensures high performance position in the marketplace in terms of sales and 
profit. Park et al. did not find  a link between the persistence of profit and the ability to 
avoid competition.  
Dubois, de Mouzon, Scott-Morton, and Seabright (2015) examined the 
relationship between market size and innovation in the pharmaceutical industry in the 
United States. Dubois et al. measured elasticity of innovation as number of new 
molecules launched in the market for a given therapeutic class, and the market size in 
terms of revenue sales. Dubois et al. documented that large market size may induce 
innovation and innovation creates sales and market. Dubois documented that innovation 
might intensify competition in the marketplace, and reduce prices and profit margins. 
Dubois et al. found a significant positive elasticity of 23.1%, indicating that additional 
$2.5 billion in additional revenue is required to induce an invention of one additional 
molecule. Dubois et al. documented that economic costs to develop a new molecule are 
estimated $800 million to $1 billion, and marketing costs represent 50% of revenue sales. 
Dubois et al. asserted that innovation is becoming more difficult and expensive over time, 
and the costs for regulatory approval are rising. 
Ambrammal and Sharma (2014) examined the innovation activities focusing on 
investment in research and development, and patent policy as measures of innovation in 
Indian organizations. Ambrammal and Sharma examined the innovation in multiple 
industries, including the pharmaceutical industry. Ambrammal and Sharma documented 
that innovation is critical in obtaining a competitive advantage in the marketplace, and 
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demonstrated that foreign business leaders within the pharmaceutical industry are 
relocating their R&D activities into India to capture the growing market size.  
Diversification strategy. Rusu, Kuokkanen, and Heier (2011) employed a case 
study approach to explore the current business practices focusing on diversification 
strategies, generic competition, and pipeline management. Rusu et al. discussed the 
diversification strategies, including expansion in new markets or business areas through 
acquisitions (such as entering animal health market), expansion of portfolios (for 
example, by including biotechnology products), or geographical expansion (for example, 
increased presence in high growth emerging markets). Rusu et al. emphasized the 
importance of the pipeline management strategies that include continuous introduction of 
new compounds, and timing of market entry to compensate for losses as a result of 
increased competition of already established markets. Rusu et al. found that the pipeline 
management could be established through mergers and acquisitions, and through 
prioritization of research and development activities (by discontinuing projects, out-
licensing technologies to other research organizations or pharmaceutical companies, or 
partnering and co-developing molecules with other organizations).  
Barei and Ross (2015) employed qualitative study through interviews, and 
explored the innovation model in the organizations’ management systems, business 
models, and product portfolios within the generic pharmaceutical industry. Barei et al. 
focused on the re-innovation, where generic pharmaceutical manufacturers and marketers 
are improving existing product attributes, new configurations, replacing new components, 
or using new technology to produce new innovative products. Barei et al. discussed the 
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challenges that generic pharmaceutical organizations’ leaders are facing in intensified 
competitive environment, such as: (a) product differentiation through improved 
management processes, restructured business models, and value proposition to 
customers; (b) optimization of product quality; (c) reduction of manufacturing costs; or 
(d) reduction of time to market. Barei et al. found that organizations that implement new 
competitive strategies employ re-innovation model into their product portfolio and 
business models to provide cost-effective products to meet the demand, and health care 
systems’ requirements for high quality accessible treatments.  
Strategic alliances. Liu, Pu, and Schramm (2016) examined the role of strategic 
alliances among organizations and their financial performance focusing on innovation 
(such as patents) in pharmaceutical industry. Liu et al. documented that business leaders 
engage in partnerships with other organizations in the value chain model during different 
product life cycle stages. Liu et al. documented stronger responses in early stages of 
product development, or in later stages, during product line extensions. Liu et al. found 
that alliances and strategic partnerships with other organizations (in the area of 
marketing, research and development, or manufacturing) is important driver of 
innovation and critical factor that influences organizational financial performance.  
Marketing instruments. Song and Han (2016) examined the strategy choices and 
the use of marketing mix instruments (product, price, promotion, and place) in the 
marketing of pharmaceuticals. Song and Han recommended development and 
implementation of a different mix of marketing strategies during different stages of 
product life cycle to extend the product life and achieve the company goals. Song and 
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Han also documented that determining the marketing strategies depends on 
organizations’ capabilities, priorities, and opportunities. Similarly, Kumar et al. (2017) 
noted organizational leaders determine the dominance of a marketing variable or a mix of 
variables during different stages of product life cycle, and allocate resources accordingly 
due to the factor time-varying effectiveness of marketing activity.  
Song and Han (2016) documented that the marketing instrument “place”, which 
determines where and how the product will be sold, is insignificant in the marketing of 
pharmaceuticals because of the market nature and characteristics (regulated market), 
strategic decisions regarding the marketing instrument “product” need to take place at 
early stages of product life cycle because of the time needed to develop a product, while 
strategic decisions about the marketing instruments “price” and “promotion” depend on 
the market conditions. Kumar et al. (2017) linked the drug efficacy with the investment in 
advertising. Kumar et al. asserted when investing in advertising, or marketing 
communications mix at the beginning of a new prescription medicine life cycle, a pull 
strategy (for example, by using a journal advertising targeting physicians) is more 
effective when the uncertainty about the drug’s efficacy is high, while in later stage as the 
physicians learn though experience and the uncertainty about the drug’s efficacy is 
reduced, a push strategy (through detailing, or e-detailing) is likely to be more effective 
instrument to increase sales and gain market share.  
Product life cycle management. Mullins et al. (2010) presented the product life 
cycle model as a framework that provides opportunities and threats in the marketplace 
and the industry, in order to help the organizations better anticipate changes in the 
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product’s strategic market objective, its strategy, and its marketing program. Mullins at 
al. found that products go through five distinct stages, such as introduction, growth, 
shakeout, maturity, and decline during their life cycle, or do not follow the curve because 
of multiple factors. Mullins et al. recommended by identifying and understanding the 
stage of the product life cycle, business leaders can identify the responses that marketing 
decision makers make to the changing circumstances faced by the product.  
Prajapati et al. (2013) identified and described approaches to managing and 
extending the life cycle of pharmaceutical products to maximize the return on investment. 
Prajapati et al. asserted the rise in development costs for new molecules, the decline in 
launch of new products and the productivity of research and development, caused the 
pharmaceutical companies to rely on the life cycle management strategies to maximize 
their profitability. Prajapati et al. provided a model of life cycle stages: (a) product 
development phase (involves development of new product idea), (b) approval phase 
(regulatory approval), (c) introduction phase (includes product launch and maximum 
impact on sales), (d) commercialization and quality management phase (associated with a 
period of highest sales returns and focus on increasing market share), and (e) decline 
phase (associated with product withdrawal and decline in market shares).  
Nikolopoulos, Buxton, Khammash, and Stern (2016) identified four product life 
cycle stages: (a) introduction-associated with low product sales and high marketing costs; 
(b) growth-characterized with increased product sales and introduction of lower priced 
imitation products from the competitors; (c) maturity-characterized with peak product 
sales followed by a decline, and intense market share competition; and (d) decline-
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decline of product sales and profits from product sales. Nikolopoulos et al. documented 
that the product life cycle applies to both brand and generic prescription drugs. 
Nikolopoulos et al. provided a forecasting competition model of brand and generic 
prescription drugs before and after patent expiry. Nikolopoulos et al. asserted that 
marketing managers need to understand the product life cycle model and the sales 
patterns, and apply different marketing strategies for each stage of the product life cycle 
to address these patterns.  
Wagner and Wakeman (2016) described the commercialization of a product as a 
process from product invention to post-patent expiry, and provided a model of life cycle 
stages: (a) pre-launch phase, where R&D activities and clinical trials take place; (b) 
marketing and sales phase, where companies sell patented products under exclusivity, 
and (c) post-exclusivity phase, where the patents lose exclusivity, and generic drug 
competition exists. Wagner and Wakeman discussed the speed of product 
commercialization, and the factors influencing the speed of product commercialization: 
the duration of clinical trials during pre-launch phase, and the organization’s investment 
into the product commercialization. Wagner and Wakeman documented that 
pharmaceutical organizations spend about 17% of their sales from prescription drugs on 
R&D activities. Wagner and Wakeman asserted that organizations invest more resources 
into products with high expected value (such as the economic importance of the treated 
decease and the problem it solves, and product quality), and bring these products to 
market faster than products with low expected value and return on investment.  
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Visiongain (2018b) investigated and analyzed the life cycle management 
strategies that companies are using to maximize the product commercial life and revenue 
generation, consisting of measures, such as reformulations, new combinations of drugs 
and expanded indication ranges, and the use of alliances, licensing, mergers and 
acquisitions. The team members provided forward-looking sales analysis from 2010-
2020, company directions, discussions of commercial and technological developments 
and analysis of market drivers and restraints, competition, opportunities and threats 
influencing the various aspects of product life cycle management for pharmaceuticals. 
The team members indicated that optimized product life cycle management will be of 
crucial importance to the pharmaceutical industry in the coming years.  
Pramod, Tahir, Charoo, Ansari, and Ali (2016) discussed product development 
strategies focusing on the product quality, and their impact on the product portfolio 
performances in pharmaceutical and organizations. Pramod et al. addressed the 
importance of project and product portfolio management on the organizations’ 
performance in the marketplace, and noted research and development processes are 
crucial for successfully developing innovative products. Pramod et al. emphasized the 
need of continuous product quality and process improvements throughout the life cycle 
from development through commercialization and beyond product discontinuation.  
Product portfolio management. Haezendonck, Willems, and Hillemann (2016) 
examined the development of the market growth matrix that analyzes the impact of 
investing resources in different business or products on the company’s future earnings. 
Haezendonck et al. noted organizational leaders used the market growth matrix as a tool 
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in portfolio planning with a goal balanced product portfolio. In the context of strategy 
planning for products, Haezendonck et al. discussed the implications of the resource 
requirements, the earnings potential and the different types of strategies within the four 
categories: (a) question marks: products with low market share in high-growth markets; 
(b) stars: products with high market share in a high-growth markets; (c) cash cows: 
products with high market share in low-growth markets; and (d) dogs: products with low 
market share, high costs in low growth markets. Haezendonck et al. documented that by 
identifying the state for each product in the company’s portfolio mix, and by evaluating 
the competitive strength, growth potential, profitability and costs within the matrix, 
business leaders can better identify strategies to balance the company’s portfolio and 
achieve company’s goals.  
Brand prescription drugs. Kanitz and Burmann (2012) investigated the 
management of the brand portfolio of an organization in the pharmaceutical industry 
focusing on three dimensions, such as product differentiation, indicator of origin, and the 
status of reimbursement, and their connection with the market segments and geographical 
market areas. Kanitz and Burmann asserted brand portfolio includes all the existing 
brands and sub-brands attached to product-market-offerings, including co-brands with 
other firms. Kanitz and Burmann discussed the importance of having robust brand 
portfolio on different levels, such as- product line level, therapeutic category level, or 
corporate brand level, and opportunities for product differentiation in the marketplace 
within each level. Kanitz and Burmann suggested in an increasingly competitive 
environment, marketing managers need to be able to coordinate and communicate the 
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whole brand portfolio to address the complex customer network to gain and sustain 
competitive advantage in the marketplace long term.  
Specialty pharmaceuticals. Hartman et al. (2015) provided an overview of the 
underlying factors contributing to the growth of health care expenditures in 2013, 
focusing on the prescription drug expenditures. Hartman et al. discussed the specialty 
pharmaceuticals market and published specialty pharmaceuticals accounted for less than 
1% of prescriptions dispensed in the United States, and 28% of total prescription drug 
expenditures in 2013. Hartman et al. focused on specialty drugs used to treat cancer and 
multiple sclerosis. Hartman et al. asserted specialty drugs are associated with higher 
specialty drug prices, increase in prices of existing specialty drugs, and increased 
introduction of new specialty drugs to the market. Similarly, Martin et al. (2016) 
documented increased use of higher priced specialty pharmaceuticals in 2014, focusing 
on specialty drugs used to treat hepatitis C. 
Hirsch, Balu, and Schulman (2014) discussed the nature of the specialty 
pharmaceuticals market, market dynamics and the competitive environment, the 
reimbursement plans, and pricing strategies. Hirsch et al. documented that the market 
segment is characterized with increased competition, big pharmaceutical entry to 
specialty markets, and financial crisis. Hirsch et al. identified the following market 
drivers: increasing reimbursement from health care organizations and government, 
biotech growth, and industry regulation. Hirsch et al. identified the following critical 
success factors: product differentiation, market growth, and market size at launch.  
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Generic prescription drugs. Costa-Font, McGuire, and Varol (2014) showed that 
the generic medicines are low cost alternatives to the brand medicines that lead to 
substantial health care costs savings, increased affordability worldwide, growing market 
opportunities, or intense competition by other generic medicines, brand medicines, over-
the-counter medicines, and bio-pharmaceuticals. Hartman, Martin, Lassman, and Catlin 
(2015) documented that generic drugs were priced 80-85% lower than their branded 
counterparts of the same medication. Moe-Byrne, Chambers, Harden, and McDaid (2014) 
investigated the effectiveness of behavior change interventions (such as financial 
incentives, electronic prescribing, or educational intervention) to encourage prescribing 
of generic prescription drugs. Moe-Byrne et al. documented that generic medicines are 
substitutes for branded medicines with the same quality, efficacy, and safety, priced 0-
80% lower than their branded counterparts. Generic medicines offer opportunities to the 
health care insurance organizations and governments to reduce the health care costs. 
Moe-Byrne et al. conducted a literature review focusing on the evidence for interventions 
to increase generic prescribing rates. Moe-Byrne et al. indicated that the evidence was 
insufficient to determine is a specific intervention or a combination influences the rate of 
prescribing generic drugs.  
Costa-Font et al. (2014) examined the effects of price regulations on generic drug 
entries in the market. Costa-Font et al. discussed the market structure, the market 
competition, and the market size focusing on the generic drugs, and documented that the 
generic drugs have lower net profit margins, and are subject to intense price competition 
compared to brand name drugs. Costa-Font et al. also documented that the expected sales 
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for generic drugs are a function of the branded name molecule sales prior to launch and 
the expected market penetration sales from the generic drug following market entry. 
Costa-Font et al. found that the higher expected prices of the generic drugs were, the 
lower was the time to launch of the generic drugs. Costa-Font et al. documented delays in 
the generic drug launches on products with high branded name molecules achieved 
through the use of regulatory mechanisms. Costa-Font et al. also found that (a) the 
expected market share of the generic drugs following market entry was a significant 
determinant of launch, controlling for price, therapy, molecule characteristics, 
competition, and organization, and (b) the expected generic competition at the time of 
product launch had a significant effect on the organizations’ launch strategies and market 
entry. 
New product launches. Camejo, McGrath, Miraldo, and Rutten (2013) noted 
organizational leaders continuously include new products in the management of their 
product portfolio, and documented that the introduction of new drugs is needed because 
over time, it increases the clinical effectiveness of the drugs within a specific therapeutic 
area. Camejo et al. discussed the cause and effect scenario of the innovation model on the 
product price and research and development costs, and recognized the dynamic nature of 
the model that is therapy specific, and occurs at different rates across therapeutic areas. 
According to Camejo et al., drug prices of new products and their substitutes available in 
the market are expected to decrease due to increased market competition over time, while 
the R&D costs increase causing an increase in the minimum price constraint for new 
market entrants.  
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Similarly, Matikainen et al. (2015) conducted quantitative research through 
surveys to examine the impact of new product launches on the product performance 
during various stages of product life cycle. Matikainen et al. examined determinants 
influencing the product financial performance, and customer acceptance. Matikainen et 
al. identified the following key factors that influence the new product launch success and 
product commercialization: order of market entry, marketing mix instruments (product, 
price, promotion, and distribution), sales, corporate culture, organization capabilities, 
market orientation, and customer relationship. Matikainen et al. emphasized the 
importance of relationship marketing, and recommended marketing managers to consider 
the product life cycle management model when creating marketing programs during the 
product commercialization process.  
Prajapati et al. (2013) provided an overview of the managerial activities during 
product development phase for both brand drug and generic drug launch. Prajapati et al. 
documented that the product development phase of a brand drug involves development of 
a new product idea, assessment of patentability of the drug formulation, and changes in 
formulation and methodology. Prajapati et al. noted development of a generic drug 
involves selection of the active pharmaceutical ingredient, drug formulation, patent 
search of innovator drug, establishing safety and good manufacturing practices 
requirements, and selection of appropriate type of testing to establish bioequivalence. 
Prajapati et al. recommended organizational leaders to document the progress and the 
failures of a molecule to utilize its economic potential as part of the product life cycle 
management strategies. Similarly, Khanna, Guler, and Nerkar (2016) also documented 
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the need organizational leaders to document the successes and failures of molecules 
during product development. 
Patents. Kakkar (2015) and Song and Han (2016) documented that patents are 
primary tools to establish brands in the marketplace, and enforce market exclusivity of 
inventions. Song and Han documented the use of secondary patents (such as additional 
features of the active pharmaceutical ingredient, method of use, or formulations) as a 
strategy to improve the primary patent, protect the branded drug, and maintain market 
shares in the case of competition from generics. Similarly, Berger at al. (2016) discussed 
patent strategies and documented that drug manufacturers employ various patent 
strategies during product life cycle could affect formulary planning and managed care 
decisions. Berger et al. documented that patent protection is valid for 20 years at time of 
patent filing, out of which 10 years are spent in product development and regulatory 
review, and the remaining 7-10 years life at time of approval and commercialization 
phase. 
Product differentiation. Schramm and Hu (2013) reviewed the challenges that 
brand, generic and biosimular drugs companies were facing in the marketplace, 
associated with product launch strategies, positioning and patent expiries, exclusivity in 
the marketplace and the return on investment. Schramm and Hu described the impact and 
addressed the importance of product differentiation in the pharmaceutical sector, defined 
as developing new product with existing molecule with an objective to increase patient 
convenience, or improve drug efficacy and safety profile, or find new usage. Schramm 
and Hu summarized that at times when development costs are increasing and the research 
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and development of new drugs activities are decreasing, development of differentiated 
products could be a successful strategy to extend the life of a molecule and help increase 
company profitability.  
Product line extensions. Kalepu and Nekkanti (2015) examined the use of 
product line extensions as a strategy to maximize profits and extend the life of the 
molecule in the pharmaceutical industry. Kalepu and Nekkanti found that line extensions 
have the potential to expend a market, cannibalize sales from an older generation market, 
earn considerable revenues, and increase the market share after patent expiration and the 
establishment of a generic market segment. Song and Han (2016) investigated the 
relationship between sales and pricing associated with the competition, the timing of 
market entry and the effects on market shares, the legal regulations for line extensions, 
and the exclusivity of line extensions. 
Authorized generic drugs. Appelt (2015) assessed the impact of authorized 
generic entry on generic entry post patent expiry between 2002 and 2007. Appelt 
documented organizational leaders of innovator companies that market brand-name drugs 
could introduce authorized generic drugs through their generic drug division or a generic 
drug subsidiary that markets a generic version of a brand-name drug prior to loss of 
exclusivity as a means to fight competition. Appelt argued that authorized generics 
entrants directly compete with generic entry post patent expiry, enter the market prior to 
generic entrants and capture larger market share. Appelt emphasized the importance of a 
robust product portfolio and found that brand-name companies with noncore products in 
years prior to patent expiry were more likely to launch authorized generics, and had no 
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significant impact on the likelihood of generic drug entrant entering the market and the 
number of generic entrants. 
Price. Iacocca, Sawhill, and Zhao (2013) examined the pricing of brand-name 
prescription drugs. Iacocca et al. focused on (a) the effects of the competition, (b) the age 
of the drug, (c) the manufacturer, and (d) the therapeutic purpose, and their effects on the 
pricing. Iacocca et al. collected data from 598 commonly prescribed brand prescription 
drugs in a chain store in the United States. Iacocca et al. found that (a) the number of 
brand drugs and the number of generic drugs within a therapeutic class do not explain the 
price of a brand drug; (b) newer drugs were associated with higher prices; the drug prices 
and the dozing levels had a positive correlation (for example, prices decreased as dosing 
levels increased); (c) drugs that treat uncommon and life-threatening conditions were 
priced significantly higher than drugs that threat common and non-life-threatening 
conditions; and (d) the prices among manufacturers differed. Iacocca et al. documented 
that drug efficacy, side effects, advertising costs, the production costs or supply chain 
processes might influence the manufacturer pricing decisions. Iacocca et al. did not find 
evidence to explain drug price variations. Iacocca et al. found evidence to explain what 
variables could be used to explain variations in drug prices.  
Kanavos (2014) examined the price dynamics of brand-name prescription drugs 
following generic entry and competition. Kanavos discussed the market dynamics post-
patent expiry. Kanavos obtained data from 101 molecules with expired patents for period 
1998–2010. Kanavos found that generic entry did not lead to lower brand-name 
prescription drug prices, the price elasticity of demand was low, and that even though the 
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market share of the brand-name prescription drugs eroded post-patent expiry following 
generic entry, a small market share remained. Kanavos also found that the number of 
competitors affected the prices, and the competition from generic entries does not 
necessarily lead to decreases in prices of brand-name drugs. 
Van der Shans et al. (2017) examined the impact of price erosion on the cost 
effectiveness of new therapies in the chronic obstructive pulmonary disease market, as a 
result of market competition and loss of exclusivity. Van der Shans et al. discussed the 
market nature and the pricing patterns of available treatments for lung-related chronic 
conditions. Van der Shans et al. identified the following factors influencing the minimum 
new product price: the cost of capital, the cost of regulation, the market size, the patent 
time, and the speed of market introduction. Using the cost effectiveness model, Van der 
Shans et al. computed the cost effectiveness of each drug compared to their substitutes, 
and discussed the observed price trends. Van der Shans et al. found that even though 
prices decreased over time, the potential for price erosion was dependent on the market 
characteristics, such as the improvements in clinical effectiveness, the changing price of 
competitive products, the number of competitors, the launch of new drugs, and the degree 
of generic introduction.  
Promotion and advertising. Datta and Dave (2017) examined the effects of 
promotion on physicians’ prescribing behavior. Datta and Dave documented that 
promotional instruments include direct to consumer advertising via print media or 
broadcast, advertising in professional journals, and direct to physician promotions 
through detailing and sampling. Datta and Dave documented that detailing and sampling 
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accounted for 83% of the pharmaceutical budget. Datta and Dave found detailing impacts 
the prescribing on the promoted brand drug and does not impact the number of the scripts 
within the therapy class.  
Similarly, Haughton et al. (2015) examined the marketing efforts across various 
stages of product life cycle on large number of pharmaceutical brands and their effects on 
price elasticity of demand and sales. Haughton et al. documented that new product 
introductions and innovations require substantial marketing efforts, regardless of the 
effects, and proposed diffusion of innovation model to model the effect of pharmaceutical 
marketing efforts with emphasis on promotional instruments, such as detailing, and 
medical journal advertising. Haughton et al. found that marketing efforts differ across 
product life cycle stages. 
Ruiz-Conde, Wieringa, and Leeflang (2014) examined the effectiveness of 
pharmaceutical marketing focusing on detailing, sales, and new development products, 
and the impact of scientific reviews on sales and marketing expenditures. Ruiz-Conde et 
al. noted that the pharmaceutical industry spent $10.7 billion on promotions, and 
documented that the pharmaceutical industry is an important contributor to the health and 
prolonged lives of people. Ruiz-Conde et al. found that appropriate marketing spending 
strategy significantly influences product sales, the return on investment, market share, 
and the length of the stage of product life cycle. Ruiz-Conde et al. emphasized the need 
of marketing budget allocation, and implementation of different marketing strategies 
during stages of product life cycle. Ruiz-Conde et al. suggested investment in marketing 
activities directed to the physician in the first 12 months after new product introduction to 
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increase the trial rate, and decline in spend during maturity stage and increase of return 
on investment.  
Schulz et al. (2014) examined the marketing efforts of pharmaceutical sales 
representatives directed at the physician (detailing, product information included with the 
medication, and product information provided by the sales representative) and marketing 
efforts directed at the patient (direct-to-consumer advertising), and their impact on the 
sales and the demand of branded prescription drugs in the United States. Schulz et al. 
documented that the effects of the marketing efforts on the demand are small and depend 
on the product market characteristics. Schulz et al. asserted that detailing was the main 
driver for demand, followed by product information provided by the sales representative, 
and DTC advertising. Schulz et al. also documented that detailing is more effective tool 
to drive demand compared to direct-to-consumer advertising.  
Ju and Park (2015) examined the use of marketing communication strategies 
focusing on direct to consumer advertising strategies, messaging, and spending. Ju and 
Park identified the following factors that influence advertising: the product life cycle, the 
market characteristics and the market size, the product attributes and usage, and the 
purpose of the treatment (continuous, occasional, or repetitive use). Ju and Park 
documented that advertisement expenditures depend on the competitiveness within a 
therapy class, and the return on investment on sales during the life cycle of brand 
prescription drugs. Ju and Park noted direct to consumer advertising is effective 
marketing tool for a brand recall and raising awareness. Ju and Park found strong 
relationship between communication strategies and therapeutic categories, different 
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levels of spending across different therapy classes. Ju and Park suggested factors, such 
as- the competitive environment and the stage of the product life cycle, need to be taken 
into consideration when creating marketing communications strategy for a product. 
Market dynamics. The health care industry accounted for 17.5% of the gross 
national product in 2014 in the United States, and the expenditures for pharmaceuticals 
represented 12.2% of the total health care expenditures in 2014 (Martin et al., 2016). 
Prescription sales accounted for $448.2 billion in 2016 in the United States, an increase 
of 5.8% compared with 2015, driven by the increased prices of existing products, 
spending on new products, and the volume of drug utilization and mix (Schumock et al., 
2017). Schumock et al. provided a framework for projecting medicines expenditures in 
the United States that captured the impact of patent expirations, new product launches, 
the regulatory, industry, and market developments. The basis for the projections of 
medicines expenditures included historical trends, knowledge of the life cycle of existing 
products, and R&D pipelines or new product launches.  
Berndt, Nass, Kleinrock, and Aitken (2015) discussed the sales and economic and 
financial returns in the pharmaceutical industry. Berndt et al. analyzed the economic 
returns of prescription drugs launched in period 1991-2009, and compared revenue 
fluctuations over time to determine patterns in sales and profits from pharmaceutical 
innovation. Berndt et al. demonstrated that present value of lifetime net economic returns 
reached peak and upward trend in sales in period 1995-2004, and then declined in period 
2005-2009 as a result of rising R&D costs and decline in demand growth. Berndt et al. 
concluded that pharmaceutical companies will not be able to maintain the rates of 
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investment needed to innovate, and documented the need for changes in health policy or 
business models to find new streams of profit.  
Supply side and demand side factors. Lee, Bloor, Hewitt, and  Maynard (2015) 
evaluated the supply side and demand side factors and their influence on the marketing 
strategies. Lee et al. documented the following supply side factors: (a) industry regulation 
(government price control intervention, market authorization procedures and the health 
care reimbursement plans, and patent expiry), (b) the effects of educational approaches, 
drug samples and generic substitution targeting physicians’ prescribing behaviors, and (c) 
the effects of reimbursement programs and savings account plans, physicians’ prescribing 
behavior targeting patients. Lee et al. identified the characteristics of prescribing 
physicians and the targeted customers (such as their attitudes, beliefs and preferences, 
number and size, purchase frequency, sensitivity and responsiveness to various marketing 
instruments, and history of past behavior) as demand side factors.  
Similarly, Rémuzat et al. (2017) documented reimbursement plans and reference 
pricing, and government price control intervention and price reevaluation as supply side 
factors. Rémuzat et al. documented the following demand side factors: (a) policies 
directed to physicians (such as prescription quota, monitoring of drug prescriptions, drug 
substitutions, and publications, education, and information), (b) policies directed to 
pharmacists related to drug substitutions, and (c) policies directed to patients (such as 
healthcare plans, and information and education). Kalcheva, McLemore, and Pant (2018) 
examined the supply side and demand side factors and their effects on innovation. 
Kalcheva et al. identified the following supply side factors: (a) the characteristics of the 
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industry (such as industry growth rate, entry and exit barriers, the characteristics of the 
focal business, competitors’ characteristics, and history of past behavior), (b) the 
characteristics of the organization (such as resources and skills), and (c) the 
characteristics of the product offerings and services offerings. 
Dunne and Dunne (2015) evaluated the developments in the demand side of the 
market for pharmaceuticals over the past several decades focusing on the physicians, 
pharmacists, and patients. Dunne and Dunne evaluated (a) the relationship between the 
insurance coverage and sales throughout product life cycle, and (b) the dynamics of the 
generic competition. Dunne and Dunne published that the increased insurance coverage 
can impact product sales. Dunne and Dunne further argued that the primary objective of 
the actors within managed care organizations were to actively manage drug benefits to 
switch individuals to lower cost alternatives, and encourage the use of generic 
prescription drugs when they become available for a branded product with the same 
active ingredient through benefit management techniques, such as tiered formularies, 
prior authorization, step edits, and higher fees to pharmacists for dispensing generics. 
Dunne and Dunne documented in the United States, payers used the generic competition 
as a primary cost containment mechanism to achieve prescription drug expenditure 
savings.  
Competition strategies. Organizational leaders within pharmaceutical companies 
need to monitor the competition to determine the industry profitability and growth. Using 
the Porter’s five forces for competitive analysis (Porter, 1985), Schramm and Hu (2013) 
identified the strong buyer power, strong supplier power, low entry barriers and intense 
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competition as forces that are shaping the pharmaceutical industry. Liao et al. (2015) 
discussed strategies to achieve competitive advantage and documented that organizations 
build competitive advantage through innovation and effective market engagement. 
Kelton et al. (2014) examined the trends in drug reimbursement by Medicaid 
programs following patent expirations, post generic entries, for numerous therapeutic 
classes. Kelton et al. researched the relationship and interactions among generic 
prescription medicine entry, prices, and market shares. Kelton et al. documented that 
generic share and price are simultaneously determined, while the number of generic 
entrants is a key determinant of generic market share and the generic-to-brand price ratio. 
Kelton et al. showed that brand prices react to generic competition and each additional 
entrant was associated with a decline in brand prices. Kelton et al. also found that the 
reimbursement for branded drugs post generic entry significantly reduced, the number of 
generic entrants influenced the percent of the reimbursement reduction, and that the 
reimbursement for branded drugs after patent expiration decreased for 2% per quarter. 
Kelton et al. concluded that the health care reimbursement programs have been able to 
provide a relief from higher drug prices for branded medications following patent 
expirations by adjusting the reimbursement for the branded drugs. 
Dunne and Dunne (2015) observed the dynamics of generic competition and 
found the following: (a) high generic utilization of commercially significant products 
after patent expiration; (b) a strong positive relationship between the number of generic 
entrants and the intensity of generic price competition; and (c) the more generic entrants, 
the more rapid the erosion in the brand product market share in units in favor to generics. 
57 
 
 
Duflos and Lichtenberg (2012) discussed strategies that organizational leaders are 
implementing for branded name drugs following patent expiration, such as market 
segmentation strategy focusing on small fraction of customers who are not prices 
sensitive, and price increases over time.  
Tenn and Wendling (2014) researched the determinants of generic entries and 
their impact on the brand sales. Tenn and Wendling examined the following key areas 
that affect the way the generic entry and the patent expiry impact on the market: (a) the 
prescribing environment, the regulatory environment, and the health insurance coverage; 
(b) the market size; and (c) the pre-patent expiry environment and bioequivalence testing. 
Variables used in the study were: product sales, price, and the age of the molecule. Tenn 
and Wendling found that both the generic entry, and the leg between the generic entry 
and patent expiry were linked to the market size at patent expiry. Tenn and Wendling also 
found that the speed of which brand sales decreased was directly proportional to the 
market size and the price of the brand prior to generic entry. Tenn and Wendling 
concluded that products that generated higher sales attracted generic competition and 
emphasized the importance of the market size. 
Duflos and Lichtenberg (2012) examined the effect of competition on the drug 
prices, marketing expenditures, and drug utilization in the United States. Duflos and 
Lichtenberg discussed the dynamic nature of the industry, market exclusivity, and the 
market structure. Duflos and Lichtenberg observed rapid increase in the generic market 
shares after the Hatch Waxman Act, and concluded that the policy makers achieved their 
primary objective, that was facilitating availability of low priced drugs after patent 
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expiration. The results reflected the insurance arrangements and the regulatory or legal 
framework relevant to the United States territory. Duflos and Lichtenberg found (a) price 
and marketing expenditure declined by 50 to 60% in periods following generic market 
entry, and (b) increased utilization in the generic drugs, and reduced utilization of 
branded prescriptions after patent expiration, while the number of prescriptions remained 
constant during the same period. Duflos and Lichtenberg concluded that the competition 
from generics does not appear to have an effect on the drug utilization, controlling for 
price and marketing. Duflos and Lichtenberg also found (a) a strong inverse relationship 
between changes in the generic drugs’ market share and changes in manufacturers and 
wholesalers’ revenues, consistent with the age profiles of the generic drugs’ market share, 
and price; (b) the changes in market structure may cause changes in utilization levels of 
other drugs within the same therapeutic area; and (c) marketing has significant impact on 
utilization.  
Kang and Montoya (2014) discussed the trends in pharmaceutical innovation and 
the impact of competition in the marketplace. Kang and Montoya also discussed the 
management of the product portfolio and the product life cycle management, the product 
development, the market entry, the market dynamics, and the competitive environment 
within the industry. Kang and Montoya documented that competitive strategy determines 
the value of innovation, and that the competitive strategy is determined by the product 
portfolio selection. Kang and Montoya provided examples of the product life cycle 
management, discussed strategies to increase the market life of existing products, and 
realignments of business models to increase profitability. Kang and Montoya documented 
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that in order to achieve organizations’ financial goals and remain competitive in the 
marketplace in the long-run, pharmaceutical manufacturers need to continue investing in 
research and development, and launch of new brands, while realigning their current 
business models to increase profitability, increase capacity in manufacturing, or reduce 
costs. 
Camejo et al. (2013) examined the relationship between the pharmaceutical price 
regulation and industry’s investment in research and development, and presented a 
theoretical structure of the dynamics between competition, pharmaceutical research, and 
cost effectiveness on lipid-lowering therapies. Camejo et al. discussed the competitive 
environment when a new drug enters the market, and identified two different types of 
competitors: (a) close substitutes from brand named drugs, and (b) generic products after 
patent expiration. Camejo, Miraldo, and Rutten (2017) discussed the justification of the 
investment in research and development using the cost effectiveness model to reflect the 
opportunity costs, and noted several business practices in place. Camejo et al. 
documented that organizational leaders may be looking into the clinical effectiveness and 
the costs of new technology compared to the close substitutes available in the 
marketplace, or other product characteristics (such as safety, tolerability, cost savings, or 
efficiency of application) during the decision-making process for investment in new 
technology or product.  
Frank and Hartman (2015) discussed the competitive environment within the 
pharmaceutical industry and the increased competition between brand drug 
manufacturers and generic drug manufacturers. Frank and Hartman evaluated the impact 
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of generic drug launch on the product price, and documented a shift in demand to the 
generic, and a major decline in prices. Frank and Hartman discussed the product 
differentiation strategies that brand drug manufacturers are pursuing to fight competition 
and retain their market shares, such as product differentiation, product line extensions, or 
offering new treatments. Frank and Hartman documented that brand drug manufacturers 
compete on product attributes and invest in marketing efforts to promote those attributes 
rather than price. Frank and Hartman asserted that generic drug manufacturers need to 
monitor and understand the defensive marketing strategies that brand drug manufacturers 
are implementing in order to identify market opportunities and successfully launch new 
products.  
Rusu et al. (2011) discussed the strategies that marketing leaders within the 
prescription brand medicines segment are implementing to fight generic competition by 
using patents and litigation. Rusu et al. documented that patents could be extended 
through effective product life cycle management that includes applying for additional 
patents to cover formulation, composition, indication, or modes of administration, 
launching generic versions of the medicines after patent expiration, etc. Chao, Hu, Zhang, 
and Wu (2014) discussed the strategies applied before and after patent expiration of 
Lipitor® (atorvastatin calcium), a brand medicine used to lower cholesterol in the blood. 
Chao et al. documented the following before patent expiration strategies: (a) direct to 
consumer advertising, (b) pricing strategy, and (c) launch of reformulations, and after 
expiration strategies: (a) change to over the counter, (b) launch of authorized generic, (c) 
rebate strategy, and (d) continuous marketing for brand. 
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Timing of market entry. Smith (2012) conducted case study research to examine 
the market access strategies in the pharmaceutical industry and medical devices, and 
identified the factors influencing the market access strategies. Smith argued that the 
market access determines the success or failure of any new pharmaceutical or medical 
technology to a large degree, and defined market access strategy as a pattern of resource 
allocation and activity decisions about what health economic value proposition to make 
to the market, and which audiences within the market access the decision-making process 
to whom to address that proposition. Smith identified the following nine differentiating 
areas of a market access strategy that managers need to be aware of: (a) heterogeneity 
within the marketing environment, (b) resource allocation choice between alternatives, 
(c) the offering of payer-perceived economic value to each targeted segment within the 
market, (d) anticipated change in the market, (e) alignment to the strengths and 
weaknesses of the product and organization, (f) alignment with the organization’s 
corporate strategies, (g) alignment with the organization’s  marketing strategies and 
goals, (h) support management of the product life cycle, and (i) alignment with the 
organizations’ financial goals.  
Fatokun, Ibrahim, and Hassali (2016) conducted quantitative research to assess 
the factors determining the market entry of a new generic medicine following patent 
expiration in Malaysia. Fatokun et al. provided an overview of the pharmaceutical 
industry in Malaysia, the generic prescription medicines availability, and the regulatory 
environment, and documented the need for development and introduction of generic 
prescription medicines in the Malaysian market to reduce the rising pharmaceutical 
62 
 
 
expenditures, and reduce the patients’ costs. Fatokun et al. identified the following 
factors influencing the generic prescription medicines availability: the market 
characteristics, the behavior of branded prescription medicine businesses, and the 
existence of incentives to promote development, production and marketing of generic 
prescription medicines. Fatokun et al. found the following: the major factor influencing 
entry decisions for domestic market-oriented generic prescription medicine businesses as 
compared with export-oriented organizations was the pre-patent expiration market value 
of the branded medicine, followed by patent clustering by branded prescription medicine 
businesses, and the earlier market entry of imported generic medicines. Fatokun et al. 
showed that the major factors driving decisions to develop and introduce a new generic 
medicine into the Malaysian pharmaceutical market were consistent with the business 
model of the generic pharmaceutical industry.  
Stros and Lee (2015) examined how order-of-market entry affects the level of 
sales of prescription medicines. Stros and Lee evaluated the impact of marketing 
activities on pharmaceutical sales, focusing on (a) product (innovativeness, 
differentiation, quality, branding, and packaging), (b) price, (c) promotion (personal 
selling, advertising, word-of-mouth, and sampling), (d) distribution, and (e) order-of-
entry effects (first entrant, early market entry, late market entry, and market share). Stros 
and Lee discussed the application of the product life cycle model on the management of 
the marketing efforts for brand and generic prescription medicines, and the competitive 
environment and dynamics during drug life cycle from the moment of market 
introduction. Stros and Lee documented that marketing-mix effectiveness varies over 
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time, and that organizational leaders need to tailor their marketing strategies to the market 
requirements.  
Stros and Lee (2015) argued that early market entry strategy is characterized by 
relatively high advertising elasticity because of the many new customers in search of 
product information, while in the mature stage, many customers perform repeat purchases 
and have substantial experience with the product, resulting in lower information needs 
and increased price sensitivity. Stros and Lee documented that product design is critical 
determinant of the product sales for both early and late market entrants, where early 
market entrants are associated with innovativeness, while late market entrants are 
characterized by implementation of a differentiated product strategy, lower promotional 
costs, and lower price to gain market share. Stros and Lee recommended monitoring and 
allocations in marketing expenditures over time after product introductions to the market, 
and monitoring of the competitive environment, to achieve organizations’ financial goals. 
Stros and Lee provided guidelines to organizational leaders regarding order-of-market 
entry, and recommended consideration of (a) the governmental approval status, (b) the 
company’s and the competitors’ medical drug research status and progress, and (c) the 
company’s strategic decisions regarding market entry.    
Similarly, Ridley and Régnier (2016) evaluated the impact of timing of market 
entry on product sales focusing on order-of-market entry, therapeutic advantage, market 
share, and number of competitors. Ridley and Régnier analyzed 44 drugs that were 
approved during 2007 and 2009. Ridley and Régnier found that launch speed and 
therapeutic value impact product sales. Ridley and Régnier documented that first market 
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entrants with high therapeutic value achieved highest sales and market shares followed by 
second entrants and additional followers, and that late entrants with therapeutic value 
higher than first entrants outperformed the competitors in terms of product sales and 
market shares. Alt and Helmstädter (2018) examined the timing of market entry focusing 
on the therapeutic advantage and found that first market entrants are not most successful 
in the marketplace, and that later entrant with better product attributes and therapy 
advantage could have better market success. 
DiMasi and Chakravarthy (2016) examined the market entry of innovative drugs 
and the timing of patent filings. DiMasi and Chakravarthy analyzed data of drugs 
approved for marketing in the United States from 43 therapeutic classes during 1998 and 
2008, focusing on the timing of market entry and the timing of patent filings. DiMasi and 
Chakravarthy documented that the second entrant entered the market 2.7 years later after 
the first market entrant, while other molecules were still in development phase.  
Min, Kim, and Zhan (2017) examined the impact of market size on market entry. 
Min et al. discussed the relationship between market size the profit potential for market 
entrants post entry and documented that the market size does not always drive decisions 
on market entry. Min et al. identified market characteristics and organizational 
characteristics as factors influencing the decisions on market entry.  
Andrade, Sermet, and Pichetti (2016) examined the market access and order of 
market entry of pharmaceutical organizations in complex environments. Andrade et al. 
focused on the main obstacles of the market access, the market access performance 
evaluation, and the investment during various phases of the product life cycle. Andrade et 
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al. provided an overview of the pharmaceutical industry, the regulatory environment, the 
environmental dynamics, and the challenges that business leaders within pharmaceutical 
organizations are facing in the marketplace. Andrade et al. found that the market access 
was associated with (a) pricing and reimbursement, (b) evidence of the product value, 
and (c) the economic and the financial returns. Andrade et al. also found that the 
investment in market access was highest during the earlier phases of product life cycle, 
such as: (a) the phase before product introduction when pricing and reimbursement 
options were negotiated with the national Drug Agency, (b) the phase before product life 
cycle when the access to formularies was managed, and (c) during commercialization. 
Andrade et al. noted time to market, product introduction, and market penetration were 
the most used criteria to evaluate the market performance, and critical to achieve sales 
and revenue generation.  
Yu and Gupta (2014) examined the competition among generic entrants in the 
first three years of sales after patent expiration, focusing on the effects of timing of 
market entry. Yu and Gupta included the effects of detailing, distribution of free samples, 
prices, journal advertising, and molecule characteristics. Yu and Gupta found that generic 
entrants that launched products earlier achieved greater sales, market shares, and profits, 
compared to the entrants that launched second or third, and demonstrated that timing of 
market entry had a significant influence on sales, and market share.  
Measuring marketing value. Liao et al. (2015) noted the primary source of 
competitive advantage in business-to-business relationships is through coordination of 
complex networks of company activities and relationships. Liao et al. documented that 
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the relationships among organizational performance, organizational resources, and 
strategies, interrelate with the external environment and influence the organizational 
financial success. Organizational leaders are increasingly aligning their activities around 
the customer (Nenonen & Storbacka, 2014). Organizational leaders need to measure the 
return on marketing investment on the organizational performance including value 
creation for customers and suppliers, brand equity and customer equity.  
Kumar (2015) evaluated the investment in marketing activities as a strategic 
orientation and as a source of sustainable competitive advantage in changing business 
environments focusing on the customer. Kumar suggested managers identify and 
implement strategic orientations that enable the organization to sustain performance, 
especially in rapidly changing market conditions. Kumar discussed the evolution of 
marketing, and documented that investment in marketing activities is an organization’s 
capability necessary for long-term performance, developed through superior 
understanding of customer needs, market actions, and competitive actions. Kumar 
focused on marketing effectiveness and efficiency, organization’s value through customer 
engagements, and technological developments. Kumar found that investment in 
marketing activities had a positive effect on organization’s performance in short-term and 
long-term period, and that the advantage, profit and sales generation was greater in 
organizations with integrated marketing. 
Customer lifetime value model. Nenonen and Storbacka (2014) defined the 
customer lifetime value model as a measure in the customer’ selection process used to 
identify high profit customers and to improve the customer relationships through 
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marketing resources allocation across marketing communication channels and customers. 
Nenonen and Storbacka provided evidence to support the positive relationship between 
the customer lifetime value model and organizational and customer value creation. In 
their later study, Nenonen and Storbacka (2016) examined the relationship between 
market action and shareholder value, and showed that marketing activities influence the 
organizational performance. Nenonen and Storbacka focused on the following variables: 
(a) marketing strategies and tactics, (b) customer impact, (c) marketing assets, (d) market 
impact, (e) impact of the value on the organization, (f) competition, and (g) environment. 
Nenonen and Storbacka documented that organizational leaders need to have both 
financial and nonfinancial metrics in place to measure the return on marketing 
investment, and to develop distinct long-term and short-term marketing goals and 
programs to increase the customer equity. Nenonen and Storbacka asserted organizational 
leaders could use the findings from the existing literature relative to the value creation as 
an input in creating and executing effective marketing programs through different 
channels of communications to further differentiate in the marketplace and increase the 
collaboration in relationship marketing.  
Corporate reputation. Erden, Klang, Sydler, and Von Krogh (2015) examined the 
relationship between corporate reputation focusing on knowledge stocks and 
organizational performance in the pharmaceutical industry. Erden et al. asserted that 
corporate reputation is a belief about organizations' past and future actions that shape 
how stakeholders interact with them, and provides the organizations with a competitive 
advantage in the marketplace. Erden et al. found that the favorable reputation through 
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knowledge stocks increases the revenue generation, and that the benefits of knowledge 
stocks result from continuously filing patents. Erden et al. documented that corporate 
reputation is a tool to acquire and retain customers, investors and employees.  
Chen et al. (2016) conducted qualitative study through interviews to explore the 
effects of corporate reputation on brand image strategy. Chen et al. identified these uses 
of corporate reputation: (a) corporate communication, used to develop relationship with 
stakeholders, (b) value creation, used as an intangible asset to create value in the future, 
and (b) strategic resources, used to influence the competition. Chen et al. asserted 
organizational leaders use corporate reputation to improve their brand segmentation, 
positioning and differentiation strategies.  
Patent-based measures. Wagner and Wakerman (2016) documented that 
organizational leaders use patent-based indicators to measure innovation and the 
outcomes from the innovation, focusing on product quality, the economic importance of 
the treated decease and the problem it solves, and the patent protection process. Wagner 
and Wakerman found that the number of patent applications and product family size 
correlate positively with the speed of product launch, and negatively with pre-clinical 
trials. Wagner and Wakerman provided evidence and explained that in a situation of 
uncertainty during the patenting process, organizational leaders postpone their decisions 
regarding development products until the uncertainty is resolved and patent granted, 
which in turn, speeds up the process of product commercialization.  
Chen et al. (2014) examined the relationship between corporate market value, and 
patent quality indicators, such as patent position, and technology advantage in the U.S. 
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pharmaceutical industry. Chen et al. found a positive relationship between market value 
and patents. Chen et al. showed the market value of pharmaceutical companies with high 
patent counts was higher than the market value of pharmaceutical companies with low 
patent counts. Chen et al. recommended organizational leaders should invest in 
technology, and increase the innovative value of their patents and their potential in order 
to gain competitive advantage.  
Challenges in the business models and product life cycle management. Rusu 
et al. (2011) examined the current business models and practices of four largest 
pharmaceutical companies worldwide, based on revenues reported in 2010. Rusu et al. 
identified and discussed key areas and strategic initiatives that marketing leaders employ 
in business practices that define organizations’ business models. The key areas of focus 
included: (a) offerings (for example, service model vs therapies), (b) the target markets 
(mass market vs niche), and (c) the organization (through making connections vs 
integration), while the strategic initiatives include (a) innovation path (by incorporating 
minimum changes in high risk, high margin model), (b) integration path (focusing on the 
heath care value chain model) , and (c) de-risk path (by redirecting the efforts to less 
regulated markets, such as consumer health markets). Rusu et al. identified the social 
corporate responsibility as a major challenge in the business models that organizational 
leaders are facing, that includes the way drugs are developed, marketed, and used (Rusu 
et al., 2011), and could have potential impact on the revenues. Rusu et al. recommended 
continuous revision of organizations’ social corporate responsibility policies to meet the 
changing needs of the stakeholders and the marketplace. 
70 
 
 
Sabatier et al. (2012) conducted qualitative case study research through interviews 
to explore the impact of technological discontinuation on the business models in the 
pharmaceutical industry. Sabatier et al. identified the following factors that trigger 
disruption in business models: (a) transformations in the health care system (personalized 
medicine, shift from product to service logic, or nanobiotechnology), (b) introduction of 
new ways of collaboration (new ways to innovate, new ways to lower the costs of drugs, 
or new market entrants from other industries), (c) changes in current business practices 
(for example, emergence of innovation networks formed by small actors). Sabatier et al. 
documented that the patent expiry period and the introduction of low cost generic drugs 
are major challenges for brand drug prescription companies. Sabatier et al. documented 
that change in technological discontinuities drives emergence of new business models, 
which in turn, transforms the dominant industry logic.  
Obeidat et al. (2017) conducted quantitative research through surveys to examine 
strategy implementation in the pharmaceutical industry in the Middle East. Obeidat 
documented that strategy is a tool organizational leaders use to conduct organizational 
operations, achieve organizational objectives, achieve position in the market, and gain 
competitive advantage in the marketplace. Obeidat et al. focused on the following factors 
affecting strategy implementation: operational planning, resource availability, people, 
communication, feedback, and control. Obeidat et al. found that resource availability was 
the most critical factor influencing successful strategy implementation. 
Kang and Montoya (2014) showed that the strategic alignment between 
organizational strategy, product development, and financial strategies has a significant 
71 
 
 
impact on profitability. Obeidat et al. (2017) suggested that the organizational leaders 
should align strategic functional level planning with business level planning within an 
organization. Similarly, Narayana, Prati, and Vrat (2014) documented that organizational 
leaders need to align and integrate the technical information, materials, finances, and 
order information to sustain in the marketplace success in the pharmaceutical business.  
Prajapati et al. (2013) identified and discussed various challenges in different 
phases of a product life cycle: (a) in product development phase: identification of high-
quality drugs, use of existing research, management of patent applications, and 
compilation of clinical trial results; (b) in approval phase: collecting and archiving 
documentation for regulatory approval, preparation for technology transfer, and 
management of agreements submittal and approval; (c) in product introduction phase: 
coordination of marketing, sales, and production to successfully launch the product on 
time, and preparation of new product supply; (d) in commercialization and quality 
management phase: management of product supply, labeling, and packaging, 
documentation compliance, and supplier audits; and (e) in product decline phase: product 
line extensions and generic competition entry. Prajapati et al. documented opportunities 
and key areas of focus in each phase of product life cycle to maximize the return of 
investment: the development phase is associated with opportunities for product 
enhancements through dosage form variations or design of technology, the product 
introduction phase is associated with opportunities for new product development and 
introduction processes, the commercialization and quality management phase is 
associated with opportunities for line extensions (new uses or indications) and 
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improvements in manufacturing processes, and the decline phase is associated with 
opportunities for patent extensions, pricing strategies, or switching products from 
prescription to over-the-counter medications. Prajapati et al. asserted that development of 
a successful product life cycle management requires coordination of information from 
multiple sources, such as product information, patent knowledge, competition, 
manufacturing, and sales and distribution. 
Patent challenges. Song and Han (2016) examined current business models of 
organizations within the pharmaceutical industry and challenges associated with loss of 
patent protection. Song and Han documented that the current business models of 
innovator organizations are designed to lose core business and product portfolio every 
10-12 years after market entry, which could have a negative impact on the revenue sales 
and market performance, causing organizational leaders to look for new revenue streams, 
and mergers and acquisitions. Song and Han published drugs with more than a $100 
billion in sales will lose patent protection in the coming years, causing significant 
revenue losses and market position. Song and Han discussed the importance of 
development and implementation of different marketing strategies during various stages 
of the product life cycle to maximize the product lifetime value. 
Song and Han (2016) identified these strategic design possibilities during prior to 
loss of patent protection stage: the use of patent settlement agreements to prevent 
competition, innovation through product modifications, out-licensing to exploit the 
market conditions, and through strategic alliances with generic drug manufacturers to 
diversify the portfolio or enter a new generic market. Song and Haan documented the 
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following strategies during loss of patent protection stage: patent term restorations or 
clinical trials to prevent competition, innovation through introduction of new indications 
or new business models, continuation of the existing product lines and brand image to 
exploit market conditions, and launch of authorized generics to diversify the portfolio or 
enter a new generic market. Song and Haan documented the following strategies during 
post loss of patent protection stage: application for patent extensions to prevent 
competition, innovation through introduction of new indications, implementation of new 
business models, or switch of prescription to over-the-counter medicines, differentiation 
of the existing product line through brand advertising to exploit market conditions, and 
launch of secondary brands or authorized generics to diversify the portfolio or enter a 
new generic market. 
Similarly, Kakkar (2015) discussed strategies to mitigate the loss of revenues after 
patent expiry, such as launch of authorized generics, introduction of new indications and 
formulations, or price reductions. Kakkar identified the following factors that affect the 
strategy choices: the return on investment, product opportunities, and the competitive 
landscape. Kakkar documented the importance of thorough product life cycle 
management to extend the commercial life of a product, retain market position, and drive 
growth.  
Grabowski, DiMasi, and Long (2015) examined the causes and effects of patent 
challenges and their effect on the market life of drugs. Grabowski et al. discussed the 
regulatory framework within the industry, the rapidly changing environment and the 
industry trends, the increased competition, and the high development costs. Grabowski et 
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al. found that patent challenges are more common for higher revenue drugs. Grabowski et 
al. documented that organizational leaders use patenting strategies, new formulations, and 
other product line extensions to extend the length of market exclusivity for therapies 
facing generic drug competition. 
Similarly, Grabowski et al. (2014) examined the market exclusivity of new 
molecular entities, the generic drug market penetration, and the patent challenges under 
Paragraph IV of the Waxman Hatch act. Grabowski et al. investigated the impact of 
Paragraph IV decisions on the brand drug sales, and documented that Paragraph IV 
decisions determine whether a generic drug can enter the market prior to patent expiry 
date. Grabowski et al. discussed the regulatory environment in the United States, the 
Waxman Hatch Act and the Paragraph IV statute, the industry trends, and the barriers to 
entry for generic competitors.  
In a later study, Grabowski et al., (2016) found that the brand drugs rapidly lost 
sales after generic entry, and at least 94% of the new molecular entities accounting for 
$250 million in sales faced at least one Paragraph IV patent challenge from a generic 
drug manufacturer in 2013-2014. Grabowski et al. documented an increase in frequency 
of Paragraph IV patent challenges, earlier occurrences of patent challenges during the 
brand drug life cycle, and intensified generic drug market erosion over the last ten years. 
Grabowski et al. emphasized the need for strategies for both generic and brand name 
drugs.  
Branstetter, Chatterjee, and Higgins (2016) discussed the regulatory environment 
in the United States, the Waxman Hatch Act, and the Paragraph certification options for 
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generic manufacturers. Branstetter et al. explained the filing for Paragraph certifications 
and documented that Paragraph IV provides an opportunity for market exclusivity for 180 
days to generic manufacturers if their Abbreviated New Drug Applications (ANDAs) are 
FDA approved. Branstetter et al. documented that rapid decline in price and intensified 
competition from generic entries after the 180 day period, followed by rapid decline in 
brand sales and revenues, and loss of market share. Using data in period 2000-2008 for 
the hypertension market in the United States, Branstetter et al. documented that revenues 
of a branded product declined on an average 56% during the first year after Paragraph IV 
entry, and 89%. Branstetter et al. asserted reformulations (for example, extended release, 
or once per day therapy versions) could be effective tool for brand manufacturers to fight 
competition from generic entry following Paragraph IV approval. 
Managerial issues. Narayana et al. (2014) examined the managerial issues in the 
pharmaceutical industry globally, focusing on the non-behavioral issues in pricing, 
medical expenses, supply chain and operations and manufacturing, and behavioral issues 
on consumer-physician’s level. Narayana et al. discussed current trends in the 
pharmaceutical industry, and described the pharmaceutical industry as the complex of 
processes, operations, and organizations involved in the discovery, development, and 
manufacture of drugs and medications. Narayana et al. identified the following focus 
areas: improvement of efficiency and profitability, management of R&D through 
strategic relationships, improvement of technological competences, and effective 
management of business processes and knowledge. Narayana et al. emphasized the need 
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for integrated approach from drug discovery through commercialization to final 
consumption to improve strategic decision making. 
Similarly, Shabaninejad, Mehralian, Rashidian, Baratimarnani, and Rasekh (2014) 
assessed managerial issues in the pharmaceutical industry focusing on key factors that 
influence the competitiveness in the marketplace. Shabaninejad et al. documented that the 
pharmaceutical industry is characterized with intensified competition, strict regulations, 
long drug development processes, high levels of uncertainty in drug development 
processes, and high costs for research and development. Shabaninejad et al. identified the 
following factors that affect competitiveness: human capital, organizational practices, 
strategy and effectiveness, capability to innovate, market infrastructure, and the 
pharmaceutical regulation. Shabaninejad et al. emphasized the need for organizational 
leaders to recognize the factors affecting the current business models and competitiveness 
in the marketplace and recommended to include them in the decision-making processes 
and strategy planning. 
Drug shortages. Parsons et al. (2016) addressed the current trend of shortages of 
generic drugs where multiple therapeutic markets are affected as a critical challenge for 
the prescription drugs market. Parsons et al. discussed the multifactorial origins for short 
supply in the marketplace, the association between the number of suppliers and drug 
shortages, the impact on the patients, the regulatory environment in the United States, and 
the relationship among business practices, revenue generation, and the manufacture and 
marketing of prescription drugs, focusing on cancer drugs. Parsons et al. documented that 
drugs with a generic equivalent on the market were more likely to report drug shortages. 
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Parsons et al. emphasized the need of changes in the regulatory requirements, policies, 
and processes specific to generic drugs market segment, and the need for changes in 
organizations’ business models to meet the end customer needs.  
Transition and Summary 
The purpose of this qualitative case study was to explore the perspectives of 
business professionals, managers, involved in the decision-making process for 
development and implementation of marketing strategies on the marketing efforts during 
the management of product life cycle. Data were collected through semistructured 
interviews (face-to-face interviews and telephone interviews) and were analyzed using 
interpretative analysis. The central question in the study was: How do marketing 
managers within pharmaceutical companies pursue marketing during various stages of 
product life cycle? I examined the problem through the general systems theory and the 
evolutionary systems theory, focusing on the ongoing interactions between the complex 
systems (such as the organization, or the product life cycle) and its likewise complex 
operating environment.  
In Section 1 of the study, I provided the research problem, the purpose statement, 
the research question, the nature of the study, the significance of the study, the 
assumptions, limitations and delimitations, the conceptual framework, and the literature 
review. The literature review contained concise summaries of the literature in the area of 
marketing branded and generic prescription medicines, product life cycle management, 
market trends, and challenges of pharmaceutical organizations. In literature review, 
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different points of view were compared and contrasted, and the relationship of the study 
to previous research and findings was explained (Walden University, 2018). 
Section 2 of the study covered the details of the project, such as the role of the 
researcher, the participants in the study, the population and sampling, the ethical research, 
the research method and the research design, the data collection instruments, data 
analysis, and the data validation techniques. Section 3 of the study covered the 
presentation of findings, the application to professional practice, implications to social 
change, the recommendations for action and further study, and the reflections of my 
experience. 
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Section 2: The Project 
This section included a description of the role of the researcher, the participants in 
the study, population and sampling, ethical research, the research method and design, the 
data collection instruments and technique, the data organization technique, data analysis, 
and data reliability and validity. 
Purpose Statement 
The purpose of this qualitative case study was to explore the marketing efforts 
during various stages of product life cycle, determine the best practices to pursue 
marketing strategies, identify the factors that are strongly associated with the revenue 
generation and market shares, and the challenges associated with marketing strategy 
implementation in the pharmaceutical industry. I collected data through in-depth, 
semistructured interviews (face-to-face interviews and telephone interviews), and 
analyzed the data. A qualitative case study description of the participants’ experiences 
and views was developed by asking the participants to share their personal lived 
experiences related to marketing strategy development and implementation. The scope of 
the study was in central Ohio. 
Role of the Researcher 
The role of the researcher in qualitative case study research was to gain deep 
understanding of the topic under study through the participants’ views and experiences 
(Fusch & Ness, 2015). Fusch and Ness (2015), and Haahr, Norlyk, and Hall (2014) 
documented that the researcher is a key instrument to collect data who interacts with the 
participants to obtain rich data regarding their experiences relative to the problem under 
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investigation. Cridland, Jones, Caputi, and Magee (2015) documented that the researcher 
facilitates the flow of communication, identifies cues, and selects the participants in the 
study. Cridland et al., and Darawsheh (2014) documented that the role of the researcher is 
to collect, organize, and analyze the data to gain understanding of the topic under study. 
Collins and Cooper (2014) and Roulston and Shelton (2015) also documented that the 
researchers are the main instruments in obtaining data from the participants in the study 
and added instrumentation rigor and bias management are major challenges that 
researchers face in conducting qualitative research through interviewing as a data 
generation method. However, the researcher as instrument might affect the 
trustworthiness and the quality of the research study (Collins & Cooper, 2014; Elo et al., 
2014). My role in the data collection and analysis was to serve as a key instrument to 
collect, organize, and analyze data to capture the meaning of business practices in 
marketing of prescription medicines within the pharmaceutical industry as described by 
the participants. 
I used multiple methods to collect data, including interviews with the participants 
and a review of secondary data sources. I used semistructured open-ended interview 
questions as shown in Appendix B during the interview process. Yin (2017) documented 
that the use of open-ended questions in qualitative studies can provide flexibility and 
clarity and encourage complete answers. The review of secondary data sources included a 
review of company documents available on public websites and government databases. 
The documentation included a review of annual reports, press releases, and marketing 
materials related to the implemented marketing strategies, corporate business strategies, 
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and the product life cycle management and their impact on the market performance in 
terms of sales and innovation. The review of archival records located on government 
websites included a review of data on industry developments, industry news, information 
about drugs, etc. 
The Belmont Report contains guidelines and basic ethical principles to protect 
human subjects and requires researchers to (a) treat all persons with respect, (b) treat all 
persons in an ethical manner, and (c) treat all persons with justice (Office of National 
Research Protection, 2018). I adhered to the guidelines established in the Belmont Report. 
I treated each participant in an ethical manner and with respect while I adhered to justice 
during the research. 
Following the principles of case study research design, my role was to explore the 
participants’ views and experiences by attempting to understand and interpret their 
perspectives on marketing strategy during various stages of product life cycle of 
prescription medicines. Darawsheh (2014) documented that the interpretivist inquiry 
allows the researcher to view the topic under investigation holistically, get close to the 
participants, and interpret their views and experiences of the research problem as 
appropriate. In data collection, I engaged in active interaction with the participants during 
the interviewing process. In data analysis, I interacted with the participants to obtain their 
feedback on my interpretation of their experiences.  
De Massis and Kotlar (2014) addressed the importance of recognizing and 
controlling for bias during the interviewing and the research process. I recognized the 
active role in data collection and interpretation might result in potential bias. The 
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relationship between the researcher and the participants during the data collection process 
might raise ethical issues that needed to be addressed. I adhered to the ethical standards 
throughout the entire research process by following the Walden University’s procedures 
and policies. I attempted to maintain objectivity by monitoring my subjectivity during 
and the research process and maintain self-awareness.  
To maintain confidentiality of the participants in the study, I followed the 
following steps: (a) the participants’ identities were known only to me; (b) the electronic 
communications were stored in an email account accessible only by me; (c) the 
recordings and the written communications were stored in a locked cabinet accessible 
only by me; and (d) the computer used to store, organize, and analyze the data collected 
was accessed only by me. In facilitating the interviews, I followed the interview protocol 
(see Appendix C) to guide me through the interview process and remain within the 
bounds of the interview process. I introduced myself, notified the participants that I will 
be taking notes, and that the conversations will be recorded during the interviews. I then 
verbally went through the informed consent form at the beginning of each interview. I 
received the participants’ consent via emailing prior to scheduling the interviews with the 
participants.  
Participants 
The participants in the study were business professionals, managers, who have 
experience with development and implementation of marketing strategies, working in an 
organization that has been in business for more than 10 years within the pharmaceutical 
industry in central Ohio. The participants were middle managers who held positions as 
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product managers, brand managers, marketing managers, directors within marketing and 
sales, sales managers, or pharmaceutical marketing consultants. Quy Nguyen, Corley, 
and Kraatz (2014) documented that middle managers usually hold positions two levels 
below the CEO of an organization. Mullins et al. (2010) documented that the title 
marketing manager is broad, and includes many people with numerous titles, who are 
directly involved with marketing activities in the organization, and could be located in 
marketing or sales departments, other departments within the organization, or contracted 
out to organizational partners outside the organization. Wirtz, Tuzovic, and Kuppelwieser 
(2014) documented that the nature of the marketing managers’ role and responsibilities 
varies depending on the organizational structure within an organization, and the 
marketing processes. The primary responsibilities of marketing managers include 
developing and implementing strategic marketing programs and action plans (Malshe, 
Johnson, & Viio, 2017), pertaining to product development, pricing, promotion, and 
distribution (Grimmer, Kilburn, & Miles, 2016). Marketing managers are involved in 
market positioning, marketing research, social media, competitive intelligence, sales, and 
public relations (Wirtz et al., 2014). Xu, Frankwick, and Ramirez (2016) documented that 
marketing managers lack the authority to perform all the activities specified in the 
marketing plans, make all the decisions relative to the marketing strategy formulation and 
implementation, and the analysis. 
Xu et al. (2016) documented that product managers are involved primarily in new 
product development, and management of existing products focusing on activities that 
include underlying product related factors that determine failure or success of new or 
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existing products. Xu et al. noted that product managers are directly involved into the 
formulation and implementation of a marketing strategy. Malshe et al. (2017) 
documented that product managers develop the campaign plans for a product in 
collaboration with the sales management, and that the product market position, the 
market segmentation, and the optimal sales goals need to be defined in strong 
collaboration among product management, sales management, marketing management, 
and product development. Mulki, Jaramillo, Goad, and Pesquera (2015) documented that 
the primary roles of the sales people and account managers include working proactively 
with customers and proposing value, to generate sales opportunities for the products and 
services offered. Malshe et al. (2017) documented that the sales people are involved in 
the decision-making process of formulating marketing programs, and their 
responsibilities include implementation of the marketing strategy. Singh and Jayanti 
(2013) documented that consultants focus primarily on understanding and resolving 
customer problems, brand positioning, and commercialization of new medicines, and are 
directly involved in the marketing strategy formulation activities early in the process 
prior to a product launch decision.  
The inclusion of managers holding different job titles allowed exploration of the 
topic from multiple perspectives. Morley, Scullion, Collings, and Schuler, (2015) 
documented that the multiactor approach is more effective in understanding the different 
views of business practices, and capturing complexity, compared to a single-source 
approach. Story, Raddats, Burton, Zolkiewski, and Baines (2016) demonstrated that 
researchers could use a multiactor approach to explore the topic under study when data 
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collected from the participants need to cover actual processes, social interactions, and 
activities, including the causes and the consequences of the activities, resulting from the 
participants’ actions. Reypens, Lievens, and Blazevic (2016) discussed the importance of 
capturing the multifaceted accounts, and the application of the multiactor approach to 
explain the marketing activities and documented that the actions of the individuals 
holding different job positions comprise the network level processes and the chain of 
focal events. 
Gill (2014) documented that one of the challenges in qualitative studies is 
selection of the participants relative to their experiences, and suggested selecting 
participants who have experience with the topic under study rather than selecting 
participants who have perspectives on the topic. Robinson (2014) presented a four point 
approach to sampling in qualitative research: (a) define a sample universe by identifying 
and applying inclusion and exclusion criteria, (b) select a sample size, (c) select a sample 
strategy by purposeful sampling to specify categories of persons to be included in the 
sample, and (d) source the sample through recruitment of participants from the target 
population. I used criterion sampling strategy to establish the criteria, and purposeful 
sampling strategy to learn more about the topic under study following the model 
described by Robinson (2014). Gould et al. (2014) documented that purposeful sampling 
strategy could be used to identify the individuals involved in development and 
implementation of marketing strategies. Purposeful sampling strategy is used to identify 
participants that will be able to address and answer a research question (Cleary et al., 
2014; Elo et al., 2014; Reypens et al., 2016; Robinson, 2014). Criterion sampling strategy 
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is used to select participants in the study who meet predetermined criteria (Elo et al., 
2014; Palinkas, Horwitz, Green, Wisdom, Duan, and Hoagwood, 2015; Robinson, 2014).  
In participants’ recruitment, I adhered to the Walden University Institution 
Review Board’s (IRB) guidelines and the Belmont Report. I carefully selected the 
participants who have direct experience with the topic under study. I identified the 
pharmaceutical company and the molecules using the FDA orange book and identified 
and obtained contact information on qualified potential participants within the 
organization selected on LinkedIn. I selected an online form of recruitment to reach out 
and recruit participants geographically dispersed, who reside in the United States. 
Shapka, Domene, Khan, and Yang (2016) documented that online forms of requirement 
of participants in research studies suit well when participants are geographically 
dispersed. The decision makers on marketing strategies in the pharmaceutical industry 
reside in various geographic locations (McNally & Schmidt, 2011).  
I reached out and contacted the individuals through emails asking for participation 
in the study. I selected five individuals for initial interviewing. The five individuals were 
provided with email invitation to participants (see Appendix A), and the informed 
consent form. The email invitation to participants and the informed consent form 
contained information about the study, the methodology employed, the nature of the 
study, the procedure for data collection, potential risks and benefits, and assurance of 
confidentiality. I included information about the approximate time for interview, and the 
key areas of focus. In online forms of recruitment of participants, researchers could send 
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introductory email to the participants explaining the objective of the study, the areas of 
focus, and guidelines (Pearce, Thøgersen-Ntoumani, & Duda, 2014).  
I asked the potential participants to indicate their consent by replying to the 
invitation email with the words, “I consent.” I provided information in the information 
consent form about the ethical protection, such as voluntary participation, non-exposure 
to the participants’ identities, authorized person will only access the data collected, and 
that the data will be stored in a locked cabinet for period of 5 years, as per the Walden 
University DBA requirements. Three individuals responded to the invitation email and 
consented to participate in the study by replying with the words “I consent.” I conducted 
a total of three interviews (two face-to-face interviews and one telephone interview). I 
evaluated for eligibility those who agreed to participate in the study. I distributed the 
questions prior to the interview, so that the participants become familiar with the subject 
and topic and know what to expect. 
I conducted member checking with the participants in the study in follow-up 
interviews after I completed each interview with each participant. Birt, Scott, Cavers, 
Campbell, and Walter (2016); Harvey (2015); Impellizzeri, Savinsky, King, and Leitch-
Alford (2017); and Thomas (2017) documented that researchers use member checking to 
assess the accuracy of the reported information. Harvey explained the process of member 
checking, and noted during member checking, the researcher reaches out to the persons 
who provided information during the interviews, provides the study participants with 
interpretative summaries of the answers of the interview questions, and asks them to 
comment on the accuracy of the reported information. Birt et al. (2016) discussed the 
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different methods of member checking: (a) transcript review by returning the interview 
transcripts transcribed verbatim (appropriate to check factual information), (b) member 
check interview using the transcript (allows the researcher to confirm, validate, and 
modify the interview text), (c) member check interview using analyses of single 
participant’s data (each participant receives researcher’s interpretation of the interviews 
with the intent to verify, confirm, or modify the interpretation), (d) member check focus 
group, and (e) member checking using synthetized analyzed data, where the researcher 
returns synthetized themes to the participants to validate the findings.  
Similarly, Thomas (2017) and Varpio, Ajjawi, Monrouxe, O'Brien, and Rees 
(2017) discussed ways to conduct member checking: through interview transcript 
transcribed verbatim or interpretative summary of the interview information. Varpio et al. 
noted that member checking could be conducted at two stages of the study to validate the 
researcher’s interpretation of the data: after the completion of the initial interviews with 
the participants to validate the interpretation of the participants’ opinions, and after the 
initial or final data analysis, to validate the interpretation of the findings. Varpio et al. 
also discussed the methodological challenges associated with the member checking 
process, and documented: (a) participants’ low response rate to validate interview 
transcripts transcribed verbatim in transcript review, (b) participants’ honest feedback 
during follow-up interviews due to the participants’ perception of the researcher, and (c) 
the time difference between data collection and data analysis during which the 
participants may change their perspectives on the research topic.  
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I conducted member checking follow-up interviews with the participants in the 
study using analyses of single participant’s data after the completion of the interviews. 
During member checking, each participant received my interpretation of the participant’s 
responses in the form of a synopsis of the answers for each interview question in a 
follow-up interview to confirm the accuracy of the interpretation. The interpretations 
included journal notes taken during the interviews about verbal cues (such as changes in 
voice, or intonations) and nonverbal cues (such as body language). Thomas (2017) 
pointed out the interpretative nature of member checking interviews and noted in member 
checking interviews participants could reflect on their thoughts and behaviors. 
Research Method and Design 
The research method and design included a description of the method and design 
used in the study, and a justification for using the method and design in the study. The 
research method and design derived logically from the applied business problem 
statement.  
Research Method 
Researchers use qualitative and quantitative research methodologies, and mixed 
methods to explore, describe and understand the socially constructed experiences 
depending on the nature of the research question and the ontology (Venkatesh, Brown, & 
Sullivan, 2016). I used qualitative research method by conducting semistructured, in-
depth interviews to explore and understand the views and experiences of business 
professionals involved in marketing strategies development and implementation due to 
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the exploratory nature of the study. I selected qualitative research method based on the 
nature of the research question.  
Marketing strategy implementation is a social construction of experiences. Cocks 
(2014) documented that the process of strategy implementation involves complex 
interactions among individuals within an organization. Gill (2014) documented that 
construct approaches are ontologically consistent with the qualitative research methods 
and focus on the interpretation of the meanings of others. Interpretative researchers 
understand that research is an interactive process shaped by the gender, ethnicity, social 
class, personal history, beliefs and attitudes, or race of the participants involved in the 
study, and researcher (Denzin, 2017; Darawsheh, 2014). The concept of marketing 
strategy development and implementation during various product life cycles has different 
meanings among business practitioners in the pharmaceutical industry. Qualitative 
research method is appropriate method to help explore the ways in which a topic under 
investigation may be understood (Tight, 2016). I explored the views and experiences of 
business professionals involved in marketing strategies development and implementation 
to better understand the topic under study.   
Hlady-Rispal and Jouison-Laffitte (2014) documented that researchers use 
qualitative research method to explore and understand the meaning that individuals or 
groups ascribe to a specific problem, and generate knowledge that otherwise cannot be 
obtained by using quantitative research. Quantitative research method is appropriate to 
investigate relationships among components of a topic, qualitative research method is 
employed to explore and understand the topic under study through interpretation, while 
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the use of mixed methods reflects an attempt to provide an in-depth understanding of the 
topic under study (Flick, 2017). 
The ontological position of the researcher relates to the nature of reality (Tsang, 
2014). I was influenced by the social constructivist worldview view as a philosophical 
worldview as described by Alvarez, Barney, McBride, and Wuebker (2014), where the 
reality and meaning are socially constructed, and the knowledge is created through social 
interactions within a group. Tsang (2014) noted that researchers, drawn from the 
interpretative research method selected and the constructivism as an ontological position, 
assume that the meaning is embedded in the participants’ lived experiences and the 
meaning is mediated through the researcher’s own perceptions. 
Research Design 
Yin (2017) and Cronin (2014) documented that case study research design is 
appropriate when the unit of analysis is organizations or relationships that are difficult to 
access, and have a complex structure. Case study research design is well suited when 
researchers attempt to explore and describe business practices (Anderson, Leahy, 
DelValle, Sherman, & Tansey, 2014; Govindan & Fattahi, 2017; Möller & Parvinen, 
2015; Sabatier et al., 2012). I selected a case study research design within the qualitative 
research methodology.  
Yin (2017) documented that case study research can include a single case study or 
multiple case studies. Fiat, Cook, Zhang, Renshaw, DeCano, and Merrick (2017) and 
Govindan and Fattahi (2017) documented that single case study research design provides 
a rigorous approach for achieving credibility, and documenting and advancing effective 
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business practices, or behavior analysis. Single case studies provide an opportunity to 
researchers to capture the context in which the topic under study occurs in more detail, 
and provide in-depth, rich data, and details of evidence (Brossart, Vannest, Davis, & 
Patience, 2014; Mariotto, Zanni, & Moraes, 2014; Yin, 2012). Multiple case studies are 
appropriate when researchers attempt to validate the findings from a single case study 
externally, through comparisons of cases (Anderson et al., 2014; Ketokivi & Choi, 2014; 
Yin, 2013; Yin, 2017). In this study, a single case study approach was selected within the 
case study research design over multiple case studies. 
A qualitative case study is an in-depth exploration of the topic under study using 
multiple data sources that allows multiple perspectives of the complexity of the topic in a 
real life context to be revealed (Hyett et al., 2014; Morse, 2015a; Wiggins et al., 2014; 
Yin, 2017). In qualitative case study research design, the participants in the study 
describe their own lived experiences (Khankeh et al., 2015), providing insights into the 
nature of the topic under study (Cronin, 2014). Mariotto et al. (2014) documented that 
researchers who employ qualitative case study research design are concerned with 
understanding social constructivism from the perspectives of the participants involved in 
the study. Researchers employ qualitative research methodology to explore and interpret 
the meaning of the topic under study through the participants’ view and experiences, and 
discover new insights (Hlady-Rispal & Jouison-Laffitte, 2014). Qualitative case study 
research was appropriate research design. Other qualitative research designs, 
phenomenological, ethnography, narrative research, or grounded theory, were not 
selected because the goal of the doctoral study is to construct the meaning of the topic 
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under study using variety of data sources that will ensure exploring the topic through 
multiple perspectives regarding marketing solutions. Yin (2017) documented that the 
essence of a case study is to throw light on decisions: why they were taken, how they 
were implemented, and with what result. The goal of this qualitative case study was to 
illuminate decisions regarding marketing strategies focusing on why these decisions were 
taken, how were the decisions implemented, and with what result.  
In qualitative case study research, data are collected through semistructured, in-
depth interviews that have the potential to produce rich descriptions by the participants 
involved in the study (Cronin, 2014). Intersubjectivity in generating knowledge about the 
topic under study exists. Alvarez et al. (2014) noted that the knowledge and 
understanding of the topic under study is generated through social interaction between the 
researcher and the participants in the study through interviews.  
Researchers achieve data saturation at the point when they generate no new data 
in data collection (Ando, Cousins, & Young, 2014; Marshall, Cardon, Poddar, & 
Fontenot, 2013; Morse, 2015b; Varpio et al., 2017). Ando et al. (2014), Elo et al. (2014); 
and Harvey (2015) documented that interviews continue until data saturation is achieved. 
I interviewed three individuals, managers, followed by member checking follow-up 
interviews. If data saturation was not achieved by the third participant, the interviews 
would have continued until saturation was achieved. 
Population and Sampling 
Population. The general population in this study was business professionals on a 
management level who have experience working in organizations within the 
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pharmaceutical industry in the United States. In 2013, the population in this study 
consisted of 1,380 marketing managers and 930 sales managers employed in 
organizations of all sizes within the pharmaceutical and medicine manufacturing industry 
segment, in metropolitan and nonmetropolitan areas in every State and the District of 
Columbia for a population size of 2,310 (United States Department of Labor, 2018). The 
specific population was three to five business professionals on a management level, who 
were involved in decision-making processes, and developed and implemented marketing 
strategies, and employed in the same organization within marketing department in central 
Ohio for more than five years.  
Sampling. I used a purposeful sampling strategy (Elo et al., 2014), which 
involved choosing the participants to understand the topic under study. Reypens et al. 
(2016) and Palinkas et al. (2015) documented that purposeful sampling is used to identify 
participants who are able to provide rich data to answer a research question. Hogle and 
Moberg (2014) documented that purposeful sampling is used in qualitative research to 
select information-rich cases relative to specific topic area. Elo et al. (2014) documented 
that in a situation when researchers are looking for information-rich cases, the purposeful 
sampling could be employed to develop a comprehensive understanding about the topic 
or the problem being studied. Purposeful sampling was in alignment with my research 
problem under study because the objective was to identify participants who possessed in-
depth knowledge in the topic under study, and were able to provide rich data in their 
responses.  
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Elo et al. (2014) documented that qualitative researchers use this sampling 
strategy to construct samples of participants who meet predetermined criteria. Karatas 
and Oral (2015), and Yüksel and Yıldırım (2015) documented that criterion sampling is 
used to select participants who meet predetermined criteria. Yüksel and Yıldırım noted in 
criterion sampling, researchers specify the criteria for all participants in order to select 
participants with shared experiences. I used criterion sampling as a specific sampling 
strategy because it involved reviewing and studying all cases that meet some 
predetermined criterion of importance. This criterion sampling strategy was in alignment 
with the design and was appropriate sampling strategy for my research inquiry because 
all participants in the study must meet specific predetermined criteria. 
Inclusion Criteria. The inclusion criteria for choosing the participants (three 
initial interviews and member checking follow-up interviews) included voluntary 
participation in the study, extensive knowledge of marketing strategy development and 
implementation in the pharmaceutical industry, and the participants’ willingness to share 
the lived experiences about effective marketing strategies during various stages of 
product life cycle. Only managers who had extensive, in-depth knowledge about the 
problem under study were included in the study. I excluded participants who do not meet 
the inclusion criteria.  
Justification for the Number of Participants. Differences in opinions among 
researchers about the sample size in qualitative research exist. Malterud, Siersma, and  
Guassora (2016) and Walden University (2018) did not document a minimum, maximum, 
or optimal number of participants for qualitative case studies. Marshall et al. (2013) and 
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Robinson (2014) documented that the requirements for a sample size in qualitative 
research are not set. Similarly, Cleary et al. (2014) and Marquis et al. (2014) did not find 
standard tests for estimating adequate sample size for reaching saturation. Gill (2014) 
documented that sample sizes in qualitative research should range between five and six 
participants. When selecting a sample size in a qualitative case study, researchers need to 
make sure the sample size is sufficient to provide in-depth information about the problem 
under study (Cleary et al., 2014; Moustakas, 1994), use multiple data sources (Hyett et 
al., 2014; Tsang, 2014), demonstrate rigor (Fusch & Ness, 2015), and ensure data 
saturation (Ando et al., 2014; Morse, 2015b). Similarly, Malterud et al. (2016) 
recommended researchers to consider the purpose of the study, and ensure data saturation 
and redundancy in the emerging themes when determining sample sizes in qualitative 
studies. The sample size in qualitative research studies is justified by interviewing a small 
number of participants in the study until data saturation is achieved (Ando et al., 2014; 
Palinkas et al., 2015; Roy, Zvonkovic, Goldberg, Sharp, & LaRossa, 2015). The sample 
size of three to five managers involved in the decision-making process regarding 
marketing strategies in the pharmaceutical industry was in alignment with Walden 
University’s DBA recommendation relative to sample size in qualitative research, aligned 
with the goals of the study, and was sufficient to answer the research question.  
Marshall et al. (2013) documented that researchers could start assessing the data 
saturation after the first interview. I started assessing the data saturation after the first 
member checking follow-up interview with the participants in the study. The data 
saturation is determined and reached when no new additional information is obtained 
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(Marshall et al., 2013; Morse, 2015b; Nelson, 2016; Varpio et al., 2017), the linking of 
the concepts of the member checking follow-up interviews and the initial interviews 
reveal no additional categories (Harvey, 2015), and no more emergent patterns in the data 
are identified (Ando et al., 2014; Roy et al., 2015; Vaprio et al., 2017). In this study, the 
data saturation was determined and reached when no new additional information was 
obtained from the interviews and the member checking follow-up interviews, and no 
more emergent patterns in the data were identified. Data saturation was achieved by the 
third participant in the study. The interviews were culminated at the point when data 
saturation was achieved, and there was no new information obtained from the three 
consecutive research participants in the study. Since data saturation was achieved by the 
third participant in the study, I stopped collecting data and did not recruit additional 
participants in the study. If data saturation was not achieved by the third participant in the 
study, I would have continued collecting data through interviewing and recruiting 
participants in the study until no new information were generated. Marshall et al. (2013) 
and Morse (2015b) documented that researchers should continue collecting data through 
interviews until no new data are generated. 
Criteria for Selecting Participants. The population selected for the study was 
appropriate because large number of managers from different pharmaceutical companies 
or within one pharmaceutical company was located in different areas throughout the 
United States. I identified the organization using FDA Orange Book. I obtained contact 
information of the participants through LinkedIn, which is the professional social 
network. LinkedIn had 433 million members by the end of April 2016, out of which 
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29.6% were from the United States (LinkedIn, 2018). I contacted people through emails 
to recruit participants within the organization identified. 
Ethical Research 
Ethical implications might occur when research involves human participants 
(Haahr et al., 2014; Lewis, 2015; Roberts, 2015). All research aspects need to be 
disclosed to the participants in the study to ensure ethical research (Brewis, 2014; 
Cridland et al., 2015). Roberts (2015) and Yin (2012) also suggested creation of an 
ethical framework by disclosing all research aspects to the participants in the study, to 
allow for ethical research. I followed the protocols of the Belmont Report (Office of 
National Research Protection, 2018) to protect the confidentiality of the participants and 
treat the participants in an ethical manner.  
I began data collection after obtaining permission from the Walden University 
IRB. The Institutional Review Board granted a permission to conduct the study and 
offered an approval number in order to ensure ethical research in this qualitative study. 
My IRB approval number is 09-20-17-0351746. The IRB form was electronically 
submitted and included the following information: (a) a description of the research study, 
(b) data confidentiality and integrity, (c) data collection instruments, (d) description of 
the participants in the study, (e) audience of the study, (f) potential risks and benefits, and 
(g) information on obtaining informed consent from participants.  
The access to the general population and the potential participants in the study 
was public (the individuals’ contact information was listed on LinkedIn). The interviews 
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with the participants took place outside workplaces in non-working hours for the 
participants. Gaining access to the population was possible.  
Brewis (2014) documented that informed consent is required to ensure ethical 
research, when human participants are involved, that includes information about the 
recruitment of the participants, voluntariness, risks and benefits of the research for the 
participants, and handling and confidentiality of personal data. Cridland et al. (2015) also 
documented the importance of addressing potential risks to participants through 
establishing ethical framework by obtaining informed consent, protecting the 
participants’ privacy, and ensuring confidentiality. I used informed consent form to 
manage potential ethical concerns that might occur during the interview process.  
The informed consent was included in the email invitation (see Appendix A). 
Each contacted individual had an opportunity to review the informed consent prior to 
prior to making a decision whether or not to take part in my study, before replying to the 
email with a name and contact information. The contacted individuals had an opportunity 
to not respond at all, or respond as volunteers. The volunteers who expressed interest to 
participate in the study consented to participate by emailing me the words “I consent.” 
All participants indicated their consent by emailing me the words “I consent.” I scheduled 
the interviews with the participants after I received the emails with the consent.  
I verbally went through the informed consent form at the beginning of each 
interview to ensure that participants have a full understanding of their part in the study, 
including withdrawal without penalty, and how to withdraw from the study (Walden 
University, 2018). If any issues occurred during the interview process, I would have had 
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in-depth conversation with the participant in the study to clarify information, and if 
needed, refer to proper Walden university representatives for further clarification. I will 
share a summary of the findings with the participants in the study after I obtain study 
approval.  
The informed consent form contained information about the methodology, data 
collection instrument and tools, the focus areas of discussion, the nature of the study, the 
potential risks and benefits from the study, the audience in the study. To ensure 
compliance with ethical research, I included information about the, voluntary 
participation in the study, and the right to withdraw at any time, protection of identity, 
and that the participants’ names or any other names including organizations that they 
mention during the interview will not be revealed. Haahr et al. (2014), Jamal et al. 
(2014), and Roberts (2015) documented the importance of protection of participants’ 
identity and confidentiality. I included information about the compensation and 
incentives stating that no payments, compensation, or other gifts will be provided for the 
interview participation. I also included information about data storage, stating that the 
data will be kept confidential in a locked cabinet for period of 5 years and then destroyed 
by shredding following the model described by Faulds et al. (2016), and only I will have 
access to the data.  
Data Collection Instruments 
I collected data from multiple data sources to address the research question. Data 
collected included data from participants’ responses to open-ended interview questions, 
the literature, and a review of secondary data sources. The secondary data sources 
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included company documents located on public websites, news articles, press releases, 
marketing materials located on public websites, and government databases. Yin (2017) 
documented that researchers should use minimum of two sources of data in a case study. 
Walden University (2018) also required the use of minimum of two data collection 
methods in a case study. De Massis and Kotlar (2014) asserted case studies should have 
data collected by multiple means, such as interviews, direct observations, documentation, 
historical records, and surveys. De Massis and Kotlar explained the use of multiple data 
collection methods adds to the understanding of the topic under study, strengthens the 
findings, and enhances the data credibility. The use of multiple data sources in this study 
was in alignment with the Walden University’s DBA policy relative to the use of 
minimum of two data collection methods.  
I was the primary data collection instrument for this study. I collected the 
qualitative data from the participants’ responses to interview questions. Using the 
criterion sampling strategy, I obtained the data from participants who meet the inclusion 
criteria. I discussed the confidentiality and ethical issues with the participants before the 
interviews, I transcribed the interviews after the completion and I de-identified the data 
collected through interviews. I asked each participant in the study the same open-ended 
questions to describe their lived experiences on marketing practices during various stages 
of product life cycle. Each participant was able to expand on the interview questions to 
describe adequately these experiences. The participants were able to skip a question if 
they do not want to respond. Smith and Osborn (2014) addressed the flexibility in 
conducting interviews, and documented that every question of the interview questions 
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does not have to be asked and that the interview does not have to follow the sequence of 
the schedule.  
In this study, I developed the interview questions. The interview questions were 
open-ended questions designed to address the research question under study. The 
interview questions can be found in Appendix B. The interview focused on the following 
areas: (a) the marketing strategy efforts during various stages of product life cycle, (b) the 
factors associated with revenue generation, and market share, and profitability, (c) the 
key success factors in the decision-making process, and (d) the strategic activities 
essential in executing business strategies. Interview questions 1 through 3 were used to 
address and describe the marketing practices, and strategies (premarket and postmarket) 
in terms of: (a) marketing mix (product, price, place, and promotion), (b) sales goals, (c) 
customers, (d) competition/market, (e) targeted market shares, and (f) marketing goal 
during various stages of product life cycle. Interview questions 4 through 8 were used to 
identify and address the participants’ views on (a) the factors influencing the 
organizations’ performance in terms of market share, revenue generation, and 
profitability, (b) the factors influencing the decision-making process in development and 
implementation of a marketing strategy, and (c) challenges in the current models of the 
company’s product portfolio management. The interview question 9 was used to explore 
the participants’ views on the company’s strategic activities. Interview question 10 was 
used to identify the key success factors for a pharmaceutical drug manufacturer in order 
to fight competition.  
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I ensured validity in the study by following several procedures, such as member 
checking of the data interpretation, triangulation of the data, the use of participants’ 
words in data analysis and presentation of findings, etc., found in qualitative studies. I 
demonstrated rigor in the qualitative research by carefully selecting participants who 
have experience in marketing to match the central research question, and obtained rich 
data through semistructured face-to-face interviews, and telephone interviews. I asked 
open-ended questions to avoid influencing the contents of the participants’ descriptions 
and avoided leading questions that could introduce bias. The interviews were extensive 
and reflected the participants’ actual experience. To promote validity and reliability in 
information, I provided the participants with the interview questions before the interview 
to better prepare the participants for the interview. To ensure reliability, the transcriptions 
needed to be accurate and convey the meaning of the participants’ responses.  
I considered collecting data through face-to-face interviews, telephone interviews, 
or email interviews. I obtained the data through face-to-face interviews and telephone 
interviews, which I recorded and then transcribed. I took notes during the face-to-face 
interviews and telephone interviews. I conducted member checking follow-up interviews 
after each interview in the form of a synopsis of the interview to validate the accuracy of 
my interpretations of the participants’ responses. I did not conduct email interviews. In 
case I needed to conduct email interviews, the email interviews would have been 
transcribed as they were conducted.  
The obtained qualitative data were transcribed verbatim and compiled in 
Microsoft Office Excel® spreadsheets and the qualitative data analysis software program, 
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NVivo®. Using Excel spreadsheets and the NVivo qualitative data analysis software in 
data analysis, I used coding to reduce the data gathered from the participants into 
segments, developed a list of codes from the interview transcript relating to the marketing 
efforts during product life cycle and factors influencing the decision-making process, and 
identified themes. To ensure reliability, I established consistency in the definitions of 
codes throughout the data analysis process by constantly comparing data with the codes 
and by writing memos about the codes and their definitions. Maguire et al. (2014) 
documented that researchers ensure reliability in developing codes by constant data 
comparison. From the presenting themes, I constructed the essence statement describing 
the topic under study in the population selected.  
I reviewed company documents located on public websites, press releases, 
marketing materials located on public websites, company websites, and government 
databases in addition to the interviews. Company documents included annual reports, 
such as Form 10k and Form 10Q, financial information, archived events, marketing 
material and press releases located on public websites. Government databases included 
government websites, for example, U.S. Department of Health and Human Services, and 
the U.S. Food and Drug Administration, that include publicly available resources and 
information about drugs, the industry, news, the development and approval process, etc. 
De Massis and Kotlar (2014), and Houghton, Casey, Shaw, and Murphy (2015) 
documented that documents are used to corroborate the information collected through 
additional sources. I used company documents and government databases to compare and 
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show the extents to which the review from secondary data sources corroborated the study 
findings.  
Data Collection Technique 
Cridland et al. (2015) documented that semistructured interviews involve in-depth 
conversations between the researcher and the participant during interviewing to gain in-
depth understanding on the participants’ views on the topic under study. I collected data 
through semistructured, in-depth interviews conducted through face-to-face interviews 
and a telephone interview to explore the views of three business professionals on a 
management level, employed in the marketing department in a successful organization 
located in central Ohio, who developed and implemented marketing strategies on a daily 
basis within the pharmaceutical industry in the United States. I conducted a total of three 
interviews. The objective of this qualitative case study was to explore and determine best 
practices among marketing managers within pharmaceutical companies on marketing 
efforts. Semistructured, in-depth interviewing was an appropriate method for data 
collection because it allowed examination of the participants’ perspectives through 
dialogue. The pilot study validated the interview questions. 
Gill (2014) documented that the purpose of the interview is to gather descriptions 
of the participants’ lived experiences and recognized the interpretative nature of the 
meaning of the topic under study described. Kallio, Pietila, Johnson, and Kangasniemi 
(2016) documented that in-depth interviewing allows obtaining rich data from the 
participants on the research topic under study. Semistructured interviews follow an 
agenda driven format or interview protocol designed by the researcher, and allow the 
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researcher to ask the participants probing questions focusing on their perspectives 
pertaining to the topic under study (Cridland et al., 2015; Halabi & Carroll, 2015; Kallio 
et al., 2016). I created an interview protocol to guide the participants during the 
interviewing (see Appendix C). Smith and Osborn (2014) documented that the interview 
protocol is a guide rather than a rigid structure, and pointed out the role of the interviewer 
as an active listener during the interviewing.  
The process of data collection started after I received the IRB approval. The 
recruitment of the participants was conducted via email. I used public means to identify 
the participants. I obtained contact information of the participants through LinkedIn. I 
emailed the potential participants the introductory email script (see Appendix A), and 
attached the Informed Consent Form in the email invitation to provide the contacted 
individuals with an option to review the Informed Consent Form prior to making a 
decision whether or not to take part in my study. The volunteers who expressed interest to 
participate in the study consented to participate by emailing me the words “I consent.” I 
received the participants’ consents prior to scheduling the interviews. The three 
participants in the study consented to participate by emailing the words “I consent.” I 
acknowledged the receipt of the consents by replying to the participants’ emails. 
I scheduled each interview with the participants after I received the consents. The 
interviews with the participants took place outside workplaces in non-working hours for 
the participants. I conducted two face-to-face interviews and one telephone interview 
based on the participants’ preferences and availability. The two face-to-face interviews 
took place in private rooms at libraries. I followed the participants’ preferences on the 
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selection of the interview technique to conduct interviews, which allowed the participants 
to feel comfortable providing responses to the open-ended questions.  
The geographical location of the participants and the researcher, resource savings 
(for example, reduction in travel costs), the convenience, and the participants’ availability 
to interview influenced my decision to use face-to-face interviews and telephone 
interviews as techniques to conduct interviews. Mealer and Jones (2014) documented that 
in qualitative research, even though face-to-face interviews have been dominant 
interview technique, other interview techniques, such as telephone interviews, have been 
introduced, and widely accepted and used among researchers. I considered telephone 
interviews in addition to face-to-face interviews because of some of the benefits that 
these techniques offer. Oates (2015) noted that telephone interviews allow inclusion of 
participants across a wider geographical scale, they do not involve travel, and they 
require less time and money. Halabi and Carroll (2015) noted that even though telephone 
interviews have been widely used in quantitative research, in qualitative research they are 
equally viable option to other established methods of qualitative data collection. I did not 
conduct email interviews. Pearce et al. (2014) documented that email interviews as a 
form of computer-mediated communication have been introduced and used in qualitative 
research as a result of the development and use of new communication forms. 
Oates (2015) documented that compared to telephone interviews and email 
interviews, face-to-face interviews have distinct advantage in providing additional 
information through nonverbal cues, such as body language, voice, and intonation. Some 
of the major disadvantages of telephone and email interviewing is the absence of verbal 
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cues (in email interviews) and non-verbal cues in both telephone and email interviews, 
compared to face-to-face interviews. Ward, Gott, and Hoare (2015) documented that 
telephone interviews provide nonvisual linguistic cues that researchers should consider. 
Pearce et al. (2014) documented that the importance of the nonverbal cues may vary 
depending on the research objective. Ward et al. (2015) noted the lack of face-to-face 
communication with study participants could result in miscommunication and 
misinterpretation of the data collection technique addressed to the participants and the 
answers provided. I was not concerned with the nonverbal cues to answer the research 
question posed in this study because the nonverbal cues, such as body language and the 
voice and intonation I observed during the interview process did not provide additional 
information. The face-to-face interviews lasted between 50 and 60 minutes, while the 
telephone interview lasted about 45 minutes. I followed the Interview protocol (see 
Appendix C) to guide me through the interviews. I recorded the verbal responses 
obtained through the two face-to-face interviews and one telephone interview using 
telephone, an iPhone 7® smartphone after I obtained permission to record from each 
participant.  
I briefly described the purpose of the study and the interview process at the 
beginning of each interview. I verbally went through the informed consent form to ensure 
that participants have a full understanding of their part in the study. I asked each 
participant for permission to turn on the audio recording feature of the telephone, iPhone 
7, and started recording after obtaining permission. I introduced the participants with 
generic codes, such as INT1, INT2, and INT3, to conceal their identities. I went through 
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the open-ended interview questions as shown in Appendix B. I began with question 1 
through question 10. I continued the interviews with the additional wrap-up questions. I 
distributed the interview questions prior to the interview, so that the participants become 
familiar with the subject and topic and know what to expect. I took notes during the 
interviews. At the end of each interview I discussed with the participants the member 
checking process and the next steps. I closed each interview by thanking the participants 
for their participation. 
During the interview process I observed the nonverbal cues, such as body 
language, and voice and intonation, and took notes. During the face-to-face interviews I 
observed the participants’ body language, and the voice and intonation. The two 
participants felt comfortable answering the questions. During the telephone interview I 
looked for changes in voice and intonation. The participant felt comfortable answering 
the questions. I concluded the non-verbal cues I observed during the face-to-face and 
telephone interviews did not provide any additional information.  
After each interview, I downloaded the recordings on my password protected 
computer accessible only by me. I deleted the interview recordings from the telephone 
after I downloaded the recordings. I transcribed verbatim the interview recordings in a 
transcript by typing what I heard.  
I reviewed and analyzed the interview transcripts and prepared interpretative 
reports which consisted summary answers in a form of synopsis for each question, 
representing my interpretations of the participants’ responses for each interview. I 
emailed the interpretative reports back to the participants to review and verify the 
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accuracy of my interpretations of the interview responses. Each participant had an 
opportunity to engage in member checking and validate the answers and my 
interpretations. Each participant had approximately 1 week to review and respond. All 
three participants responded to my invitation to participate in member checking follow-
up interviews. I conducted one face-to-face and two telephone follow-up interviews 
based on the participants’ availability and preferences. The member checking follow-up 
interviews lasted between 10 minutes and 25 minutes. The face-to-face follow-up 
interview took place in a private room at a library.  
During the follow-up interviews I asked each participant to review the report with 
the summary answers and validate my interpretations. The three participants confirmed 
the accuracy of my reports and did not provide any corrections. Participant INT1 
provided additional information to question 7. Participant INT2 provided additional 
information for questions 2 and 7. Participant INT3 provided additional information for 
question 2. I combined the interview transcripts from the initial interviews with the new 
data collected from the follow-up interviews for data analysis. 
Cronin (2014), De Massis and Kotlar (2014), and Houghton et al. (2015) asserted 
triangulation strengthens the evidence from additional data collection sources focusing on 
the confirmation of data. I ensured triangulation by comparing data collected from 
multiple data sources. I triangulated the data collected through interviews and member 
checking and compared this data to the review of secondary data such as company 
documents, company websites, and government databases with the intent to show to what 
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extent the study findings confirm or disconfirm the review of company documents and 
government databases.  
The review of secondary data, such as company documents and government 
websites, enhanced my understanding of the industry trends, the regulatory environment, 
and the company operations. Company documents included annual reports, such as Form 
10k and Form 10Q, financial information, archived events, marketing material and press 
releases. The review of the annual reports and archived events gleaned information on the 
company operations, financial performance, market segmentation, product performance, 
innovation strategies, corporate initiatives, industry trends, etc. The review of press 
releases and marketing materials provided information about the company’s product, 
financial and corporate news, events, activities, and marketing tools and techniques. 
Government databases included government websites, such as U.S. Department of Health 
and Human Services and the U.S. Food and Drug Administration. The review of 
government databases gleaned information about pharmaceuticals, the industry, the 
development and approval process, the regulatory environment, etc.  
Documents used in the study were publicly available. De Massis and Kotlar 
(2014) documented that publicly available documents are unobtrusive data sources. I did 
not ask the participants for internal documents because internal documents might contain 
sensitive information or could raise privacy concerns or participants’ discomfort. During 
the research process I was able to easily access the publicly available information and 
documents. 
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Pilot Study 
I conducted a pilot study after the IRB approval, prior to collecting data for the 
study. Kallio et al. (2016) documented that conducting a pilot study is useful to test the 
reliability and validity of the interview questions, can enhance the quality of the interview 
questions, and can help identify areas of potential bias. Cridland et al. (2015) noted pilot 
testing of the interview protocol is useful to estimate the time needed to conduct an 
interview, or identify questions that are confusing or open to misinterpretation. I recruited 
one individual, a marketing manager, and conducted a face-to-face interview using the 
initial interview questions I developed for the study. I obtained the individual’s contact 
information via LinkedIn. I recruited the participant by email request. I obtained consent 
from the participant prior to the interview via email. The interview took place in a private 
room at a library. The initial interview lasted approximately 50 minutes. I tested the 
interview questions (are they clear enough, or do they make sense), the length of time of 
the interview (verified that the interview will not take more than one hour), tested the 
recording and conducting of the interview, and the member checking process. During the 
interview I observed the non-verbal cues, such as body language, voice and intonation, 
and took notes during the interview. Post interview, I asked the participant if the 
interview questions were clear, critical areas relative to the research question that I have 
not considered, and for additional suggestions for the interview questions. I received 
good rich data during the interview. After the interview I transcribed the data, and then 
prepared summaries of each response for each question to prepare for member checking. 
I emailed the summarized answers back to the participant and scheduled follow-up 
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interview to validate my interpretation of the participant’s responses. The follow-up 
interview took place in a private room at a library, approximately 1 week after the initial 
interview. The follow-up interview lasted approximately 20 minutes. During the member 
checking, I asked the participant to review the interpretative report of the interview for 
accuracy. The participant validated the accuracy of the interpretative report. No new 
information was collected during the follow-up interview. Based on the participant’s 
responses on the interview and follow-up questions, I chose not to revise the interview 
instrument. The pilot test helped me validate the interview questions and provided clarity 
whether the interview questions are clear and easily understood.  
Data Organization Technique 
I conducted two face-to-face interviews and one telephone interview. I made 
backups of the qualitative data by copying the emails to a word processing document, and 
by printing out every email sent to the participants and received from the participants and 
kept them in a secure file. I transcribed verbatim the recorded interviews after each 
interview. I made written copies of each recording by typing what I heard, including 
pauses, in a word processing document. I wrote down notes in the text as I transcribed. 
These notes were useful in data analysis. I made backups of the text documents and the 
recordings to an external hard drive. I printed out the text documents as an additional 
security measure, and kept the hard copies in a separate, secure box file.  
I organized the files and data received from the participants in folders. I labeled 
the folders as follows: Email Requests for Participation, Email Communications, 
Participants Consents, Transcribed Interviews, Interpretative Reports, Member Checking 
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Follow-up Interviews, Combined Transcripts, etc. I labeled the transcribed interview 
transcripts from the initial interviews as Transcribed Interview Participant INT1, 
Transcribed Interview Participant INT2, and Transcribed Interview Participant INT3. I 
labeled the interpretative reports, which comprised of summary of the interview 
responses, as Interpretative Report_INT1, Interpretative Report_INT2, and Interpretative 
Report_INT3. I labeled the combined transcripts, which comprised of the initial interview 
transcripts combined with the additional data collected through the follow-up interviews, 
as INT1_Combined Transcript, INT2_Combined Transcript and INT3_Combined 
Transcript.  
I recorded emerging understandings in a codebook, a research log, or a reflective 
journal. I used the codebook, the research log, and the reflective journal to track and 
organize the evidence to support the data analysis. A codebook consists of word 
frequencies generated from the analysis of the interview transcripts, which lead to 
development of categories and themes (Ando et al., 2014). Researchers use research logs 
or reflective journals to document issues experienced with the data analysis during the 
research process (Elo et al., 2014; Williams, 2015). I generated a codebook consisting of 
codes developed from the interview transcripts using thematic analysis. I used a research 
log of the data collection instruments and processes, and the methods for data analysis, 
coding, and interpretation. In the research log, I documented any issues I found when 
cross-referencing the transcribed interviews with the audio recordings. The reflective 
journal consisted of analysis notes, process notes, personal notes, and any issues I 
experienced during the research.  
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I applied the following measures to secure the data obtained from the participants: 
the data stored on a personal computer, telephone, and external hard drive were password 
protected, accessible only by me; and the printed materials were stored in a secure file, 
accessible only by me. I will store the data for 5 years, after which I will destroy all the 
data on the following ways: (a) all printed materials will be destroyed by shredding; (b) I 
will delete permanently all data stored on a personal computer, telephone, and external 
hard drive; and (c) I will delete permanently all emails received from the participants in 
the study, and sent to the participants by me from the email account. I received the 
following types of emails from the participants: consents to participate in the study, 
communications regarding scheduling the initial interviews, and confirmations on follow-
up interviewing. 
Data Analysis 
I conveyed a qualitative, case study research study through primary interviews to 
explore the lived experiences of the participants regarding marketing solutions during 
various stages of product life cycle in the pharmaceutical industry in central Ohio. I 
obtained multiple facets of the topic under study, which is marketing strategies during 
product life cycle in the pharmaceutical industry, by conducting three interviews, 
followed by member checking follow-up interviews. Participants in the study were 
managers, involved in development and implementation of marketing strategies, 
employed in an organization in the prescription medicine segment within the 
pharmaceutical industry. Each interview took approximately 1 hour of each participant’s 
time.  
116 
 
 
The central research question addressed in the research study was: how do 
marketing managers within pharmaceutical companies pursue marketing (product, price, 
place, and promotion) during various stages of the product life cycle? The interview 
questions (see Appendix B) consisted of open-ended questions and focused on the 
following business aspects: (a) marketing strategy efforts in the pharmaceutical industry; 
(b) the factors associated with revenue generation, market share and profitability; (c) the 
key success factors in the decision-making process; and (d) the strategic activities 
essential in executing business strategies. The interview questions as shown in Appendix 
B allowed for response grouping into themes. 
I followed Yin’s (2017) five-step data analysis process for a case study: (a) 
compiling, (b) disassembling, (c) reassembling, (d) interpreting, and (e) concluding. The 
process of data analysis in this study included the following: (a) transcribing the 
interviews, (b) reading and re-reading the data to gain detailed insights into the topic 
under study, (c) developing meaningful codes and themes, and (d) linking codes to 
themes or categories that can provide rich description of the topic under investigation. I 
used coding, content and theme analyses to describe the participants’ views in the study.  
Colorafi and Evans (2016) documented that researchers use content and theme 
analysis to describe and present the participants’ experiences. Smith and Firth (2011) and 
St. Pierre and Jackson (2014) defined thematic analysis as an interpretive process in 
which researchers search data for patterns systematically to provide a rich description of 
the topic under study and noted that generating themes from data is a widely used 
analytical method in qualitative research. I used the data analysis process to develop 
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themes and categories supported with data, and gain an understanding of the analytical 
process and drawing conclusions based on qualitative data. 
Following Yin’s five-step analysis process, I started the data analysis with 
compilation of data from recordings and interview notes. I transcribed the interviews 
manually after the completion of each interview by typing what I heard in a Microsoft 
Office Word® document. I did not use any software to transcribe the interviews. 
Transcribing the interviews manually enabled me to familiarize myself with the 
participants’ responses and understand the data. Listening to, reading the responses for 
each participant under each interview question, and comparing the transcripts with the 
recordings word by word helped me ensure accuracy in transcribing.  
I de-identified the data collected through interviews. The coding for the 
participants’ responses was INT1, INT2, and INT3. I then analyzed, interpreted, and 
created a synopsis of each interview question for each interview. I conducted member 
checking follow-up interviews by reaching out to the three participants who provided 
information during the interview process to assess and validate the accuracy of the 
reported information and the interpretations. I combined the data obtained from the 
follow-up interviews with the initial interview transcripts in Word documents and used 
the combined reports further in the data analysis process. I entered all data into Excel 
spreadsheets. I continuously added newly collected data to the previously collected data 
after each interview. I started grouping the participants’ responses under each interview 
question (for example, I grouped Question 1 answers, Question 2 answers, Question 3 
answers, etc.). I read and re-read the answers under each interview question and reviewed 
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the individual answers under each participant to gain a deeper understanding of the 
participants’ responses. The side-by-side comparison of the participants’ responses under 
each interview question allowed for identifying overreaching themes and determining if 
data saturation was achieved. After the completion of the third combined interview 
transcript, I prepared and formatted the combined transcripts in Word documents for each 
participant for importing in NVivo.  
I used coding to reduce the data gathered into segments. Colorafi and Evans 
(2016) defined the coding process as an establishment of concepts from data and noted 
that coding involves ongoing interpretation and examination of textual data. To develop 
codes, I used a combination of preexisting codes and themes developed prior to actual 
data collection and open codes and themes or emergent categories that emerged from the 
data collected through interviews. Colorafi and Evans documented that researchers could 
use a combination of predeveloped codes and emerging codes from the data. St. Pierre 
and Jackson (2014) argued that the use of preexisting codes only might limit the analysis 
to the prefigured codes rather than opening up the codes to reflect the views of the 
participants used in traditional qualitative research and suggested the use of emergent 
categories to supplement the preexisting codes.  
I developed the preexisting codes by using Microsoft Office Excel spreadsheets. I 
developed the preexisting codes to match the central research question relating to the 
marketing elements, such as- product, price, place and promotion, supplemented with 
information about the customers, sales, competition, and marketing goal (see Table 1). 
The stages of product life cycle were initially identified as premarket phase (focusing on 
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marketing activities during 1 year prior to launch date), introduction phase, 1 year post-
launch, and after one year of launch, given the complexity of the prescription medicine 
market segment (see Table 1). To answer the question about the factors influencing the 
decision-making process, the same coding process was applied through developing a 
combination of preexisting and emergent categories from the textual data (see Table 2). 
Table 1 provides a list of initial codes developed from the interview questions 
relating to the central research question. 
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Table 1 
A List of Initial Codes for Marketing Efforts During the Product Life Cycle in the 
Prescription Medicine Segment  
Codes 
Premarket 
Phase (One 
Year Prior 
to Launch) 
Introduction 
Phase 
One Year 
Post-Launch 
After One Year 
Post-Launch 
Product     
   Thematic Category     
   Participants’ Responses     
Price      
   Thematic Category     
   Participants’ Responses     
Distribution     
   Thematic Category     
   Participants’ Responses     
Promotion     
   Thematic Category     
   Participants’ Responses     
Sales     
   Thematic Category     
   Participants’ Responses     
Customers     
   Thematic Category     
   Participants’ Responses     
Competition     
   Thematic Category     
   Participants’ Responses     
Marketing goal     
   Thematic Category     
   Participants’ Responses     
 
Table 2 provides a list of initial codes developed from the interview questions 
relating to the factors influencing the decision-making process. 
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Table 2 
A List of Initial Codes for Factors Influencing the Decision-Making Process 
Codes 
Thematic 
Category 
Participants’ 
Responses 
Key success factors   
Factors associated with market share, revenue 
generation, and profitability 
  
Challenges and factors influencing the current 
models of product portfolio mix 
  
Strategic activities in executing business 
strategies 
  
Challenges within the industry   
 
These generated preexisting codes developed from the interview questions needed 
further exploration and revision. Further development and revisions of the initial codes 
were established through the development of the open codes that emerged from the  
textual data obtained from the interview transcripts. The following process applied:  
I started the process of developing open codes after the first interview by using 
Excel spreadsheets. I developed a list of codes and quotes from each interview transcript 
relating to the marketing efforts during product life cycle and factors influencing the 
decision-making process. I developed codes by considering each phrase or paragraph of 
the transcript in an attempt to summarize what the participants in the study were 
describing. Key phrases were summarized using participants’ own words, as a means of 
staying ‘true’ to the data (Smith & Firth, 2011). I cross-referenced the codes developed 
from the three interviews and compiled a list of codes and quotes. I searched for patterns, 
and organized the codes into interconnected themes, subthemes, and categories. I cross-
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referenced the open codes and the themes that emerged from the textual data with the 
preexisting codes, and compiled the revised list of codes, themes, and subthemes.  
I developed the open codes that emerged from the data by using primarily Excel 
spreadsheets supplemented with the computer program NVivo. I first developed codes, 
themes, and categories using Excel spreadsheets for the three participants. I then repeated 
the process of developing codes by using NVivo 11 Plus for the three participants. The 
use of NVivo software was useful in organizing the data, categorizing the data, 
discovering themes, and visualization of the data. Using the NVivo software I continued 
to work through the data, searched for patterns, and grouped the codes and subthemes 
into broader categories. 
Smith and Firth (2011) documented that researchers could use Word documents 
or Excel spreadsheets to create coding matrices and emphasized the disadvantage of 
using word or excel spreadsheets when large volumes of data are involved. Smith and 
Firth also discussed the application of computer programs (such as MAXQDA®, 
ATLAS.TI®, and NVivo) in qualitative research. Smith and Firth documented that 
computer programs for data analysis are useful to overcome difficulties associated with 
managing large volumes of data using spreadsheets and can be used to summarize data in 
a series of matrices from which it is possible to conduct thematic analysis. Paulus and 
Lester (2016) discussed the use of a software program in data analysis and documented 
the benefits of using qualitative data analysis software programs, such as efficient work 
with large data sets, and easier data management. Zamawe (2015) documented that the 
123 
 
 
use of a software program in data analysis ensures easier, efficient, and effective coding 
compared to manual coding. 
I evaluated the relationship between the key themes that emerged from the data 
and the conceptual framework. The conceptual frameworks I used in the study were the 
general systems theory and the evolutionary systems theory. The general systems theory 
developed by Bertalanffy (1972) was used to explain the interconnectivity among the 
departments within an organization and its environment. Drawn from the concept of the 
general systems theory, the data related to the conceptual framework by describing the 
participants’ views on the strategic activities, such as collaboration with other research 
companies to co-develop, co-promote, or outsource certain functions within the 
organization, and the effects of the industry and the market changes on the decision-
making processes. The evolutionary systems theory developed by Laszlo and Laszlo 
(1997) was used to explain the product life cycle model. Drawn from the concept of the 
evolutionary systems theory, the data related to the conceptual framework of the study by 
describing and interpreting the participants’ views on the marketing strategies, primary 
objectives, and activities that marketers are undertaking during various stages of product 
life cycle, from the idea, to result, and maintenance, to accomplish the company’s 
objectives in the marketplace.  
The themes that emerged from the data linked and expanded the conceptual 
framework for both theories through the research findings, participants’ responses, and 
the review of the literature on the conceptual framework. The research findings led to the 
identification of four main themes and seven subthemes. The four main themes were: (a) 
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marketing function, (b) product life cycle phases, (c) factors influencing the decision-
making process, and (d) strategic activities in executing business strategies. The seven 
subthemes were further broken down to categories. 
Carter, Bryant-Lukosius, DiCenso, Blythe, and Neville (2014); Flick (2017); 
Houghton et al. (2015); and Yin (2017) documented that qualitative researchers use 
triangulation to develop a comprehensive understanding of the topic under study and test 
validity through the use of multiple methods or data sources. De Massis and Kotlar 
(2014) and Houghton et al. (2015) documented that the purpose of triangulation is to 
confirm data through comparing data from multiple sources to explore the extent to 
which findings could be confirmed, and to ensure completeness of data through gathering 
multiple perspectives from multiple sources to portray as complete picture as possible of 
the topic under study. Carter et al. (2014) and Flick (2017) discussed the four ways of 
triangulation: (a) method triangulation-collecting data using multiple methods, (b) data 
source triangulation-collecting data using multiple data sources, (c) theory triangulation-
interpreting data through the use of different theories, and (d) investigator triangulation-
using two or more researchers to analyze data and provide multiple observations.  
I used methodological triangulation in this study as a data analysis process to 
validate the findings of the interviews. I triangulated the participants’ responses with 
company documents and government websites, and the literature. For example, if 
participants being interviewed stated certain product premarket and postmarket strategies, 
my own experience within the pharmaceutical industry coupled with scholarly research 
on the effectiveness of the implementation of marketing strategies during various stages 
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of product life cycle, and a review of company documents and company websites served 
to support the participants’ responses.  
The review of secondary data included a review of company documents, press 
releases, and government websites. The review of company documents yielded insights 
into the industry trends, the company operations, corporate initiatives, financial 
performance, product performance, market segmentation, etc. The review of government 
databases yielded insights into the industry, the development and approval process of 
pharmaceuticals, the regulatory environment, etc. The review of the secondary data 
sources provided insightful information about product positioning, promotional activities, 
the effect of competition on the product and market performance in terms of sales, the 
effect of timing of market entry, the effect of product life cycle programs, innovation 
strategies, risk factors, government regulations, etc. I compared the participants’ 
responses to the review of the secondary data sources to show the extents the secondary 
data sources align with the participants’ responses.  
Reliability and Validity 
Qualitative researchers tend to focus on gaining deep understanding on the topic 
under study with a limited number of participants, with purpose to explore deeply the 
topic under study or experience to build further knowledge, while in quantitative 
research, the objective is to generalize the study to other settings, or cases (Tsang, 2014). 
To establish quality in qualitative research, researchers need to establish validity and 
reliability in research (Leung, 2015; Yin, 2013). Yin (2017) documented that the quality 
of any research design can be judged according to the following logical tests: (a) 
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construct validity (identifying correct operational measures for the concepts under study, 
p. 40), (b) credibility, (c) transferability (can the study’s findings be generalized), and (d) 
reliability (demonstrating that data collection procedures can be repeated with the same 
results). Houghton et al. (2015) documented that qualitative rigor, which is similar to 
reliability and validity in quantitative research is (a) an attempt to access the accuracy of 
the findings, as best described by the participants and the researcher; (b) is useful for 
establishing consistency of the study methods over time; and (c) provides an accurate 
representation of the population studied. To assess rigor, or validity and reliability in 
qualitative research, I followed the concepts presented by Morse (2015a) who, drawn 
from the model of trustworthiness, addressed the following components to build trust: (a) 
credibility (truth value), (b) transferability (applicability), (c) data dependability 
(consistency), and (d) confirmability (neutrality). Tracy (2010) presented and explored 
eight key indicators of quality in qualitative research, such as: (a) worthy topic (the 
research topic is relevant, interesting, timely, and significant), (b) rich rigor (use of 
appropriate theoretical constructs, date and time in the field, sample, context, and data 
collection and analysis processes), (c) sincerity (the study includes reflection of the 
researcher, potential biases, and transparency about the methods and challenges), (d) 
credibility (thick description of data, or details) (e) resonance (transferrable findings, and 
generalization), (f) significant contribution, (g) ethics, and (h) meaningful coherence (the 
use of methods and procedures are in alignment with the employed research 
methodology; and showing interconnectivity among interview questions, conceptual 
framework, findings, and literature review). 
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Reliability or Data Dependability 
Morse (2015a) and Houghton et al. (2015) documented that researchers achieve 
dependability (audit trail) in qualitative, or reliability in quantitative research by (a) 
describing the specific purpose of the study, (b) discussing how and why the researchers 
selected the participants for the study, (c) describing how the data were collected and 
how long the data collection lasted, (d) explaining how the data were reduced or 
transformed for analysis, (e) discussing the interpretation and presentation of the research 
findings, and (f) communicating the specific techniques used to determine the credibility 
of the data. Houghton et al. proposed the following strategies to establish dependability: 
(a) peer participation in data analysis, (b) providing a detailed description of the research 
methodology and design, or (c) repeating the study step by step to see if the results might 
be similar to the initial findings. Colorafi and Evans (2016) proposed clearly describing 
the researcher’s role in data collection, and the use of the same questions in the same 
order during interviewing as strategies to achieve dependability. Elo et al. (2014) also 
documented that dependability in qualitative research is similar to reliability in 
quantitative research and could be achieved by establishing an audit trail or reflective 
journal and tracking the process from the beginning to the end. Petty, Thomson, and Stew 
(2012) documented that to ensure dependability, the researcher needs to track all changes 
during the research process, and document those changes. To establish dependability in 
research, I used the following strategies: (a) use of a reflective journal to document and 
track all changes during the research process, (b) provided detailed description of the 
research method and design, (c) described the purpose of the study, (d) discussed how 
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and why the participants were selected, (e) described my role in data collection and 
analysis, (f) asked each participant in the study the same questions in the same order, (g) 
described the data collection process, the coding process and the establishment of 
emergent themes and categories, (h) discussed the interpretation and presentation of 
findings, (i) discussed the techniques used to determine credibility of data, and (j) 
conducted a pilot study to test the validity of the interview questions, identify questions 
that are confusing or could be misinterpreted, and the length of time of the interview. 
Validity 
Credibility. Morse (2015a) documented that credibility, similar to internal 
validity in quantitative research, refers to checking for the representativeness of the data 
as a whole, and could be established through member checking (feedback from 
participants in the study), reviewing the individual transcripts, looking for similarities 
within and across study participants, peer examination, or using participants’ own words. 
Houghton et al. (2015) recognized the interpretative nature of the qualitative research, 
where each participant of the study, the researcher, and the audience have their own 
personal perspective, influenced by their culture, experience, the curriculum, the 
environment, and other contextual influences. Member checking as a technique to 
establish credibility involves obtaining feedback from the participant in the interview to 
ensure that the researcher’s interpretations (reported as themes) are accurate 
representations of the participants’ experiences, and are recognized by the participants 
(Harvey, 2015; Houghton et al., 2015; Thomas, 2017).  
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Tracy (2010) and Petty et al. (2012) referred to credibility as trustworthiness and 
plausibility in findings, and noted that in order to establish credibility, the researcher need 
to include (a) thick, rich description of data, (b) concrete and sufficient details from the 
interview transcripts so that the readers can come to their own conclusions on the topic 
under investigation, and (c) showing the readers the participants’ views by using the 
words of the participants. Tracy suggested the use of triangulation, link with the literature 
review and the conceptual framework, and multivocality (in terms of recognizing the 
cultural differences between the researcher, and the participants) as strategies to enhance 
credibility in qualitative research. Flick (2017) documented that researchers could use 
triangulation where the researchers use multiple sources, methods, theories and 
investigators to support the findings to provide evidence. Leung (2015) also documented 
that triangulation of data could enhance the validity of findings, and address credibility, 
and defined triangulation as the use of variety of data collection sources, investigators, 
methods, or theories to provide evidence. Yin (2012) documented that triangulation 
supports validity in research and incorporates three sources of data that are compared and 
contrasted to determine whether the sources of data are in alignment and could support 
the findings. 
To establish credibility in the research study, I conducted a pilot study to validate 
the interview questions and check for clarity. I obtained rich data from carefully selected 
participants through (a) semistructured interviews, (b) prolonged engagement with the 
participants by building trust and (c) checking for misinformation that stems from 
distortions introduced by the research and the participants. I conducted member checking 
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through follow-up interviews with the participants in the study after the completion of the 
interviews. I triangulated the data from the semistructured interviews, the member 
checking, and the research log with company documents, government websites, and the 
literature.  
I clarified the information, the accuracy, and the credibility of the findings 
through (a) follow-ups with the participants, (b) comparison of the participants’ responses 
to a review of company documents and government websites, and (c) use the words of 
the participants in data analysis and interpretation and presentation of findings. To 
convey the meaning of the participants’ descriptions, I obtained (a) detailed field notes by 
recording the face-to-face interviews with a telephone, iPhone 7, and taking notes during 
the interviews; and (b) accurate transcriptions of the interviews. E-mail interviews would 
have been transcribed automatically. I did not conduct email interviews.  
Transferability. Houghton et al. (2015) defined transferability in qualitative 
research, that is similar to external research in quantitative research, as “the ability to 
transfer research findings from one group to another,” and referred to the extent of 
applicability of research findings or study participants to other settings, or situations (p. 
153). Colorafi and Evans (2016) documented that transferability shows whether the study 
findings could be applied to other studies and includes discussions of generalizability. 
Houghton et al. (2015) provided the following strategies to establish transferability: (a) 
providing description of the population under study, and (b) the geographical boundaries 
of the study. Yin (2013) referred to transferability as a criterion of conceptualizing a 
gradient of similarity for settings, people, times, and contexts, from most closely similar 
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to least similar to those in the research study and provided strategies to establish 
transferability: (a) thick description of the participants in the study, (b) the geographical 
location, and (c) rich description of the topic under investigation. Mojtahed, Nunes, 
Martins, and Peng (2014) documented that the use of semistructured interviews with 
open-ended questions allows the researchers to establish transferability of research 
findings to other settings or populations. Following the strategies proposed by Houghton 
et al. (2015), I provided rich description of the population under study, and the 
geographical location of the study to establish transferability. 
Confirmability. Houghton et al. (2015) documented that confirmability in 
qualitative research, or objectivity in quantitative research, means reflexivity, where the 
researcher needs to provide field notes about their personal biases, personal feelings, and 
insights, and how they affect the research. Tracy (2010) used the term sincerity to address 
confirmability in qualitative research. De Massis and Kotlar (2014) recommended 
truthful presentation of findings and stressed the importance of personal bias. Strategy to 
establish confirmability is asking the participants in the study to clarify information, or 
definitions of terms (Houghton et al., 2015; Roy et al., 2015; Tracy, 2010). To establish 
confirmability, I used the following strategies: (a) described in details my personal biases, 
preconceived ideas and values, and the possible effects on the participants and the 
situation in the Reflections section, and (b) described my role in the data collection 
process and any relationship I have had with the topic, participants, or area in the Role of 
the Researcher section in the study (Walden University, 2018).  
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Data Saturation. The concept of data saturation is needed to assess the content 
validity of the study (Elo et al., 2014; Morse, Lowery, & Steury, 2014; Nelson, 2016). 
Achieving data saturation is a challenge in qualitative research because of the absence of 
explicit guidelines of determining data saturation (Nelson, 2016; Marshall et al., 2013; 
Morse et al., 2014). Researchers achieve data saturation when no new information is 
obtained during data collection (Ando, et al. 2014; Marshall et al., 2013; Robinson, 2014; 
Vaprio et al., 2017). Morse (2015b) documented that data saturation is achieved when no 
new themes emerge from the data, no further coding is needed, and replication of themes 
and categories is ensured. I collected new data through interviewing participants until no 
new information is obtained, and no new themes emerged from the data to achieve data 
saturation.  
The constant comparative method relies on the process of constant comparison to 
ensure data saturation (Cronin, 2014; Fox & Moreland, 2015). Constantinou, Georgiou, 
and Perdikogianni (2017) documented that the constant comparative method consists of 
the following four stages: (a) comparing each theme that emerges from the data, (b) 
integrating themes and properties, and (c) writing the results. The constant comparative 
method involves comparison of new data to the previously collected data that are already 
coded, on an ongoing basis (Ando et al., 2014; Constantinou et al., 2017; Fox & 
Moreland, 2015; Morse, 2015b). I used constant comparative method in this study that 
allowed for constant comparison of the collected data to ensure data saturation. In data 
analysis, the newly collected data were added to the previously collected data and 
developed codes to determine if further coding was needed, and to test the developed 
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themes by checking if new themes emerged from the data until the data indicated 
replication or redundancy.  
Transition and Summary 
The purpose of this qualitative case study was to explore the marketing efforts 
during various stages of product life cycle in the pharmaceutical industry. A pilot test was 
conducted to validate the interview questions. Data were collected through in-depth, 
semistructured interviews, and a review of secondary data. The semistructured interviews 
(face-to-face interviews and telephone interviews) were recorded, transcribed, analyzed, 
and validated. Three business professionals on a management level within the same 
organization in central Ohio, who developed and implemented marketing strategies, 
participated in the interviews. I began data collection after obtaining permission from 
Walden University IRB. The secondary data included company documents and 
government databases. I triangulated the participants’ responses with company 
documents and government websites, and the literature. 
Section 2 of the study provided detailed description of the role of the researcher, 
the participants in the study, the population and sampling, and the ethical research, the 
research method and design, the data collection process, the coding process, the selection 
of the participants, data analysis, and the techniques used to establish validity. Section 3 
of the study included the presentation of findings, the application to professional practice, 
and implications to social change, the recommendations for action and further study, and 
the reflections of my experience with the research process. 
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Section 3: Application to Professional Practice and Implications for Change 
This section included presentation of the findings, applications to professional 
practice, implications for social change, recommendations for action, recommendations 
for further research, and reflections. 
Introduction 
The purpose of this qualitative case study was to determine the best practices 
among marketing managers within pharmaceutical companies on how to pursue 
marketing strategies during various stages of product life cycle. Data collection was 
multidimensional and included semistructured interviews of business professionals on a 
management level employed within a marketing department at a company in central Ohio 
of the United States and a review of secondary data. I conducted two face-to-face 
interviews at public halls, and one telephone interview. Data saturation was achieved 
with the third participant; therefore, the interviews did not continue. I transcribed the 
interview responses word for word in a transcript after the completion of each interview. 
I conducted member checking follow-up interviews after the completion of each 
interview. The analyses of the interview transcripts resulted in the identification of codes 
and quotes, and emergent themes. The following emergent themes derived from the data: 
(a) marketing as a function, (b) product life cycle phases, (c) factors influencing the 
decision-making processes, and (d) strategic activities in executing business strategies. 
All emergent themes and subthemes contributed significantly to answering the 
overarching research question. In presentation of findings, under each emergent theme I 
documented the approaches that the managers identified as critical or essential. The 
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results from the interviews included participants’ responses. The themes that emerged 
from the data were compared with themes from the literature. A review of secondary data 
included company documents, such as annual reports, news releases, and websites, plus 
government databases. I conducted methodological triangulation of data collected 
through the interviews and member checking, and compared these data to the review of 
secondary data, and the literature. I tied the findings to the conceptual framework and the 
existing literature on effective business practice. 
Presentation of Findings 
The study findings are of potential value to managers in the pharmaceutical 
industry who develop and implement marketing programs and strategies during various 
stages of product life cycle. In this section, I provide a presentation of the findings, an 
overview of the participants’ responses, describe the emerged themes and discuss the 
findings in relation to the themes, and how themes are tied to the conceptual framework 
and literature.  
The overarching research question in this qualitative case study was: How do 
marketing managers within pharmaceutical companies pursue marketing (product, price, 
place, and promotion) during various stages of the product life cycle? I collected data 
through multiple data sources to answer the research question. Data collected included 
participants’ responses through interviews, a review of secondary data, such as company 
documents, company websites, and government databases, and a review of the literature. 
The participants included business professionals on a management level employed within 
a marketing department at a company in central Ohio of the United States. The 
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participants took part in semistructured interviews. I conducted two face-to-face 
interviews, and one telephone interview. The interviews lasted between 45 and 60 
minutes. The face-to-face interviews took place at public halls, where the participants felt 
comfortable with providing responses to the interview questions. Participants were asked 
10 open-ended questions (see Appendix B), and responded to follow-up questions. I 
coded the names of the participants with the pseudonyms INT1, INT2, and INT3. I 
transcribed the interview responses word by word in a transcript after the completion of 
each interview.  
Data saturation was achieved with the third participant. I did not continue the 
interviews when no new information or themes emerged from the third interview. Ando 
et al. (2014) noted that data saturation is achieved when no new information emerges 
from the data. To ensure data saturation, I used the constant comparison method in data 
analysis. After each interview I continuously added the newly collected data to the 
previously collected data. I developed codes to determine if further coding was needed, 
and to test the developed themes by checking if new themes emerged from the data until 
the data indicated replication or redundancy. Ando et al. (2014); Constantinou et al. 
(2017); Cronin (2014); and Fox and Moreland (2015) documented that the constant 
comparison method involves comparison of new data to the previously collected data that 
are already coded on an ongoing basis.  
Data credibility was achieved through member checking. Member checking was 
conducted after the completion of each interview. In member checking, each participant 
received a summary of the responses for each interview question. Member checking was 
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conducted to validate my interpretations of the participants’ responses and to confirm 
data saturation was achieved. Impellizzeri et al. (2017) documented that researchers use 
member checking to ensure each participant’s response is represented accurately in the 
reporting and establish trustworthiness in qualitative research.  
In data analysis, I combined the interview transcripts with the new data from the 
member checking follow-up interviews for each participant response. I primarily used 
Excel spreadsheets to analyze the data supplemented with NVivo software. The analyses 
of the interview transcripts resulted in the identification of codes and quotes, and 
emergent themes. The results from the interviews included responses from each 
participant.  
I followed Yin’s (2017) five-step data analysis process for a case study. Yin 
identified the following five steps for data analysis: (a) compiling, (b) disassembling, (c) 
reassembling, (d) interpreting, and (e) concluding. I read and re-read the collected data 
through the interviews to familiarize myself with the responses and compared the 
participants’ responses on each question. I entered the data into Excel first, and uploaded 
the data in the NVivo software. I compiled the data by disassembling, reassembling, and 
coding of the data. I worked through the data to discover codes, themes, and categories. 
The themes emerged from the developed codes, patterns, and relationships. I then cross-
referenced the themes and the collected data through constant comparison.  
The secondary data sources included company documents, such as annual reports, 
financial information, and archived events located on public websites, news articles, press 
releases, marketing materials located on public websites, and government databases. I 
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compared the participants’ responses to the company documents and government 
databases to show the extents the secondary data sources align with the participants’ 
responses and strengthen the study findings. Ospina, Esteve, and Lee (2017) documented 
that the use of multiple data sources enhances the credibility in research. 
Themes that emerged from data analysis were compared with themes from the 
literature. I conducted methodological triangulation of data collected through the 
interviews and member checking and compared this data to the review of secondary data 
sources, such as company documents and government websites, and the literature. 
Writing a reflective journal helped track research changes and minimize personal bias. I 
tied the findings to the conceptual framework and the existing literature on effective 
business practice. 
Emergent Themes 
The research findings led to identification of emergent themes and subthemes as 
shown in Figure 1. I grouped the research findings into four main themes. The four main 
themes encompassed: (a) marketing function, (b) product life cycle phases, (c) factors 
influencing the decision-making process, and (d) strategic activities in executing business 
strategies. The four themes were in alignment with the research question. Each main 
theme was further broken down into subthemes. Each subtheme was further broken down 
into emergent key terms and categories. I then related the themes to the company 
documents and government databases, and the literature. 
The first main theme was marketing function, and this theme was not broken 
down further into subthemes. The second main theme was product life cycle phases, 
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which was broken down into two subthemes. Under the second main theme, the 
subthemes included premarket phase and postmarket phase. The third main theme was  
factors influencing the decision-making process, which was broken down into four 
subthemes. Under the third main theme, the subthemes included factors associated with 
market share, revenue generation, and profitability, challenges and factors influencing the 
current models of product portfolio mix, and key success factors to fight competition. 
The fourth main theme was strategic activities in executing business strategies, which 
was broken down into two subthemes. Under the fourth main theme, the subthemes 
included strategic activities in executing business strategies and alignment of marketing 
programs with corporate and business strategies. 
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Figure 1. Research results. 
Theme 1: Marketing Function 
The first main theme was the marketing function. Participants discussed 
marketing as a function in terms of product, price, place, and promotion during the 
management of a product life cycle. The following key terms emerged from the data: 
marketing activities, product positioning, branding, product life cycle programs, pricing, 
competition and market, sales, planning of promotional activities, and forecasting (see 
Table 3).  
Table 3 provides a list of initial codes developed from the interview questions 
relating to the marketing as a function. 
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Table 3 
A List of Emergent Codes for Marketing as a Function 
Key Terms Participants Responses 
Product attributes INT1: Continuous unique offering of high quality, safe, and 
effective products at a competitive price. 
 INT2: Unique innovative product that is patent protected. 
 INT3: Quality and safe products at a competitive price through 
our distribution channels. 
Branding INT2: Establish powerful brand differentiation.  
 INT3: Develop and communicate the brand vision and brand 
positioning. 
Product life cycle 
programs 
INT2: It is difficult to generalize and describe just one strategy 
that would apply to all of our products. 
 INT3: Employing the right life cycle management strategies is a 
key to success. 
Price INT1: Develop pricing strategies and continuous price revisions 
of our products.  
Competition and 
market 
INT1: We monitor closely the competition, market trends, and 
the market positioning of our products and respond accordingly. 
 INT2: I monitor the market and the competition to get an insight 
of the pre-market dynamics for development products, and 
newly launched products. 
 INT3: The knowledge about the competition, the competitive 
landscape, and the marketplace needs to be included into the 
strategic decision making. 
Sales INT1: Customer portfolio management and strong collaboration 
with the sales team to ensure sales targets are achieved. 
 INT2: Support sales teams in product positioning. 
 INT3: Work closely with the sales force regarding business 
opportunities and monitor performance. 
Promotion INT1: Design and coordinate promotional activities and 
campaigns using multiple channels. 
 INT2: Product detailing is important promotional activity. 
 INT3: Invest heavily in promotion and advertisement of certain 
products through product detailing or samples, and publications 
and other channels of communication. 
Forecasting INT1: I develop sales forecasts and manage the operating plan 
budget and profitability. 
 INT2: Develop forecasts, analyze product profit & loss. 
  INT3: Marketing is responsible for developing forecasts. 
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Marketing activities during premarket and postmarket phase. Research findings 
revealed marketing teams manage marketing activities and define marketing mix models 
for development products, new product launches, and commercial products. Participant 
INT1 responded marketing teams “conduct market research, develop forecasts, target 
market shares and sales goals, select customers, and define launch plans and marketing 
mix models.” Participant INT2 listed research on market needs, market opportunities, 
market positioning and segmentation, product positioning, branding, pricing models, 
forecasting, planning of promotional activities, messages, targeting customers and 
contracting, competitor analysis; life cycle planning, and defining marketing mix models 
and reimbursement models. Participant INT3 corroborated the participants INT1 and 
INT2 responses and stated, “marketing is responsible for developing forecast, defining 
marketing mix models, defining market positioning, life cycle management, assessing 
market and competitive landscape, and competitor analysis.” 
Product positioning. Product positioning included product attributes and patents. 
Participants identified product quality, safety, and efficacy as key product attributes. 
Participants responded that marketing teams pursued marketing through the continuous 
unique offering of high quality, safe, and effective products. Participant INT1 reported 
“continuous unique offering of high quality, safe, and effective products at a competitive 
price.” Participant INT2 reported “I have to start with the product attributes: product 
quality, safety and efficacy.” Participant INT3 reported “quality and safe products at a 
competitive price through our distribution channels.” Findings aligned with the secondary 
data sources on product positioning. Paich et al. (2011) and Arafat, Ahmed, and Arafat 
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(2017) documented safety, efficacy, tolerability, side effects, and mode of administration 
as factors influencing the key components for treatment options. Camejo et al. (2013), 
Moe-Byrne et al. (2014), Prajapati et al. (2013), and Schramm and Hu (2013) also 
discussed product quality, safety, and efficacy for treatment options. 
Participants discussed the branded prescription medicines and reported branded 
drugs are patent protected. Participant INT2 reported “we offer unique innovative product 
that is patent protected, not a commodity.” Arafat et al. (2017), Berger et al. (2016), 
Kakkar (2015), and Song and Han (2016) discussed patents as a tool to enforce 
exclusivity in the marketplace. 
Branding. Participants INT2 and INT3 reported that marketing teams develop the 
brand vision, brand positioning, and brand communication plans. Participant INT2 
reported “we need to establish powerful brand differentiation in a marketplace based on 
the product unique features, safety and efficacy.” Participant INT3 reported marketing 
teams “develop and communicate the brand vision and brand positioning.” Jasper et al. 
(2017) documented that brand strategy needs to be an integral part of a marketing 
strategy. Chen et al. (2016) linked branding strategy to corporate reputation, and 
documented that branding strategy is useful to gain trust from physicians.  
Product life cycle programs. Participants responded that marketing teams develop 
product life cycle planning strategies, and that marketing programs are product focused, 
and may not be applicable to all products. Participant INT2 stated “it is difficult to 
generalize and describe just one strategy that would apply to all of our products.” 
Participant INT3 reported “our marketing programs are product specific.” Sabatier et al. 
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(2012) noted marketing programs are product specific. Paich et al. (2011) addressed the 
need to investigate the market segments by therapy, product, or patient segments.  
Participants emphasized the need to know what the company portfolio mix is, 
how each product is positioned at what stage of a life cycle in the pipeline, and the 
customer product portfolio mix. Participant INT3 reported “employing the right life cycle 
management strategies to each one of the products is a key to success.” Findings aligned 
with the secondary data sources regarding the importance of product life cycle 
management. Mullins et al. (2010), Prajapati et al. (2013), Nikolopoulos at al. (2016), and 
Wagner and Wakeman (2016) documented the importance of a product life cycle 
management, and developed product life cycle models. 
Pricing. INT1 and INT3 reported products are offered at a competitive price 
through selected distribution channels and customers. All participants responded 
marketing teams develop pricing strategies and models, develop reimbursement models, 
and conduct continuous product price revisions throughout the product life cycle. 
Participants INT1 and INT2 reported marketing teams collaborate with payer experts and 
teams to develop pricing models. 
Competition and market. Participants reported that marketing teams conduct 
research on market needs, market opportunities and market trends, monitor closely the 
competition, position development and existing products in the marketplace, and respond 
accordingly to competition. Participant INT1 reported “we monitor closely the 
competition, market trends, and the market positioning of our products and respond 
accordingly.” Participant INT3 corroborated the participants INT1 and INT2 responses 
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and stated “the knowledge about the competition, the competitive landscape, and the 
marketplace needs to be included into the strategic decision making.”  
Sales. Participants responded that marketing teams develop sales forecasts, 
manage customer portfolios, target customers and contracting, and collaborate with the 
sales team in product positioning, ensuring sales targets are achieved. Participant INT1 
reported marketing teams perform “customer portfolio management and strong 
collaboration with the sales team to ensure sales targets are achieved.” Participant INT2 
reported marketing teams “support sales teams in product positioning.” Participant INT3 
reported marketing teams “work closely with the sales force regarding business 
opportunities and monitor performance.” Malshe et al. (2017) and Riggs et al. (2016) 
documented that salespersons are involved in the formulation and implementation of 
marketing programs and strategies. 
Planning of promotional activities. Participant INT1 reported marketing teams 
design and coordinate promotional activities and campaigns using multiple channels. 
Participant INT2 reported “product detailing is important promotional activity.” 
Participant INT3 added “marketing teams invest heavily in promotion and advertisement 
of certain products through product detailing or samples, and publications and other 
channels of communication.” Participant INT3 further added “the investment in 
promotion and advertising depends on where the product in the life cycle is.” Findings 
aligned with the secondary data sources regarding the planning of promotional activities. 
Forecasting. Participants identified developing forecasts as a marketing function. 
Participant INT1 reported “I develop sales forecasts and manage the operating plan 
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budget and profitability.” Participant INT2 reported marketing teams develop forecasts 
and analyze product profit & loss.” Participant INT3 corroborated the participants INT1 
and INT2 responses and stated “marketing is responsible for developing forecasts and the 
marketing mix model.” 
Theme 2: Product Life Cycle Phases 
The second main theme was product life cycle phases. Product life cycle phases 
that emerged from the data could be divided into two categories as shown in Figure 2: 
premarket phase, and postmarket phase or commercialization. Premarket life cycle phases 
that emerged from the data are: discovery, phase I of development, phase II of 
development, and phase III of development. Postmarket phases that emerged from the 
data are: introduction phase, growth phase, maturity phase, and decline phase. 
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Figure 2. Product life cycle phases. 
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Premarket phase: The following phases emerged from the data: discovery phase 
and development phases: Phase I of development, Phase II of development, and Phase III 
of development. Participant INT2 reported “product goes from discovery to development. 
Participant INT3 reported “pre-market could be described from discovery, through 
development phases: Phase I, II, and III.” Participant INT1 and INT3 explained in detail 
the activities associated with each phase. Participant INT1 responded:  
Product goes from discovery phase, where promising molecules are identified; 
then then enters Phase I , where the research and development team works on 
establishing safety dosages and manufacturing; then Phase II where safety and 
efficacy tests are performed; then Phase III where product is defined, clinical 
trials expand on a larger population; followed with submission to regulatory 
agencies for approval.  
Participant INT3 corroborated participant INT1 response and added in Phase III of 
development “the data from the trials are usually compared to existing treatments and 
therapies.” Participant INT3 documented that each development phase “could take many 
years to complete.” Findings aligned with the secondary data sources regarding the 
premarket phase. Prajapati et al. (2013) documented that the development phase of a 
brand drug involves development of a new product idea, assessment of patentability of 
the drug formulation, and changes in formulation and methodology. 
Marketing involvement during premarket phase. All participants reported that in 
development phase, their involvement in pre-launch activities is low at early stages of 
development and increases over time as new development product gets closer to launch. 
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Participant INT1 added “R&D team decides what products will be launched largely based 
on medical and regulatory decision making.” Participants responded that there are cross-
functional teams that oversee all aspects of the upcoming launches and the R&D pipeline, 
and that marketing has designated personnel focusing on new product launches. 
Participant INT1 stated “launch strategy is a result of a collaborative effort among 
various groups.” Participant INT2 stated “we work closely with regulatory and the launch 
team to ensure compliance and align the launch strategies.” Eng and Ozdemir (2014), 
Chang et al. (2014), and Herhausen (2016) discussed the integration of marketing with 
other functional groups into launch teams, and documented that team leadership, external 
communication, group cohesiveness, and goal clarity were determinants of new product 
development team performance. 
Marketing focus and marketing strategy. Participants reported marketing focus 
during the premarket phase is to gain an insight into the market and the market dynamics, 
develop forecasts, develop marketing plans and marketing mix models for the 
development products, and define launch plans (see Table 4). Participant INT2 reported 
“I develop marketing plans and promotional materials; monitor the market and the 
competition to get an insight on the pre-market dynamics, support the sales teams in 
product positioning, develop forecasts, and manage the internal regulatory reviews.” 
Participant INT1 reported “we look into the market - if the market is already established, 
we identify what kinds of existing molecules and treatments are available.”  
Table 4 provides a list of codes that emerged from the data relating to the 
marketing efforts during a premarket phase. 
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Table 4 
A List of Emergent Codes for Marketing Efforts During the Premarket Phase in the 
Branded Prescription Medicine Segment  
Codes 
Participant INT1 
Responses 
Participant INT2 
Responses 
Participant INT3 
Responses 
Product 
INT1: Discovery and 
development. 
 INT2: From 
discovery to 
development. 
INT3:  From 
discovery, through 
development phases. 
Price No price established. No price established. No price established. 
Distribution No distribution exists. 
  
Promotion 
Planning of 
promotional activities. 
Planning of 
promotional activities. 
Planning of 
promotional 
activities. 
Sales No sales exist. 
  
Competition 
INT1: Competition 
could be insignificant, 
or there might be other 
market entrants. 
INT2: There could be 
little or no 
competition, or market 
could be already 
established. 
INT3: Competition 
might exist. 
Market  
INT1: Research and 
determine the market. 
INT2: Research on 
market needs, market 
opportunities, market 
positioning and 
segmentation. 
 
Marketing 
focus 
INT1: Determine 
market size, 
characteristics, and 
competition. 
INT2: Define 
marketing mix model, 
reimbursement 
models. 
INT3: Determine 
marketing mix model. 
Marketing 
strategy 
INT1: Determine 
market size, 
characteristics, and 
competition. 
INT2: Define 
marketing mix model 
in preparation for 
lunch, reimbursement 
models. 
INT3: Determine 
marketing mix model. 
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Postmarket phase. The following phases emerged from the data: introduction 
phase, growth phase, maturity phase, and decline phase as shown in Figure 2.  
Introduction phase. The following key terms emerged from the data: product, 
timing of market entry, price, customers, distribution, promotion, sales and market 
shares, market, competition, marketing focus and marketing strategy, and post product 
launch period. Camejo et al. (2013), and Matikainen et al. (2015) documented the 
following factors that influence the success of new product launch: order of market entry, 
marketing mix instruments (product, price, promotion, and distribution), sales, corporate 
culture, organization capabilities, market orientation, and customer relationship. Camejo 
et al. (2013) noted organizational leaders continuously include new products in their 
product portfolio and documented that the introduction of new drugs is needed because it 
increases the clinical effectiveness of the drugs within a specific therapeutic area over 
time. 
Product. The following key terms emerged from the data: product attributes 
(quality, safety, and efficacy), patent protection, and product supply. Participants 
responded the launch strategy includes offering high quality, safe, and effective branded 
products to customers. Participants INT1 and INT2 discussed patent protection. 
Participant INT2 stated “the key is to offer unique innovative product that is patent 
protected, not a commodity.” Participant INT1 stated “when branded drug enters the 
market, it is patent protected for number of years. That means that no one else can enter 
the market with the same product or indication offering until patent expiry.” Participant 
INT1 expanded “there could be alternatives to the therapeutic treatment from other 
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brands or even generics.” Participant INT1 listed product supply as an important factor of 
a launch strategy and reported “if we do not have product ready to supply at the time of 
regulatory approval, then we are losing revenues and underperform on the market.” 
Findings aligned with the secondary data sources on product attributes, patent protection, 
and product supply. 
Timing of market entry. Participants stated that marketing teams target the 
product launch at time of regulatory approval. Participants INT1 and INT3 stated any 
delay in regulatory approval delays launch, which might affect the market performance in 
terms of loses in market shares and sales, depending on the competition in the 
marketplace. Findings aligned with the secondary data sources that the timing of market 
entry might affect market performance in terms of sales and market shares. Participant 
INT2 added “marketing announces the product launch, prepares and publishes marketing 
materials, conducts sales training, distributes the product to targeted customers.” 
Price. Iacocca et al. (2013) documented that newer drugs were associated with 
higher prices. Participants reported price is high at time of launch. Participant INT1 
reported “price incorporates the higher R&D costs, and the costs to manufacture the 
goods.” Participant INT2 corroborated the participant INT1 response and stated “price is 
high to incorporate higher costs.” Participants INT2 and INT3 reported after launch the 
marketing teams apply continuous price revisions and factors in the influence of the 
payers’ groups and policies regarding reimbursement plans. Participant INT3 stated 
“strategic pricing changes start from introduction and continue throughout the life of the 
drug. Pricing strategies depend on the government policies, and there might be issues 
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with the reimbursement.” Camejo et al. (2013) documented that drug prices are expected 
to decrease over time due to competition, while R&D costs increase. 
Customers and distribution. Participants INT1 and INT2 listed the following 
customers: wholesale distributors, retail pharmacies, group purchasing organizations, 
hospitals, and the government. Participant INT1 reported that at time of launch the 
distribution is selective through ordering systems in place. Song and Han (2016) 
documented that the marketing instrument “place” is insignificant in the marketing of 
pharmaceuticals because of the market characteristics. 
Promotion. Haughton et al. (2015) documented that new product introductions 
and innovations require substantial marketing efforts with emphasis on promotional 
instruments, such as detailing, and medical journal advertising. Participants reported at 
time of launch, the promotional expenditures are high and consist of multiple channels, 
such as detailing and samples, publications in medical journals, medical meetings, 
maintaining websites regarding product information, selective advertisement, targeting 
medical professionals or patients. Participant INT1 indicated “promotion is through sales 
representatives who reach out to physicians.” Participant INT1 reported “we distribute 
samples and literature to physicians, we advertise our products in medical journals or 
television for certain products, then medical meetings, websites for key products 
including information on clinical trials, and so on.” Participant INT2 reported “promotion 
includes providing rebates or discounts to hospitals, or retail pharmacies; maintaining 
educational websites to provide information to health care professionals or patients 
regarding certain products; and detailing and distributing samples to physicians.” 
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Participant INT2 documented that detailing and sampling are “important part of the 
promotion strategy.” Participant INT3 corroborated the participants INT 1 and INT2 
responses and stated “we generate awareness through promotional activities using 
different channels- websites, sampling, etc.” Findings aligned with the secondary data 
sources regarding the use of promotional instruments. 
Sales and market shares. Participants reported that at time of launch and during 
introduction phase, sales and market shares are low due to the market not being familiar 
with the product and its benefits or uses. Participant INT2 added “we have the forecast 
established, however, we don’t know if the drug is going to achieve commercial success.” 
Participant INT1 added “profits are insignificant as well.”  
Market. Following key terms emerged from the data: market size and market 
characteristics. Participants indicated at time of launch and during introduction phase, the 
market is small, and the targeted audience is not familiar with the product, its uses, the 
effect, and the benefits. Participant INT1 stated “at the time of launch, when product 
receives regulatory approval, the product is not known to the market.” Participant INT2 
recorded “the market is small, targeted audience is not familiar with the product and its 
uses and effect.” Participant INT3 corroborated the participants INT1 and INT2 
responses and stated “the market is not familiar with the drug or its benefits.” Participant 
INT1 added “uncertain if product will be accepted among the broader population and if it 
is going to achieve a commercial success.”  
Participants discussed the market characteristics. Participant INT1 stated:  
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We operate in highly regulated and competitive markets. Many new drugs that we 
introduce to the market compete with other branded or generic medicines at some 
point of the drug life cycle (as early as at the point of the new drug introduction, 
or at the point of patent expiry).  
Participant INT2 identified “the disease area, the criticality of the patients’ illness, and 
the complexity of the product use” as factors that need to be considered when creating a 
launch strategy. Participant INT3 stated “the knowledge about the competition, the 
competitive landscape, and the marketplace needs to be included into the strategic 
decision making.” 
Competition. Participants reported the following scenarios regarding the 
competition in the marketplace at time of lunch: no competition, insignificant 
competition, or established market, depending on the launch product and the decease 
area. Participant INT1 stated “competition could be insignificant at this point. Or, there 
might be other market entrants already there.” Participants INT1 and INT2 identified 
different scenarios regarding competition and market entry. Participant INT1 stated:  
We compete on the market based on product quality, safety, and efficacy. If a 
treatment is already available on the market for the same condition, then it might 
be difficult to maintain sales targets and market shares and differentiate from the 
competition. 
Participant INT2 reported the existence of “little or no competition, or market could be 
already established.” Participant INT2 stated:  
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That’s why the strategies are product specific and these strategies could be timely. 
What worked for a specific brand 5 years ago or 10 years ago might not be 
applicable any more due to the rapidly changing regulatory environment, the 
industry, and the competition.  
Participant INT3 reported at time of launch “competition might exist.” Findings aligned 
with the secondary data sources regarding the effects of competition. 
Marketing focus and marketing strategy. Participants responded marketing focus 
and strategy during product launch and introduction phase is to increase product 
knowledge, generate product awareness through promotion, and establish a market (see 
Table 5). Participant INT1 reported “the marketing goal and strategy is to establish a 
market and generate awareness and interest for the product.” Participant INT2 stated “the 
marketing focus is to increase the knowledge about the product attributes through 
multiple channels, such as web sites, social media, publications, product sampling and 
campaigns; increase the product usage and establish the market.” Participant INT3 stated 
“we market branded drugs, so, the market is not familiar with the drug or its benefits. 
Marketing focus is on establishing the market and generating awareness through 
promotional activities using different channels- websites, sampling, etc.”  
Participants INT2 and INT3 emphasized the need for establishing brand strategy 
to differentiate in the marketplace. Participant INT2 stated “a need to establish powerful 
brand differentiation in a marketplace based on the product unique features, safety and 
efficacy.” Participant INT3 reported that marketing teams “develop and communicate the 
brand vision and brand positioning.” 
157 
 
 
Post product launch period. All participants reported that introduction phase 
could take number of years, and during first year post launch, marketing teams are still in 
introduction phase and in a process to establishing a market for the product, through 
generating awareness and promotional activities. Participant INT2 reported “introduction 
phase could take from 2 years to 4 years in an average.” Participant INT2 reported 
“immediately post launch, we start monitoring the markets, the competitor moves, and 
the industry movement, apply price revisions, invest and improve promotional programs, 
and analyze product profit & loss, and its position in the company portfolio.” Participant 
INT2 added “we start collecting, monitoring and analyzing patient complaints, and their 
experience from product usage; start the management of the product life cycle to 
optimize the life of the product and maximize the value and commercial potential.” 
Table 5 provides a list of codes that emerged from the data relating to the 
marketing efforts during an introduction phase. 
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Table 5 
A List of Emergent Codes for Marketing Efforts During the Introduction Phase in the 
Branded Prescription Medicine Segment  
Codes 
Participant INT1 
Responses 
Participant INT2 
Responses 
Participant INT3 
Responses 
Product 
INT1: Quality, safe, 
and efficient branded 
drugs. 
INT2: Unique 
innovative product 
that is patent 
protected, not a 
commodity.  
INT3: The launch of 
the product should be at 
the time of regulatory 
approval. 
Price INT1: High price. 
INT2: Price is 
high. 
INT3: Pricing strategies 
depend on the 
government policies. 
Distribution INT1: Selective. 
  
Promotion 
INT1: High investment 
in promotion. 
INT2: Investment 
in promotion. 
INT3: Investment in 
promotion. 
Sales 
INT1: Low sales. Over 
time, more people are 
using the product. 
INT2: Sales are 
low.  
Competition 
INT1: Competition 
could be insignificant, 
or there might be other 
market entrants. 
INT2: There could 
be little or no 
competition, or 
market could be 
already 
established. 
INT3: Competition 
might exist. 
Market  
INT1: Highly regulated 
and competitive 
markets. 
INT2: The market 
is small, targeted 
audience is not 
familiar with the 
product and its 
uses and effect. 
INT3: The market is 
not familiar with the 
drug or its benefits. 
Marketing 
focus 
INT1: Establishing a 
market for the product 
though generating 
awareness. 
 
INT3: Establishing the 
market and generating 
awareness. 
Marketing 
strategy 
INT1: Investment in 
promotional activities. 
INT2: Establish a 
powerful brand 
differentiation. 
INT3: Through 
promotional activities 
using different 
channels- websites, 
sampling, etc. 
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Growth phase. The following key terms emerged from the data: characteristics, 
promotion, and marketing focus and marketing strategy. 
Characteristics. Participants described the following characteristics of the growth 
phase: increased and growing market because more people are using the product, formed 
brand preference, high price, increased sales, increased demand, increased profit, 
increased distribution, and increased product awareness (see Table 6). Participants INT1 
and INT2 reported profits are high because of the increased sales, increasing demand, and 
high prices. Participant INT1 stated “distribution is increased because of the higher 
increased demand and sales.” Participant INT2 emphasized the need for continuous price 
revisions and reported “if market is already established, there might be few new players 
in the marketplace; competition is increasing, which leads to price revisions and 
reductions.” Participant INT3 reported growth phase is characterized with increased 
product consumption, increased competition, and implemented strategic price changes. 
Promotion. Participants INT1 and INT3 discussed the need to continue investing 
in promotional activities. Participant INT1 reported “moderate investment in promotional 
and advertising mainly to increase brand preference and brand benefits, and allowing for 
word of mouth recommendations.” Participant INT2 reported “product awareness is 
increasing”. Participant INT3 reported:  
Marketing team could focus on brand loyalty through advertising and promoting 
the drug benefits and how the formulation works. The rationale is physicians are 
familiar with the drug. Despite the competition, campaigns like this could be 
rewarding. Post market, outcome studies are invaluable to prove and strengthen 
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marketing messages, and build trust in the product, hence, these studies could be 
very expensive, and might not be part of the R&D budget. 
Marketing focus and marketing strategy. Participants INT1 and INT3 identified 
market penetration, market segmentation and brand preference as powerful strategies to 
increase the product consumption over time. Participant INT1 reported “the marketing 
strategy is focusing on market penetration and brand preference.” Participant INT3 
recorded “in growth phase, focus is on maximizing brand loyalty through scientific and 
clinical evidence.” Participant INT3 expanded “if product is safe, effective, and 
convenient for the patient (for example, offering once daily or twice daily formulations), 
the interest in the product and consumption might increase over time.” Participant INT3 
added “if multiple formulations exist, LCM strategy could be maximizing market share 
through targeting different customers for selected formulations, in combination of 
different pricing strategies.” 
Table 6 provides a list of codes that emerged from the data relating to the 
marketing efforts during a growth phase. 
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Table 6 
A List of Emergent Codes for Marketing Efforts During the Growth Phase in the Branded 
Prescription Medicine Segment  
Codes 
Participant INT1 
Responses 
Participant INT2 
Responses 
Participant INT3 
Responses 
Product 
INT1: Product line 
extensions. 
INT2: Add additional 
services and features. 
INT3: Formulation 
expansions. 
Price INT1: Price revisions. 
INT2: Price revisions 
and reductions. 
INT3: Strategic price 
changes. 
Distribution 
INT1: Increased 
distribution.   
Promotion 
INT1: Moderate 
investment in 
promotional and 
advertising. 
INT2: Product 
awareness is 
increasing. 
INT3: Advertising 
and promoting the 
drug benefits and how 
the formulation 
works.  
Sales 
INT1: More people 
are using the product, 
brand preference is 
formed. 
INT2: More people 
are trying and using 
the innovator drug. 
 
Competition 
 
INT2: Few new 
players in the 
marketplace. 
INT3: Increasing 
competition. 
Market  
INT1: Market is 
increasing. 
INT2: Market grows. 
INT3: Increased 
consumption. 
Marketing 
focus 
INT1: Increase brand 
preference and brand 
benefits.  
INT2: Brand 
diversification and 
differentiation. 
INT3: Maximize 
brand loyalty through 
scientific and clinical 
evidence. 
Marketing 
strategy 
INT1: Market 
penetration and brand 
preference. 
INT2: Monitor 
product performance 
and competitor moves, 
manage promotional 
activities. 
INT3: Increase 
market presence and 
enter into new market 
segments. 
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Maturity phase. The following key terms emerged from the data: characteristics, 
marketing focus and marketing strategy, and collaboration. 
Characteristics. Participants described the following characteristics of the 
maturity phase: established market, peak in sales and market shares, increased 
distribution, continuous price revisions, high competition, lower profit margins, and 
increased product awareness (see Table 7). Participants INT1 and INT2 emphasized the 
need for price revisions. Participant INT1 stated “in a mature phase, price revisions are 
required due to the high competition to maintain sales or growth.” Participant INT2 stated 
“profits remain the same or decline.” Participant INT1 reported “investment in 
advertising and promotion is moderate since most people are aware of the brand benefits 
and product characteristics.” Participant INT1 added “publication strategy is effective 
tool to demonstrate clinical superiority but timely and might not be usable within a year 
or two due to changing regulatory environment.” 
Marketing focus and marketing strategy. Participant INT1 reported “in maturity 
phase, the goal is to maximize the commercial value, increase the patients’ usage, defend 
market share, maximize profits, and extend the life of the product.” Participant INT2 
reported “the marketing goal is to maximize the value of the product and define 
successful strategies to defend the product value from new competitors.” Participant 
INT3 reported the marketing focus is to “increase the market presence and enter into new 
market segments.” 
Participants identified the following strategies during maturity or growth phase: 
product innovations in the forms of line extensions, reformulations and repositioning, 
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packaging innovations, pricing strategies, maximizing brand loyalty through promotional 
activities, entering into licensing agreements with other pharmaceutical companies, etc. 
Product line extensions and reformulations included introducing new dosage forms (for 
example, liquids), added safety features, introducing new indications, reformulations to 
improve dosing, extended release formulations, and fixed dose formulations. 
Repositioning strategies included finding new uses of existing drugs and entering new 
markets. Participant INT1 stated “new market penetration could be entering new markets 
for new uses or entering into emerging markets internationally.” Packaging innovations 
included co-packaging with complementary drugs. Pricing strategies included applying 
price revisions and strategic pricing.  
Participant INT2 added “a need of brand diversification and differentiation to 
maintain or increase market share.” Participant INT3 added “each line extension or 
reformulation might require unique approach, management, and execution.” Findings 
aligned with the secondary data sources that the strategic activities during maturity phase 
included innovation strategies. 
Participants reported these strategic activities could start as early as the launch 
phase, or during growth phase. Participants INT1 and INT3 reported the investments in 
line extensions and reformulations are highest in maturity phase. Participant INT3 stated 
“activities around formulation expansions, such as introducing different forms, dosages, 
or new improved technologies to meet the unmet market needs might happen right after 
the product is introduced to the market, and it might take years to develop.”  
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Collaboration. The participants emphasized the importance of collaboration with 
other departments and the existence of cross-functional teams to establish product 
strategies. Participant INT2 reported:  
These strategies are not solely marketing strategies; they are company strategies 
where various groups are involved into the decision making. Marketing is focused 
on ensuring a mutually agreed strategy is implemented in the marketplace through 
strong collaboration with the sales force and the customers, monitor product 
performance and competitor moves, leverage product portfolio, price revisions, 
manage promotional activities targeting healthcare professionals and patients, 
collaboration with R&D and regulatory to ensure compliance and obtaining all 
necessary approvals, and so on.  
Participant INT3 corroborated the participant INT2 response and reported “line 
extensions and reformulations are “R&D activities, hence a powerful LCM strategy to 
increase market presence and enter into new market segments during growth or maturity 
phase.”  
Table 7 provides a list of codes that emerged from the data relating to the 
marketing efforts during a maturity phase. 
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Table 7 
A List of Emergent Codes for Marketing Efforts During the Maturity Phase in the 
Branded Prescription Medicine Segment  
Codes 
Participant INT1 
Responses 
Participant INT2 
Responses 
Participant INT3 
Responses 
Product 
INT1: Add new 
features. 
INT2: Introduce new 
indications, new 
dosage forms, new 
package forms, 
reformulations. 
INT3: Product line 
extensions. 
Price INT1: Price revisions. 
INT2: Price revisions 
and reductions. 
INT3: Strategic price 
changes. 
Promotion 
INT1: Publication 
strategy is effective 
tool to demonstrate 
clinical superiority but 
timely. 
INT2: People are 
well aware of the 
drug. 
 
Sales INT1: Maintain sales. 
INT2: Sales volume 
peaks. 
INT3: Peak in sales. 
Competition 
INT1: The 
competition is high. 
INT2: Competition is 
increasing.  
Market  
INT1: Established 
market. 
INT2: Market is 
saturated. 
INT3: Established 
market. 
Marketing 
focus 
INT1: Maximize the 
commercial value, 
increase the patients’ 
usage, defend market 
share, maximize 
profits, and extend the 
life of the product.  
INT2: Maximize the 
value of the product. 
INT3: Increase market 
presence and enter into 
new market segments. 
Marketing 
strategy 
INT1: Introducing 
new dosage forms, 
added safety features, 
new indications, 
product repositioning 
strategies. 
INT2: 
Reimbursement 
support, product line 
extensions and 
reformulations, 
entering into 
licensing agreements. 
INT3: Investment in 
line extensions and 
reformulations. 
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Decline phase. The following key terms emerged from the data: characteristics, 
marketing focus and marketing strategy, and exceptions. 
Characteristics. Participants described the following characteristics of the decline 
phase: preparations to phase out the product, rapid decline in sales, market shares, profits, 
and revenues at time of patent expiry when generics enter the market, minimum 
investment in promotional activities, minimum expenditures to phase out the product (see 
Table 8). Findings aligned with the secondary data sources on the characteristics of the 
decline phase. Participant INT2 reported “at the point of patent expiry generic drugs enter 
the market and the brand sales might decline up to 80% or even 90%.” Participant INT2 
added “in most of the cases, sales, revenues, and market shares decline rapidly 
immediately or in few months following generic launch. This depends on the number of 
competitors.” Participant INT2 reported “price might remain the same, or lower to a 
certain extent, but not to the level of the generic drug price. There might be consumers 
out there who are price insensitive and loyal to the brand.” 
Marketing focus and marketing strategy. Participant INT1 identified the 
following strategies: adding new features, decision whether to discontinue the product or 
not, strategies to reduce costs, and strategies to extend the life of the product by 
extending the patent after patent expiry. Participant INT3 added common LCM strategy 
is to protect critical customers and exit unprofitable segments.” Participant INT2 
supported the participant INT1 response regarding strategic activities to extend the life of 
the product beyond patent expiry. Participant INT3 corroborated the participants INT1 
and INT2 responses on product life extension beyond patent expiry and added “this 
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works well if the product is complex enough and difficult to establish bioequivalence.” 
Participant INT3 listed the following strategies that could be applied to extend the 
product life after patent expiry: co-packaging with other branded drugs to address unmet 
patient needs and launch of authorized generics.  
Table 8 provides a list of codes that emerged from the data relating to the 
marketing efforts during a decline phase. 
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Table 8 
A List of Emergent Codes for Marketing Efforts During the Decline Phase in the Branded 
Prescription Medicine Segment  
Codes 
Participant INT1 
Responses 
Participant INT2 
Responses 
Participant INT3 
Responses 
Product 
 INT1: Add new 
features, product 
phase out. 
 INT2: Add new 
features, product phase 
out. 
INT3: Product 
phase out. 
Price INT1: Price revisions. 
INT2: Price revisions 
and reductions. 
INT3: Strategic 
price changes. 
Distribution 
INT3: Increased 
distribution.   
Promotion 
INT1: Promotional 
activities are minimal.   
Sales 
 INT1: Sales declines 
rapidly at time of 
patent expiry. 
INT2: The brand sales 
might decline up to 80% 
or even 90%. 
INT3: Sales drop 
rapidly. 
Competition 
INT1: High 
competition. 
INT2: High competition. 
INT3: Competition 
is high. 
Market  
INT1: Competition 
from generics. 
INT2: At the point of 
patent expiry generic 
drugs enter the market. 
INT3: Generics 
enter and take over 
the market. 
Marketing 
focus 
INT1: Decision 
whether to discontinue 
the product, or not. 
INT2: Product phase 
out, drug life extensions. 
INT3: Phasing out 
the product. 
Marketing 
strategy 
INT1: Phase out 
strategies. 
INT2: Phase out 
strategies, drug life 
extension strategies. 
INT3: Drug life 
extension 
strategies and exit 
unprofitable 
segments. 
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Exceptions. Participants reported not all products follow the life cycle curve and 
go through all of the phases. Participant INT2 reported:  
Some products might never increase a certain market share, or might experience 
second launch if new uses, indications, or dosage forms prove to be more 
effective than the initial ones. For some products it might take many years before 
commercial success. The disease area, the criticality of the patients’ illness, the 
complexity of the product use, could be important factors for achieving 
commercial success. If product is complicated to use, then highly likely it will 
achieve limited commercial success.  
Participant INT3 reported “one product might not go through all phases of the life cycle, 
but, on a high level, most drugs follow introduction phase, growth, maturity, and decline 
phase.” Mullins et al. (2010) documented that some products do not follow the life cycle 
curve because of multiple factors. 
Theme 3: Factors Influencing the Decision-Making Process 
The third main theme was factors influencing the decision-making process. This 
theme included the following subthemes: (a) factors associated with market share, 
revenue generation, and profitability, (b) challenges and factors influencing the current 
models of product portfolio mix, and (c) key success factors to fight competition (Table 
9).  
Table 9 provides a list of initial codes developed from the interview questions 
relating to factors influencing the decision-making processes. 
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Table 9 
A List of Emergent Codes for Factors Influencing the Decision-Making Processes 
Subtheme Key Term Emergent Code 
(a) Factors 
associated with 
market share, 
revenue 
generation, and 
profitability 
Influencing 
factors 
(a) The market size and market characteristics, (b) 
the competition, (c) the company product portfolio 
mix, (d) the product life cycle management 
strategies, and (e) the insurance preferences for 
therapeutically comparable drugs 
(b) Factors 
influencing 
product portfolio 
mix models 
Influencing 
factors 
(a) The product attributes (b) the product portfolio 
mix (c) the life cycle stage of each product, (d) price, 
(e) sales revenues, (f) profitability, (g) ability to 
produce/manufacture, (h) continuous product supply, 
(i) the market access, (j) the market dynamics, (k) 
new market development and new clinical data, (l) 
the competition, and (m) the regulatory environment. 
Managerial 
implications 
and 
challenges 
(a) Loss of market exclusivity and patent 
expirations, (b) product safety concerns, (c) pricing 
strategies,(d) competition from other branded 
medicines, biotech, and generics, (e) paragraph IV 
challenges, (f) third party reliance, (g) 
manufacturing difficulties and commodity shortages, 
(h) increasing costs for R&D and commercialization, 
(i) health insurance coverages and reimbursement 
plans, (j) high level of uncertainty in research and 
development and uncertainty in commercialization, 
(k) the ability to develop the right LCM and 
marketing strategy, and (l) strategy execution and 
implementation. 
(c) Key success 
factors to fight 
competition 
Influencing 
factors 
(a) Offering effective, safe, and high quality 
products, (b) timing of market entry, (c) price, (d) 
continuous product supply, (e) investment in 
research and development, (f) continuous 
introduction of new product launches, and (g) 
innovation.  
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Factors associated with market share, revenue generation, and profitability. 
The following factors emerged from the data: (a) the market size and market 
characteristics, (b) the competition, (c) the company product portfolio mix, (d) the 
product life cycle management strategies, and (e) the insurance preferences for 
therapeutically comparable drugs (see Table 5).  
Market and competition. Participant INT1 elaborated “the market characteristics 
include the disease characteristics, therapeutic treatments available, and the competition”: 
Participant INT1 indicated the importance of identifying the number of competitors and 
the type of competition- branded medicines, or generics competition. Participant INT1 
added: “when generics enter the market, then we are facing rapid declines in revenues.” 
Participant INT2 reported:  
If the market is saturated and there are generics or other branded drugs that are 
therapeutically comparable, then the sales, market shares and the profits are 
lower. If the company is innovator and no one else is out there on the market, then 
sales, profits and market shares are usually higher, but this again depends on the 
market size and where the product in the life cycle is. 
Findings aligned with the secondary data sources regarding the market characteristics and 
the effects of competition. Hunt (2015) and Kozlenkova et al. (2014) documented that the 
competition influences the strategy formulation. 
Relationship between decisions on determining a marketing strategy and the 
effects on market share, revenue generation, and profitability. The following theme 
categories emerged from the data: (a) optimization of life cycle management strategies 
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and marketing mix strategies and programs, (b) investment in promotion and direct-to-
consumer advertising, and (c) competition. 
Optimization of life cycle management strategies and marketing mix strategies 
and programs. Participant INT1 responded “implementing the right marketing mix and 
strategy at the right time during the product life cycle while considering the company 
portfolio mix is the key to success.” Participant INT3 corroborated this statement and 
responded “optimizing the company’s product portfolio mix, applying different LCM 
strategies at different life cycle stages to maximize the value of the drug.” Daukseviciute 
and Simkin (2015), Ruiz-Conde et al. (2014), and Song and Han (2016) documented that 
different marketing programs differ in their effectiveness and recommended resource 
allocation model for optimal mix. Kumar et al. (2017) also discussed resource allocation 
in marketing variables during product life cycle as a result of the timely effectiveness of 
the marketing efforts. 
Investment in promotion and direct to consumer advertising. Participant INT1 
responded “investment in promotional and direct to consumer advertising during launch 
and growth phase means higher promotional expenditures and lower profit margins, but 
in the long run, this pays off in achieving future sales at a later time.” Participant INT1 
added “this investment in marketing expenditures in not needed during decline phase.” 
Participant INT2 explained:  
You invest in promotion and direct to consumer advertisement to raise awareness 
and introduce the unique product to the market at a competitive price, then 
convince the audience on the effectiveness with clinical studies from patient 
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usage. In a meantime, you work with payers on reimbursement plans to ensure 
patient coverages. If you did a good job, sales will increase over time and with 
that, revenues generated from the sales, along with the market shares and 
profitability during the life of the drug. 
Participants INT3 supported participants INT1 and IT2 and stated “at the time of 
introduction the company does not make profit because of the higher R&D and 
promotional costs, but that is expected. Market shares, sales, and profitability are realized 
years later when market is established.” Ruiz-Conde et al. (2014) documented that 
increased investment in marketing activities directed to the physician in the first 12 
months after new product introduction to increase the trial rate, and decline in spend 
during maturity stage and increase of return on investment. 
Competition. Participants responded that existing competition in the marketplace 
meant lower profits and lower market shares. Participant INT1 responded “competitive 
pricing is the key” if competition existed in the marketplace. Participant INT2 added:  
A competitor enters the market with a new treatment, branded drug that has 
proven to be more effective than ours. If this occurs, then we need to review the 
pricing and possibly reduce the price, but we will face loss in market shares and 
decreased sales. 
Findings aligned with the secondary data sources on the effects of competition. 
Challenges and factors influencing the current models of product portfolio 
mix. The following subthemes emerged: influencing factors, implications, and challenges 
(see Table 9). 
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Factors influencing the current models of product portfolio mix. The following 
factors emerged from the data: (a) the product attributes (quality, safety and efficacy), (b) 
the company product portfolio mix of existing products and the portfolio mix of 
prospective molecules in development stages, (c) the life cycle stage of each product 
within the portfolio mix, (d) price, (e) sales of existing products and the projected sales 
from prospective development products, (f) profitability, (g) ability to 
produce/manufacture, (h) continuous product supply, (i) the market access, (j) the market 
dynamics, (k) new market development and new clinical data, (l) the competition, and 
(m) the regulatory environment. Participant INT1 listed the following factors:  
The product portfolio mix of commercialized products and the mix of prospective 
products in development stages, the quality and the safety of our products, the 
projected sales from each molecule in the pipeline, the competition and the 
market dynamics, the regulatory environment, new clinical data, the market 
access, the ability to produce highly complex products and continuously supply to 
the market without interruptions, and the price. 
Participant INT2 listed “the product attributes: product quality, safety and efficacy; 
product portfolio mix and the portfolio of new products, the competition within each 
therapy class, then price, sales and profitability, and capability to manufacture.” 
Participant INT3 was in alignment with participants INT1 and INT2 and listed the 
following influencing factors:  
Ability to continuously supply quality and safe products, the competition within 
each market/therapy class, new market developments and new clinical data, the 
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life cycle stage of each product within the portfolio mix and molecules in 
development pipeline, their profitability, price, and market access. 
Findings were mostly in line with the secondary data sources and agree to a certain extent 
on the factors influencing the product portfolio mix. 
Kanitz and Burmann (2012) documented the importance of having robust brand 
drug portfolio on different levels, such as- product line level, therapeutic category level, 
or corporate brand level, and opportunities for product differentiation in the marketplace 
within each level. Pramod et al. (2016) discussed the importance of project and product 
portfolio performance in early phases of development drugs. Similarly, Gascón, Lozano, 
Ponte, and de la Fuente (2017) discussed the importance of having a robust portfolio 
during research and development phase driven by organizational strategies and 
documented that the investment in research and development might require reallocation 
of resources.  
Managerial implications and challenges. The following managerial implications 
and challenges emerged from the data: (a) loss of market exclusivity and patent 
expirations, (b) product safety concerns, (c) pricing strategies, (d) competition from other 
branded medicines, biotech, and generics, (e) paragraph IV challenges, (f) third party 
reliance, (g) manufacturing difficulties and commodity shortages, (h) increasing costs for 
R&D and commercialization, (i) health insurance coverages and reimbursement plans, (j) 
high level of uncertainty in research and development of new molecules and uncertainty 
in commercialization, (k) the ability to develop the right LCM and marketing strategy, 
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and (l) strategy execution and implementation (see Table 9). Findings aligned with the 
secondary data sources related to risk factors. 
Loss of market exclusivity and patent expirations. Participant INT1 stated “most 
of our products are patent protected and our revenues and sales depend on their 
commercial success on the market. When patents expire, sales and revenues generated 
from those products decline.” Participant INT2 reported:  
A number of products in our pipeline are facing loss of patent protection or have 
already lost patent protection. With that, we are facing fierce competition from the 
generics that are about to enter the market or have already entered the market. For 
us this means rapid decline in market share and revenues, and loss of market 
exclusivity.  
Findings aligned with the secondary data sources regarding the patent protection and the 
exclusivity period. 
Product safety concerns. Participants identified product safety concerns as a 
factor influencing product sales, market positioning, and portfolio positioning. Findings 
aligned with the secondary data sources regarding the effect of product safety concerns 
on product sales. Participants documented that marketing teams use the post clinical tests 
on safety and efficacy to better understand the product market positioning. Participants 
INT1 and INT2 discussed and explained the safety concerns.  
Participant INT1 reported: over time, more people are using the product, so, our 
medical and regulatory teams are conducting post clinical tests from product 
consumptions on the safety and efficacy.” Participant INT2 corroborated participant 
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INT1 response and stated “clinical trials are usually focused on smaller group of people 
for a specific period of time. After product launch, more patients start using the product, 
and some unexpected safety issues might occur.” Participant INT2 added “a medical 
team and other experts deal with these kinds of issues and make decisions about next 
steps.” Findings aligned with the secondary data sources regarding post clinical trials. 
Participant INT1 reported a product safety concern “could significantly impact the 
product sales, and the positioning of the brand in the company’s portfolio.  
Participant INT2 corroborated the participant INT1 response and stated that product 
safety concerns “could have serious impact on the sales, or even narrowing down the 
target market. Participant INT2 added ”for us in marketing, it is important to know what 
is happening with the product from a quality and safety perspective to understand better 
the market position.”  
Participants documented that brand manufacturers use labeling change, which is a 
change of the package insert, to update information on new safety and efficacy data. 
Participants reported the labeling contains information on the product safety and efficacy, 
and is used as a guide for promotional activities. Findings aligned with the secondary 
data sources regarding the use of labeling changes.  
Pricing strategies. Participants emphasized the need for continuous price 
revisions during various stages of product life cycle. Findings aligned with the secondary 
data sources on the pricing strategies related to the need for continuous price revisions. 
Participant INT2 stated “pricing strategies are more important in situations when 
competition from other branded therapeutically comparable drugs exists within a therapy 
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class.” Participants INT1 and INT3 were in alignment with participant INT2 that 
competition highly affected the price. 
Competition from other branded medicines, biotech, and generics. Participants 
discussed the effect of competition from other branded medicines, and generics. 
Participants reported that the competition from the generics is highest at time of patent 
expiry, when generics enter and take over the market, hence market shares and brand 
drop rapidly. Participant INT2 reported:  
Generic drugs are lower cost alternatives to the brand due to the lower R&D 
costs, and coupled with the insurance and government initiatives to lower 
healthcare costs by stimulating the use of generic drugs over the brand are major 
drivers for the rapid decline in sales and market shares of branded drugs.  
Findings aligned with the secondary data sources on the effects of competition from other 
branded medicines, biotech, and generic medicines. Costa-Font et al. (2014), Hartman et 
al. (2015), and Moe-Byrne et al. (2014) documented that generic drugs are low cost 
alternatives to brand drugs that offer opportunities to the health care insurance 
organizations and governments to reduce the health care costs. 
Paragraph IV challenges. Participant INT2 explained the Paragraph IV 
challenges and reported:  
Generics might enter the market earlier than the patent expiration date. This is 
done through patent challenges or Paragraph IV certifications. In this scenario, 
generic manufacturer files ANDA challenging one or more patents of the 
innovator branded drug with an allegation that patents might be invalid or 
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expired. The branded manufacturer then files a lawsuit to defend the patents. The 
brand manufacturer could defeat the challenge and continue with market 
exclusivity until patent expiration date, or could lose the challenge, allowing for 
generic manufacturers to enter the market early prior to patent expiration date.  
Findings aligned with the secondary data sources on the paragraph IV challenges. 
Branstetter et al. (2016), Grabowski et al. (2014), and Grabowski et al. (2016) discussed 
Paragraph IV challenges and documented that under Paragraph IV, generic entry is 
allowed in the marketplace before patent expiry. Branstetter et al. explained in detail the 
Paragraph certifications options for generic manufacturers and the filing process. 
Third party reliance. Participants responded that organizations engage in 
partnership and collaboration with other research organizations, pharmaceutical 
companies, or health care institutions to co-develop, co-promote products, outsourcing 
agreements, alliances, and so on. Participant INT1 stated “our third parties, such as 
suppliers, alliances, or distributors might not perform to the level they are contractually 
obligated to, and failure to do so might jeopardize our business performance or brand 
image.” Findings aligned with the secondary data sources regarding the collaboration 
with third parties. 
Manufacturing difficulties and commodity shortages. Participants responded 
difficulties with manufacturing and commodity supply could lead to interruptions in 
product supply to customers and inability to meet the demand for a specific product. 
Participant INT1 reported “continuous product supply after launch is of critical 
importance. Delays in manufacturing and supply at the time of regulatory approval might 
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cause adverse effects like losing revenues and underperforming on the market.” 
Participant INT2 added “there could be number of reasons for manufacturing issues: 
technical, or shortages in raw materials or other commodities needed to manufacture the 
drug coupled with long lead times.” Findings aligned with the secondary data sources 
regarding the importance of continuous product supply and the effects of manufacturing 
difficulties or commodity shortages. Kozlenkova et al. (2014) and Thomas et al. (2015) 
documented manufacturing capability as an organizational competitive capability that 
affects market performance. 
Health insurance coverages and reimbursement plans. Participants responded 
that drug manufacturers compete for formulary placement. Findings aligned with the 
secondary data sources regarding the effects of government regulations and 
reimbursement programs. Participant INT2 reported “health care insurance organizations 
provide coverage and reimbursement plans to patients for a specific condition under the 
plan’s formulary.” Participnat INT2 documented “when multiple drugs therapeutically 
comparable for a specific decease exist, higher out of pocket costs could lead to reduced 
used of a drug.” Participant INT2 added “the government and payer groups play 
important role in establishing reimbursement programs for prospective consumers, 
pricing, and patient access to our drugs.” Lee et al. (2015) and Rémuzat et al. (2017) 
discussed the effects of government regulations and reimbursement plans on pricing. 
High level of uncertainty in research and development of new molecules and 
uncertainty in commercialization. Participants documented high levels of uncertainty in 
research and development of new molecules and uncertainty in commercialization. 
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Findings aligned with the secondary data sources that organizations face high levels of 
uncertainty during development. Kakkar (2015) and Shabaninejad et al. (2014) discussed 
the levels of uncertainty during drug development. 
Participants INT1 and INT3 discussed uncertainty in research and development of 
new molecules, and during commercialization. Participant INT3 stated “a lot of 
prospective molecules fail during earlier stages of development, prior to reaching 
regulatory approval.” Participant INT3 also stated uncertainty in receiving regulatory 
approval: “a number of factors affect the timing of regulatory approval, such as time 
needed for the agency to evaluate the submitted date, the decease, the complexity of data, 
and so on.” Participant INT1 reported: t is difficult to predict if new products in the 
pipeline will generate sales volumes to the extent other established products did, and for 
us, we need to be able to make up the lost revenues from new launches.” 
Effectiveness of life cycle management programs and marketing strategies. 
Participants reported that development and implementation of effective life cycle 
management strategies are product specific, with a goal is to maximize the life of the 
product, its value and market share. Participant INT1 identified the ability to develop 
effective life cycle management programs and marketing strategies as a factor 
influencing the current management of portfolio mix. Kozlenkova et al. (2014) and 
Sabatier et al. (2012) discussed business models, and organizational competencies, and 
documented that determination of a marketing strategy depends on organizations’ 
capabilities, priorities, and opportunities. Participant INT3 reported:  
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For life cycle decisions, one needs to consider the existing drug portfolio, 
determine the strategic position of each drug, how important the drug is in the 
portfolio or the therapy class, and start from there. There might be a need to 
withdraw a drug due to prioritization of another drug. 
Findings aligned with the secondary data sources regarding the effects of the product life 
cycle management programs. 
Strategy execution and implementation. Möller and Parvinen (2015) documented 
a gap in the research of marketing focusing on the theory implementation to practice and 
the effectiveness of the strategy execution. Möller and Parvinen asserted successful 
implementation of marketing strategies leads to superior returns. Möller and Parvinen 
identified the level of complexity as an influencing factor on managerial decisions and 
practices. Möller and Parvinen documented the following drivers of implementation 
complexity in marketing: (a) the characteristics of the implementation target, (b) the 
degree of inter-organizational cooperation, (c) uniqueness versus repetitiveness, (d) the 
level of embeddedness, (e) the newness of the innovation, and (f) the pace of 
implementation.  
Participants emphasized the need of successful implementation of a marketing 
strategy. Participant INT 1 identified the ability to execute a marketing strategy as a 
factor influencing the results in the marketplace and stated “how a strategy is executed 
depends on company’s internal capability, personnel knowledge, leadership support, and 
strategy alignment with the business strategy.” Participant INT2 reported “marketing is 
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focused on ensuring a mutually agreed strategy is implemented in the market place 
through strong collaboration with the sales force and the customers.”  
Key success factors to fight competition. The following key success factors 
emerged from the data: (a) offering effective, safe, and high quality products, (b) timing 
of market entry, (c) price, (d) continuous product supply, (e) investment in research and 
development, (f) continuous introduction of new product launches, and (g) innovation. 
Participant INT1 stated “making effective, safe, and convenient drugs, timing of new 
product launches, price, and continuous supply of our existing products to our 
customers.” Participant INT2 corroborated the participant INT1 response and stated 
“offering safe and high quality products to our customers, timing of market entry, and 
price.” Participant INT2 added additional key success factors ad stated “investment in 
research and development function, and continuous introduction of new innovative 
products.” Participant INT3 corroborated participants INT1 and INT2 responses and 
stated “making high quality, safe and effective products.” INT3 also listed “timing of 
regulatory approvals and new product launches” as key success factors. Findings aligned 
with the secondary data sources on the key success factors to fight competition. 
Pronker, Weenen, Commandeur, Claassen, and Osterhaus (2015) identified the 
following factors: (a) safety, (b) efficacy, (c) quality, (d) costs of goods sold, (e) 
regulatory environment, (f) intellectual property, (g) commercial, such as channels of 
communication and distribution, (h) risk management, (i) innovation, and (j) feasibility. 
Camejo et al. (2013) and Matikainen et al. (2015) emphasized the importance of 
continuous introduction of new product launches, investment in innovation and research 
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and development. DiMasi, Grabowski, and Hansen (2016) also emphasized the 
importance of investment in innovation and research and development of new drugs.  
Theme 4: Strategic Activities in Executing Business Strategies 
The forth main theme was strategic activities in executing business strategies. 
Two subthemes emerged from the interview questions: strategic activities in executing 
business strategies, and alignment of marketing programs with corporate and business 
strategies (see Table 10).  
Table 10 provides a list of initial codes developed from the interview questions 
relating to strategic activities in executing business strategies. 
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Table 10 
A List of Emergent Codes for Strategic Activities in Executing Business Strategies 
Theme Key Terms Participants' Responses 
Strategic 
activities 
Innovation 
and 
diversification 
INT1: Continuous introduction of new innovative 
products to the market is the key of long term success. 
INT1: Line extensions, reformulations, and finding new 
uses of our existing products, effective product lifecycle 
management strategies to maximize the value of each 
product and the company portfolio. 
INT2: Launch of new drugs, maintaining wide portfolio 
mix of products, finding new uses, reformulations and line 
extensions, launch of authorized generics, biosimilars or 
switching to over the counter medicines where can be 
done. 
Collaboration 
with third 
parties 
INT1: We enter into alliances with other pharmaceutical 
companies to commercialize certain products, research 
and develop innovative drugs, outsource manufacturing. 
INT2: Partnering with third parties to co-develop, or co-
market new drugs, or conduct clinical trials. 
INT3: Partnering and collaborating with other 
organizations to co-develop or co-promote products, 
conduct clinical trials. 
Alignment 
of 
marketing 
programs 
Alignment of 
marketing 
programs 
INT1: Our marketing strategies need to be defined in a 
way to support the corporate strategies, goals and 
objectives.  
INT3: Our strategic marketing programs need to carry out 
the corporate strategic programs and objectives. 
INT2: Through cross-functional teams where we discuss 
launch strategies and priorities, and commercial planning.  
 
Strategic activities in executing business strategies. Strategic activities included 
innovation and diversification strategies, and collaboration with third parties. Participants 
INT1 and INT2 reported the following strategic activities: (a) innovation in the forms of 
new product launches, line extensions of existing products through reformulations to 
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improve dosing or introduce new forms, or find new uses, or technological advances (b) 
implementation of effective product life cycle management strategies to maximize the 
value of each product, (c) maintaining wide company portfolio mix of products, (d) 
launch of authorized generics, (e) biosimilars, (f) switching to over the counter medicines 
where can be done, (h) decisions whether to discontinue product, (g) forming alliances, 
(h) acquisitions, (i) partnering with third parties to co-develop, or co-market new drugs, 
and (j) outsourcing agreements (i.e. manufacturing). Participant INT2 added: (a) 
collaboration with third parties to perform clinical trials and (b) international market 
expansion. Participant INT3 corroborated the participants INT1 and INT2 responses and 
discussed the partnership and collaboration with other research organizations, 
pharmaceutical companies, or health care institutions to co-develop, co-promote 
products, or conduct clinical trials.  
Findings aligned with the secondary data sources that the strategic activities 
included innovation strategies and collaboration with third parties. Sabatier et al. (2012) 
discussed these strategies as a way to extend the commercial life of the products and 
remain competitive in the marketplace. Song and Han (2016) documented the following 
strategies that organizational leaders that market brand name medicines could employ to 
extend the commercial life of a drug and retain market shares: (a) extension of patent 
protection through legal measures, (b) product innovations, such as product line 
extensions, introduction of new indications, introduction of follow-on drugs, (c) switches 
from prescription to over-the-counter drugs, (d) launch of authorized branded generics, 
(e) selling or licensing the drug before patent expiry to a generic manufacturer, and (f) 
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pricing strategies, marketing campaigns, promotion, and cost reduction initiatives of 
existing drugs.  
Innovation and diversification. Participants reported innovation as an important 
strategic activity, and documented that innovation could take different forms, such as 
introductions of new products, line extensions of existing products through 
reformulations to improve dosing or introduce new forms, or find new uses, or 
technological advances. Findings aligned with the secondary data sources regarding 
innovation. Barei et al. (2015) documented re-innovation through improvement of 
existing product attributes, introduction of new configurations, and using new technology 
to produce new innovative products as strategic activities in executing business strategies. 
Ambrammal and Sharma (2015), Barei at al. (2015), Dubois et al. (2015), Park et al. 
(2014), Spieth and Schneider (2016), Sternitzke (2014), and Khanna et al. (2016) 
discussed different types of innovation, and documented that innovation is critical in 
obtaining a competitive advantage in the marketplace. Barrales-Molina et al. (2014) 
discussed the importance of investing in R&D capabilities and innovation. 
Participants emphasized the importance of new product launches. Participant 
INT1 indicated “continuous introduction of new innovative products to the market is the 
key to long term success.” Findings aligned with the secondary data sources regarding the 
importance of new product introductions. Chang et al. (2014) documented that 
organizational ability to successfully develop and introduce new products to the market is 
critical determinant of organizational performance. Rusu et al. (2011) emphasized the 
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importance of the pipeline management strategies that include continuous introduction of 
new compounds, and timing of market entry. 
Collaboration with third parties as an effective business strategy. Participants 
responded that organizations collaborate and create partnerships with other research 
organizations, pharmaceutical companies, or health care institutions to co-develop, or co-
promote products; conduct clinical trials; create outsourcing agreements; form alliances, 
etc. Findings aligned with the secondary data sources regarding the importance of 
collaboration with third parties. Liu et al. (2016) and Rusu et al. (2011) documented that 
strategic partnerships with other organizations in the area of marketing, research and 
development, or manufacturing drive innovation and strengthen business strategies. Love, 
Roper, and Vahter (2014) documented that openness to external knowledge or partners in 
new product development drives innovation.  
Spithoven and Teirlinck (2015) focused on R&D outsourcing and documented 
that internal capabilities combined with outsourcing R&D activities help organizations to 
remain competitive in the marketplace, or to achieve competitiveness. Gascón et al. 
(2017) provided a model to measure the efficiency of drug development function within 
an organization. Gascón et al. indicated organizational leaders could use this model to 
determine whether the research and development function for a specific drug needs to be 
insourced or outsourced. Sabatier et al. (2012) and Vidal and Mitchell (2018) 
documented that strategic alliances and networks are necessary for product innovation. 
Alignment of marketing programs with corporate and business strategies. 
Participants INT1 and INT3 indicated the marketing programs need to be defined in a 
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way to include the corporate strategies, goals, and objectives. Mullins et al. (2010) 
documented that an organization is likely to achieve superior revenue growth, market 
share, and profitability when its competitive strategy is aligned with its marketing 
program. All participants stated that this is done through a strong collaboration between 
departments and cross-functional teams.  
Participant INT2 explained that the cross-functional teams meet to “discuss 
launch strategies and priorities, and commercial planning.” Participants INT2 and INT3 
provided examples of representations of cross-functional teams and mentioned: research 
and development, marketing, sales, manufacturing/operations, regulatory, supply chain, 
project management for new product launches, finance and other business units or teams. 
Eng and Ozdemir (2014) and Herhausen (2016) documented the need for cross-functional 
teams between research and development and marketing to achieve higher market and 
technical performance in the marketplace, and launch new products in a timely manner. 
Paich et al. (2011) documented that cross-functional teams are essential to effective 
strategic decision making, marketing initiatives, and resource allocation. 
Conceptual Framework and Research Findings 
The conceptual frameworks I used in the study were the general systems theory 
and the evolutionary systems theory. Bertalanffy (1972) developed the general systems 
theory and used the theory to explain the interconnectivity among the departments within 
an organization and its environment. The participants’ responses were in alignment with 
the general systems theory regarding the interconnectivity among the marketing 
department with other departments within the organization to execute business strategies, 
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its environment, and the collaboration with third parties to drive innovation. The 
interrelationship between the marketing unit and other units, such as research and 
development included providing management with timely information and marketing 
plans, programs, and strategies for making critical business decisions. The findings 
included fostering cross-functional collaborations between marketing and other 
functional areas, such as research and development, regulatory, finance, operations, 
supply chain, etc., and fostering business-to-business relationships with third parties to 
co-develop or co-promote products, outsource manufacturing or R&D functions, or form 
strategic alliances.  
Laszlo and Laszlo (1997) developed the evolutionary systems theory and used 
this theory to explain the dynamics, the evolution, and the coevolution of complex 
systems. The product life cycle model was drawn from the concept of the evolutionary 
systems theory. The participants’ responses were in alignment with the evolutionary 
systems theory regarding the product life cycle model. Participants described the product 
life cycle model where the product goes through the life stages from the idea generation, 
to development phases, then market introduction, followed by commercialization and 
maintenance through growth, maturity, and decline phases, until patent expiry. In each 
phase, the primary focus of a marketing strategy was to effectively allocate and 
coordinate marketing resources and activities within a specific product-market to 
maintain market competitiveness and accomplish company goals.  
The research findings yielded four main themes and additional subtheme elements 
within each theme that linked and expanded the conceptual framework for both theories 
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through the in-depth analysis of the interview responses and the literature on conceptual 
framework. Klag and Langley (2013) discussed the conceptual gap in qualitative research 
and documented the importance of the movement from the mass of words and other data 
through analysis to meaningful concepts, relations, and explanations. The identification 
of the emergent themes and subthemes and their relationship, as well as the patterns was 
critical in analyzing their meaning and how they relate to the development and 
implementation of marketing strategies and programs during various stages of product 
life cycle. 
Literature Review and Research Findings 
This subsection included an analysis in what ways the research findings confirm, 
disconfirm, or extend the knowledge in the area of marketing strategy development and 
implementation within the pharmaceutical industry. I compared and contrasted the study 
findings with the literature. In summary, the research findings did not entirely align with 
the literature. While the findings included a synthesis of numerous management activities 
as outlined in the literature, the results from the study extended the insights into the 
management of marketing of pharmaceuticals. 
Marketing function. This first main theme included the following key emergent 
categories: marketing activities, product positioning, branding, product life cycle 
programs, pricing, competition and market, sales, planning of promotional activities, and 
forecasting. While the study findings and the literature were in line with participants’ 
responses on marketing as a function, the participants’ responses revealed new insights in 
rich details in the area of marketing as a function specific to the pharmaceutical industry. 
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The participants’ responses added to the literature findings in the area of pharmaceutical 
marketing and product life cycle management. 
Marketing activity. This emergent category provided insights into pharmaceutical 
marketing as a function. The research findings revealed marketing teams are involved in 
management of marketing activities for development products, new product launches, 
and commercial products. The participants identified these  marketing activities: 
conducting market research, developing forecasts, researching market opportunities, 
market positioning and segmentation, establishing target market shares and sales goals, 
selecting customers, defining launch plans for new products, competitor analysis, 
defining reimbursement models, product positioning, branding, developing pricing 
models, product life cycle planning and management, and defining marketing mix models 
(product, price, promotion and place) for new and existing products.  
Kumar (2015), Mullins et al. (2010), and Olson et al. (2018) discussed marketing 
as a function and provided an overview of the evolution of marketing. Möller and 
Parvinen (2015) discussed the concepts of business to business marketing and marketing 
research. Song and Han (2016) discussed marketing instruments (product, price, place, 
and promotion) in the pharmaceutical industry. Payne and Frow (2017) discussed 
relationship marketing in the pharmaceutical industry and focused on marketing 
capabilities. Nätti et al. (2014) discussed the market sensing and customer linking 
capabilities in the pharmaceutical industry. Stros and Lee (2015) contributed to the area 
of pharmaceutical marketing and identified order of market entry, price, promotion, 
product, distribution, and selling as marketing determinants. Paich et al. (2011) examined 
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the impact of marketing strategies on market penetration, sales, and product quality in the 
pharmaceutical industry. While the research findings aligned with the literature, the 
interview responses yielded insights into pharmaceutical marketing as a function. The 
research findings extended the knowledge in the area of marketing of pharmaceuticals.  
Market. The consistency between the participants’ responses regarding the 
market and the literature was evident. The study findings and the literature were aligned 
with the participants’ responses on the market. The participants discussed the market size, 
market characteristics, and market performance throughout the product life cycle phases. 
The research findings revealed the market characteristics include the disease 
characteristics, the therapeutic treatments available, and the competition. This was in line 
with the literature. Duflos and Lichtenberg (2012), Min et al. (2017), and Paich (2011) 
discussed the market characteristics, market size, and market performance. The literature 
and the study findings were in line with the participants’ responses that the market 
characteristics influenced the decision-making processes. The literature and the study 
findings were in line with the participants’ responses that the disease area, the criticality 
of the patients’ illness, and the complexity of the product use are critical factors driving 
market success. 
The participants discussed the industry characteristics and the regulatory 
framework. Berndt et al. (2015), Grabowski et al. (2015), Grabowski et al. (2015), Gray 
et al. (2015), Martin et al. (2016), Schumock et al. (2017), and Song and Han (2016) 
discussed the regulatory framework within the industry, the rapidly changing 
environment and the industry trends, and the increased competition. The literature and the 
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study findings were in line with the participants’ responses that the pharmaceutical 
market is highly regulated industry and is characterized by rapid changes.  
Competition. The consistency between the participants’ responses regarding the 
competition and the literature was evident. The study findings and the literature were 
aligned with the participants’ responses on the competition. Participants discussed the 
effects of competition on the market performance throughout the product life cycle 
phases. Participants emphasized the importance of identifying the number of competitors 
and the type of competition (branded medicines or generic medicines). Participants 
reported the number of competitors influence the profits and market shares. 
Camejo et al. (2013), Duflos and Lichtenberg (2012), Dunne and Dunne (2015), 
Frank and Hartman (2015), Kang and Montoya (2014), Kelton et al. (2014), Liao et al. 
(2015), Schramm and Hu (2013), and Tenn and Wendling (2014) discussed the effect of 
competition on the drug prices, marketing expenditures, and market entry. Kelton et al. 
(2014) documented that the number of competitors influence the price and market share, 
and that brand prices react to competition. The literature and the study findings were in 
line with the participants responses that competition influenced the decision-making 
processes.  
Product life cycle phases. This second main theme included the following 
subthemes: premarket phase, and postmarket phase or commercialization. The premarket 
life cycle phases included: discovery, phase I of development, phase II of development, 
and phase III of development. The postmarket phases included: introduction phase, 
growth phase, maturity phase, and decline phase. The emergent themes from the data did 
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not follow the product life cycle models and phases outlined in the literature. While the 
research findings were in line with the literature to a certain extent, the participants’ 
responses added to the literature findings in the area of product life cycle management 
within the pharmaceutical industry. 
Mullins et al. (2010), Nikolopoulos at al. (2016), Prajapati et al. (2013), and 
Wagner and Wakeman (2016) discussed product life cycle models and phases. Mullins at 
al. documented that products go through five stages during their life cycle, such as 
introduction, growth, shakeout, maturity, and decline. Nikolopoulos at al. (2016) and 
Wagner and Wakeman (2016) presented product life cycle phases during the life of a 
molecule: from discovery of a new molecule, through development, introduction of a 
branded drug, then commercialization under patent exclusivity, and post patent expiry as 
a generic drug. Prajapati et al. identified the following product life cycle phases: 
development, approval, introduction, commercialization, and decline. The research 
findings extended the knowledge in the area of product life cycle management.  
Marketing mix instruments. The research findings included the following 
instruments: product, timing of market entry, price, promotion, product life cycle 
management strategies, and branding. Stros and Lee (2015) evaluated the impact of 
marketing activities on sales, focusing on product, price, promotion, distribution, and 
order of entry effects. While the research findings were in line with the literature to a 
great extent, the participants’ responses added to the literature findings regarding the use 
of marketing mix instruments. 
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Product. The research findings included product attributes (efficacy, quality, and 
safety), patent protection, innovativeness, and differentiation as key determinants for 
product positioning. The consistency between the participants’ responses regarding 
product positioning and the literature was evident. The research findings revealed 
organizations pursue marketing through the continuous offering of high quality, safe, and 
effective products. Arafat et al. (2017), Camejo et al. (2013), Moe-Byrne et al. (2014), 
Prajapati et a. (2013), and Schramm and Hu (2013) discussed product attributes in terms 
of product quality, safety, and efficacy. Paich (2011) documented that safety, efficacy, 
tolerability, side effects, and mode of administration are key components for treatment 
options of a specific indication. The literature and the study findings were in line with the 
participants’ responses regarding product attributes (quality, safety, and efficacy). The 
research findings revealed product safety concerns after launch could have serious impact 
the sales and market positioning. The literature and the study findings were in line with 
wit the participants’ responses that product safety is factor influencing market 
performance.  
Patents. The consistency between the participants’ responses regarding patent 
protection and patent challenges and the literature was evident. Arafat et al. (2017), 
Berger at al. (2016), Branstetter et al. (2016), Grabowski et al. (2015), Kakkar (2015), 
Rusu et al. (2011), and Song and Han (2016) discussed patent protection and patent 
challenges. The research findings were in line with the literature that patents are primary 
tools to establish brands in the marketplace and enforce market exclusivity of inventions. 
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Innovation and differentiation. The consistency between the participants’ 
responses regarding innovation and differentiation and the literature was evident. The 
research findings revealed the following forms of innovation and differentiation: 
introduction of new dosage forms, introduction of new indications, added safety features, 
reformulations to improve dosing, extended release formulations, fixed dose 
formulations, packaging innovations, product repositioning strategies, launches of 
branded authorized generics, OTC switches if applicable, new market penetration, 
entering into licensing agreements with other pharmaceutical companies to co-market or 
co-develop products, or introduction of new improved technologies. Frank and Hartman 
(2015), Kalepu and Nekkanti (2015), Sabatier et al. (2012), Schramm and Hu (2013), and 
Song and Han (2016) discussed innovation and differentiation in the marketplace. The 
research findings were in alignment with the literature that product differentiation, 
innovation, and product line extensions have the potential to improve drug efficacy and 
safety features, extend the life of a molecule after patent expiration, and increase market 
shares and revenues. 
Timing of market entry. The consistency between the participants’ responses 
regarding timing of market entry and the literature was evident. The research findings 
revealed that marketing teams target the product launch at time of regulatory approval. 
The research findings further revealed that any delay in product launch might affect the 
market performance in terms of loses in market shares and sales, depending on the 
competition in the marketplace. Andrade et al. (2016), DiMasi and Chakravarthy (2016), 
Fatokun et al. (2016), Min et al. (2017), Ridley and Régnier (2016), Smith (2012), Stros 
198 
 
 
and Lee (2015), and Yu and Gupta (2014) discussed timing of market entry in the 
pharmaceutical industry. The research findings were in alignment with the literature that 
the market access influenced the success or failure of any new pharmaceutical or medical 
technology to a large degree. 
Price. The research findings revealed strategic pricing changes start from 
introduction and continue throughout the life of the drug. The participants reported high 
prices at time of launch followed by continuous price revisions and reductions during the 
growth, maturity, and decline phases, especially in established markets and increased 
competition. Costa-Font et al. (2014), Frank and Hartman (2015), Iacocca et al. (2013), 
Kanavos (2014), and Van der Shans et al. (2017) discussed pricing patterns of available 
treatments.  
Iacocca et al. (2013) focused on examining influencing factors to explain 
variations in drug prices. Frank and Hartman (2015), Kanavos (2014), and Van der Shans 
et al. (2017) focused on the impact of generic drug launches and increased competition 
on branded drug prices, including loss of patent exclusivity period. Costa-Font et al. 
(2014) focused on generic drug entries and the effects of price regulations in the 
marketplace. While the research findings were in line with the literature to a great extent, 
the participants’ responses added to the literature findings in the area of pricing of 
branded prescription medicines during product life cycle within the pharmaceutical 
industry. 
Promotion. The consistency between the participants’ responses regarding 
promotion and advertisement and the literature was evident. The participants identified 
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product detailing or samples, publications, medical journal advertising and publications, 
medical meetings, maintaining websites regarding product information, and selective 
advertisement as important marketing activities. The participants responded marketing 
managers use promotional activities to target medical professionals or patients. The 
research findings revealed high expenditures during the introduction phase to generate 
product and brand awareness, moderate investment during the growth and maturity 
phases to increase brand preference and brand benefits, and minimum investment during 
the decline phase.  
Datta and Dave (2017), Haughton et al. (2015), Ju and Park (2015), Ruiz-Conde 
et al. (2014), and Schulz et al. (2014) discussed promotion and advertisement strategies 
and investment strategies during various stages of product life cycle. The research 
findings were in alignment with the literature that promotion is used as a tool to raise 
awareness. The research findings revealed the investment in promotion and advertising 
depends on the product life cycle phase, which is in alignment with the literature. 
Product life cycle management strategies. The research findings revealed 
marketing teams develop product life cycle planning strategies and marketing programs 
are product focused. The research findings further revealed marketing leaders need to 
know the company portfolio mix including development and commercial products, the 
life cycle stage of each product in the pipeline, and the customer product portfolio mix to 
better balance the company portfolio. Haezendonck et al. (2016), Kanitz and Burmann 
(2012), and Stros and Lee (2015) discussed product life cycle management strategies and 
the importance of identifying the state for each product in the company’s portfolio mix so 
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that business leaders can better identify strategies to balance the company’s portfolio. 
The research findings were mostly in line with the literature regarding the importance of 
having a robust portfolio on different levels.  
Branding. The research findings included creation of brand strategy and brand 
communication plans as tools to differentiate in the marketplace. Participant INT2 
discussed branding based on product attributes (safety, efficacy and tolerability). The 
research findings emphasized the need for brand positioning in the marketplace. The 
research findings were in alignment with the studies in the literature regarding the brand 
strategies. Jasper et al. (2017), Kamyabi et al. (2017), and Stros and Lee (2015) discussed 
branding strategies and emphasized the importance of implementing a branding strategy 
to differentiate in the marketplace. Chen et al. (2016) and Kamyabi et al. (2017) linked 
branding strategy to corporate reputation. Kamyabi et al. evaluated the brand impact on 
the pharmaceutical market in the Iranian market, and presented four types of branding: 
(a) therapy area branding, (b) condition branding, (c) corporate branding, and (d) product 
branding. Kamyabi et al. found corporate branding to be most useful, followed by therapy 
area, product branding, and condition branding. 
Marketing focus and marketing strategy. Prajapati et al. (2013) identified 
challenges and opportunities in different phases of product life cycle in the 
pharmaceutical industry. Prajapati et al. documented that during the introduction phase, 
the organizational focus is on the execution of technology transfer, preparation for new 
product supply, and coordination of production, sales, and marketing to meet the launch 
date. Prajapati et al. asserted in the commercialization and the quality management 
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phases teams reevaluate opportunities to add new patents aspects of the drug formulation 
(such as changes in dose, forms, reformulations, product line extensions, repackaging, 
combining the product with other products, and new scale-up strategies). Prajapati et al. 
identified the following organizational strategies: patent extensions, pricing strategies, in-
licensing, and OTC switches if applicable.  
Song and Han (2016) discussed strategies to extend the life of a commercial 
product through strong collaboration among departments, good understanding of industry 
environment, and the use of marketing mix instruments (combination of product 
attributes, pricing, and promotional strategies). Daukseviciute and Simkin (2015) and 
Kumar et al. (2017) documented the need to allocate different marketing variables 
resources during different stages of the product life cycle. Schramm and Hu (2013) 
discussed the importance of product differentiation as a successful strategy to extend the 
life of a molecule. Kalepu and Nekkanti (2015) examined the impact of product line 
extensions on market performance. Kakkar (2015) discussed strategies to mitigate 
revenue losses after patent expiry. Mullins et al. (2010) discussed generalized marketing 
efforts and strategies during various stages of product life cycle applicable to many 
industries. 
The studies in the literature did not provide an explicit and holistic overview of 
the marketing efforts and strategies during the different stages of product life cycle 
specific to branded prescription medicines within the pharmaceutical industry. While the 
research findings were in line with the studies in the literature to some extent, the 
research findings extended the knowledge of marketing focus and strategy development 
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and implementation during various stages of product lifecycle in the pharmaceutical 
industry. The interview responses revealed new insights and added new knowledge into 
the body of literature. 
In the premarket phase the research findings revealed the marketing focus was to 
gain insight into the market and the market dynamics, develop forecasts, develop 
marketing plans and marketing mix models for the development products, create 
promotional materials, define launch plans, manage the internal regulatory reviews for 
upcoming new products, life cycle planning, and support sales teams in product 
positioning. In the introduction phase participants reported the marketing focus was on 
product launch through coordination of marketing and sales to introduce the product to 
the market on the launch date and post launch activities as part of the introduction phase. 
These strategic activities as part of the introduction phase included efforts to increase 
product knowledge, generate product awareness through promotion, establish a market, 
price revisions, establish brand strategy and brand differentiation, develop and 
communicate the brand vision and brand positioning, and monitor the competition and 
market developments.  
In the growth phase the study findings showed the marketing focus was on market 
penetration, market segmentation, and brand preference to increase the product 
consumption over time. In the maturity phase participants documented the marketing 
focus was to maximize the commercial value, increase the patients’ usage, defend market 
shares, maximize profits, and extend the life of the product. The participants discussed 
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strategies to defend the product value from new competitors through price revisions and 
strategic pricing and maximize brand loyalty through promotional activities.  
The research findings revealed the following strategies during the maturity or the 
growth phases in collaboration with other departments: introducing new dosage forms 
(for example, liquids), added safety features, introducing new indications, reformulations 
to improve dosing, extended release formulations, fixed dose formulations, packaging 
innovations (for example, co-packaging with complementary drugs), labeling changes, 
product repositioning strategies, discussions on launches of branded authorized generics, 
OTC switches if applicable, new market penetration, entering into licensing agreements 
with other pharmaceutical companies, or new, improved technologies. In the decline 
phase the study findings included marketing focus on adding new features, decision 
whether to discontinue the product or not, preparations to phase out a product, strategies 
to reduce costs, minimum promotional activities, price revisions, strategies to extend the 
life of the product by extending the patent after patent expiry if applicable, co-packaging 
with other branded drugs to address unmet patient needs, and launch of authorized 
generics if applicable. 
Factors influencing the decision-making process. The third main theme 
included the following subthemes: (a) factors associated with market share, revenue 
generation, and profitability; (b) challenges and factors influencing the current models of 
product portfolio mix; and (c) key success factors to fight competition. This main theme 
included the managerial implications and challenges. While the research findings were 
mostly in line with the studies in the literature, the interview responses revealed new 
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insights and added new knowledge into the body of literature regarding the factors 
influencing the decision-making processes. The research findings extended the 
knowledge in the area of managerial implications and challenges.  
Strategy formulation and implementation. The research findings revealed the 
market characteristics (the treatments available, the market size, and the decease 
characteristics), the competition (the number of competitors, the types of competition, 
such as branded medicines, biotech, and generics, the degree of generic medicines market 
presence, and the changing price of competitive products), the stage of the product life 
cycle, product attributes (quality, safety, and efficacy), the improvements in clinical 
effectiveness, the launch of new drugs, the industry, and the regulatory environment 
influence the strategy formulation and implementation. The research findings were in 
alignment with the studies in the literature regarding the factors influencing the strategy 
formulation and implementation. Fatokun et al. (2016), Kelton et al. (2014), Schulz et al. 
(2014), Thomas et al. (2015), and Van der Shans et al. (2017) discussed the effects of 
market characteristics, the competition, and the generic entries on price, market shares, 
marketing communication plans, and strategy formulation and implementation.  
The research findings revealed the marketing programs and strategies differ in 
their effectiveness and emphasized the need to apply different marketing programs and 
strategies during different life cycle stages to maximize the value of the drug. 
Daukseviciute and Simkin (2015), Kumar et al. (2017), Mullins et al. (2010), Ruiz-Conde 
et al. (2014), and Song and Han (2016) discussed resource allocation for optimal mix and 
documented the need to optimize the product life cycle management strategies, and the 
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marketing mix strategies and programs. While the research findings were mostly in line 
with the studies in the literature, the interview responses revealed new insights and added 
new knowledge into the body of literature regarding the effectiveness of the marketing 
programs. The research findings included detailed, in-depth, rich data regarding 
marketing practices during premarket and postmarket phases.  
The research findings revealed high level of uncertainty in research and 
development of new molecules and uncertainty in commercialization. The study findings 
were in line with the literature regarding the uncertainty in research and development. 
Kakkar (2015), Shabaninejad et al. (2014), and Wagner and Wakerman (2016) 
documented the presence of uncertainty during drug development and patenting process. 
The study participants discussed the level of uncertainty during the commercialization 
whether the new launch is going to achieve market success and generate the projected 
sales revenues. Included in the data analysis was an extension of insights regarding the 
existence of uncertainty during the commercialization. 
Marketing capabilities. The study findings identified the ability to develop the 
right product lifecycle management strategies, the ability to develop marketing strategies, 
the ability to successfully introduce new products to the market, the ability to innovate, 
and the ability to execute the formulated strategies as influencing factors on strategy 
formulation, implementation, which in turn influences the organizational performance 
and market success. The research findings on marketing capabilities were in line with the 
literature. Barrales-Molina et al. (2014) and Diestre et al. (2017) discussed marketing 
dynamic capabilities and competencies to succeed in the marketplace. Chang et al. (2014) 
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discussed the effects of the capabilities of new product launch teams on market 
performance. Sabatier et al. (2012) discussed the impact of managerial competencies and 
perceptions on the organizational and market performance. Möller and Parvinen (2015) 
and Narayana et al. (2014) focused on strategy execution and implementation. 
Shabaninejad et al. (2014) discussed the capability to innovate. 
Strategic activities in executing business strategies. This fourth main theme 
included the following key emergent categories: strategic activities in executing business 
strategies, and alignment of marketing programs with corporate and business strategies. 
While the research findings regarding strategies to extend the commercial life of the 
products, drive innovation, and remain competitive in the marketplace were mostly in 
line with the studies in the literature, the interview responses revealed new insights and 
added new knowledge into the body of literature. The research findings extended the 
knowledge in the area of development and implementation of marketing strategies within 
the pharmaceutical industry. 
Strategic activities. The study findings included the following strategic activities 
in executing business strategies: (a) innovation in the form of new product launches, or 
line extensions of existing products through reformulations to improve dosing or 
introduce new forms, and find new uses; (b) implementation of effective product life 
cycle management strategies to maximize the value of each product; (c) maintaining wide 
company portfolio mix of products; (d) launch of authorized generics; (e) biosimilars; (f) 
switching to over the counter medicines where can be done, (g) decisions whether to 
discontinue product, (h) forming alliances, (i) acquisitions, (j) partnering with third 
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parties to co-develop, co-market new drugs, or conduct clinical trials, (k) outsourcing 
agreements (i.e. manufacturing), and (l) international market expansion. The research 
findings of implementation of various innovation strategies, product life cycle 
management strategies, outsourcing, partnering with third parties, etc. were in line with 
the literature. Ambrammal and Sharma (2014), Dubois et al. (2015), Park et al. (2014), 
Spieth and Schneider (2016), and Sternitzke (2014) discussed different types of 
innovation strategies and documented that innovation is critical in obtaining a 
competitive advantage in the marketplace. Barei and Ross (2015) and Rusu et al. (2011) 
discussed diversification strategies including new market expansions, portfolio 
expansions, and geographical expansions. Liu et al. (2016), Rusu et al. (2011), and Vidal 
and Mitchell (2018) identified formation of alliances and strategic partnerships with other 
organizations as important drivers of innovation.  
Alignment of marketing programs with corporate and business strategies. The 
research findings revealed the marketing programs need to carry out the corporate 
strategies, goals, and objectives. Möller and Parvinen (2015) discussed the fit among 
business strategy, marketing strategy, and market performance. Herhausen (2016), Kang 
and Montoya (2014), and Obeidat et al. (2017) discussed strategy alignment between 
different levels within an organization. While the research findings aligned with the 
literature, the interview responses yielded insights into marketing strategy and 
implementation within pharmaceutical industry. The research findings extended the 
knowledge in the area of marketing of pharmaceuticals.  
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The participants responded the alignment of the marketing programs with the 
corporate strategies is done through strong collaboration with other departments and 
cross-functional teams. Eng and Ozdemir (2014), Herhausen (2016), and Paich et al. 
(2011) discussed the need for cross-functional teams to develop and implement explicit 
strategies and programs and generate returns. The research findings of aligning marketing 
programs with corporate strategies through collaboration with other departments were 
aligned with the literature. 
Summary 
The research findings from this study aligned with the overarching research 
question and the purpose of this research. All themes and subthemes that emerged from 
the data contributed to the understanding of the research question. This study could 
contribute to the understanding of the marketing strategies and processes organizational 
leaders used to successfully deliver products to the marketplace, effective management of 
product life cycle through effective allocation of marketing mix instruments during 
commercialization, extend the life of the molecules through innovation and re-innovation, 
and maintain market competitiveness. Organizational leaders should identify the factors 
influencing the decision-making processes and align the marketing strategies with 
business strategies to maintain competitiveness.  
Application to Professional Practice 
This study increases the body of the literature for marketing strategy and product 
life cycle management of branded prescription medicines within the pharmaceutical 
industry. Four major themes emerged from the study findings that were used as a 
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foundation for recommendations for application to professional practice and further 
research. This research could potentially increase the opportunities for organizational 
leaders to capitalize on tools for optimal allocation of marketing expenditures over time, 
and assist organizational leaders to better understand the marketing practices and 
challenges related to the product life cycle management, to successfully deliver products 
in the marketplace, maximize the profitability of a product over its life cycle, extend the 
life of the molecule, or successfully maintain competitiveness in the marketplace. 
The application to professional practice of this study’s findings could include the 
application of the strategies to successfully manage marketing and product life cycle 
programs to maintain competitiveness. The participants’ marketing efforts included 
development and implementation of (a) product life cycle planning strategies and 
programs, (b) marketing strategies and programs that are product and market specific, (c) 
different marketing mix instruments in terms of product, price, place, and promotion for 
different product life cycle stages due to the time varying factor in terms of effectiveness, 
(d) business processes and tools used during new product introductions, 
commercialization and patent expiry, and (e) strategies and processes used to align 
marketing with business goals. The participants’ efforts also included management of 
communication, decision-making, coordination, and execution of the marketing strategies 
and programs, and life cycle programs. 
The participants’ decision-making processes included assessments of internal 
capabilities (such as personnel knowledge and skills, interdepartmental collaboration, 
innovation capability, and collaboration with third parties), external factors (such as 
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reliance on third parties, the competition and market trends, industry dynamics, and the 
regulatory environment), and the need for alignment of marketing programs with 
corporate and business strategies, and their effect on the organizational performance. 
Cacciolatti and Lee (2016) developed a conceptual model showing the interaction 
between the marketing capabilities (such as accountability, interdepartmental 
collaboration, customer connection, and innovativeness), marketing strategies, and the 
influence of the marketing department within an organization and their effects on the 
organizational performance. 
Implications for Social Change 
The implications for positive social change include effective marketing strategies 
and product life cycle management. The study findings may contribute new knowledge to 
pharmaceutical organizations attempting to adopt effective strategies and programs for 
addressing product life cycle management and continuous introductions of new products 
or variations to the market. The discoveries from the study may assist organizational 
leaders to better understand the challenges and business practices in implementing 
strategies during various stages of product life cycle to successfully deliver products in 
the marketplace. This new knowledge from the study findings could help the marketing 
community in gaining insight into managerial tactics and strategies that may lead to 
innovations, differentiation, and competitiveness in the marketplace.  
The study findings revealed the organizational leaders’ commitment to delivering 
high quality, safe, and effective products to patients and addressing product safety 
concerns may contribute to increasing the patients’ trust in the products consumed and 
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improved patients’ health within the communities. The new knowledge revealed that 
organizational leaders are dedicated to continuous product innovation, such as finding 
new cures or expanding product uses to other disease areas, improving existing products, 
or finding new innovative technologies to sustain in the marketplace and improve 
patients’ health. The study findings revealed that organizational leaders work with 
payers’ groups to establish reimbursement programs for prospective consumers, pricing, 
and patient access to medications. This in turn would help improve market access to 
medications and optimal pricing under the reimbursement plans, which has direct effect 
on patients’ spending and health care costs. Organizational leaders may increase 
company revenues, improve financial performance, and sustain in the marketplace using 
the strategies identified in this study. This in turn would have an effect on spending 
within the communities. 
Recommendations for Action 
Organizational leaders may consider evaluating their current marketing strategies 
and programs, and product life cycle management programs with the strategies listed in 
the main themes: (a) marketing as a function, (b) product life cycle phases, (c) the 
decision-making processes, and (d) strategic activities in executing business strategies. 
The themes involve designing marketing plans and strategies for (a) development 
products prior to market introduction, (b) new product launches at time of launch and 
during introduction period, (c) growth phase, (d) maturity phase, (e) decline phase and (f) 
patent expiry. The findings from this research study might strengthen the use of resource 
allocation model of marketing mix instruments (product, price, place, and promotion), 
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and the product life cycle model within marketing organizations. The findings also 
involve fostering cross-functional collaborations between marketing and other functional 
areas, such as research and development, regulatory, finance, supply chain, etc., and 
fostering business-to-business relationships with third parties to co-develop or co-
promote products, outsource manufacturing or R&D functions, or form strategic 
alliances. 
Aligning marketing strategies and tactics with business strategies may improve 
organizational performance, strengthen market position, and focus on the right goals. The 
findings from this study stressed the importance of continuous innovation and re-
innovation to extend the life of the product and maintain market competitiveness. A 
process to analyze internal and external capabilities and industry trends is a necessary 
recommendation to plan proactively a marketing strategy. The findings indicated that 
organizational leaders need to perform a thorough evaluation of the company product 
portfolio of development and commercial products, the product attributes, the disease 
area/market, the competition, identify strategic products, etc. before deciding on a 
strategy. 
Business professionals, managers, who have direct responsibility in development 
and implementation of marketing strategies and programs within marketing departments 
may benefit from the findings of the study. Organizational leaders who have direct 
responsibility in creating organizational business strategies and are involved in the 
decision-making may benefit from the results of the study. Organizational leaders 
interested in product life cycle management could also benefit from the study findings. I 
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will disseminate the results of this study through scholarly journals, training venues, 
seminars, and conferences. 
Fellow researchers conducting qualitative case studies through interviews may 
benefit from the study. In data collection I recorded the interviews using an iPhone 7 
smartphone. Recording the face-to-face interviews using voice memo app was simple and 
easy way to record interviews. The recordings were clear, and the sound quality was 
good. The processing of the files was successful. Recording the telephone interview using 
a call recorder app was easy and simple way to record an interview. The processing of the 
file was successful and the recording was clear. I recommend to other researchers using a 
telephone as a recording device for face-to-face or telephone interviews because of the 
ease of use. When using a telephone as a recording device, researchers need to make sure 
the telephone has enough capacity and memory space to record the interviews. 
Recommendations for Further Research 
Recommendations for further research include conducting additional exploration 
of development and implementation of marketing strategies and processes and product 
life cycle management to extend the life of the molecule and maintain market 
competitiveness. Recommendations for further research include addressing the 
limitations of this study, such as the selection of the research method, the study 
population, and the geographical area. I used qualitative research method in this study. A 
major limitation of the qualitative research method is the interpretative nature. 
Recommendation for future research could include a mixed-methods approach that 
includes both qualitative and quantitative research methods and allows for quantifying 
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outcomes and examining relationships. Future researchers could conduct studies that 
include population from geographic areas outside of central Ohio. 
Recommendations for future research include participants’ suggestions on the 
research topic. This research study focuses on development and implementation of 
marketing mix instruments and strategies for the brand prescription medicines market. 
This approach is not specific to a marketing segment or a product and provides a broad 
view of the marketing management of the branded prescription medicines market. Future 
researchers could focus on a specific market segment or disease area, a specific product, 
or specific marketing instrument. Participant INT1 suggested “If you want more specific 
life cycle management strategies, research a product, the competitive landscape, the 
decease area market, and explore the strategic activities from discovery, through launch, 
and then commercialization, including the promotional activities. Another suggestion is 
to narrow down the topic on a single marketing activity, for example, promotion.” 
Participant INT3 suggested “focusing on a single disease, therapeutic area or even a 
product and then investigate company activities and strategies in place for that specific 
product: what kind of strategies were implemented, what kind of challenges was the 
company facing at the time of launch and then during commercialization, and so on.” 
Reflections 
My expectation of conducting this research study was to gain a deeper 
understanding of the topic under study. The research I conducted expanded my 
knowledge in the area of marketing branded prescription medicines within the 
pharmaceutical industry in the United States. The process of conducting this study from 
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idea generation, through theory, to application to practice was challenging. Effective time 
management was a key to successful completion of the study. Prior to data collection, I 
expanded my knowledge on the existing literature, the research methods and designs, the 
role of the researcher, and the procedures to ensure ethical research, data confidentiality, 
and integrity. Understanding and following the procedures to conduct ethical research, 
the protocols of the Belmont Report to protect the participants’ confidentiality and treat 
the participants in an ethical manner, and the interview protocol I developed helped me 
conduct effective interviews. Cridland et al. (2015) and Haahr et al. (2014) discussed the 
steps involved in conducting effective semistructured interviews, focusing on the 
procedure to conduct ethical research. The conduct of data collection and data analysis 
exposed me to acquiring new skills I could use further in my career. The data that 
emerged from the interview responses increased my understanding on the research topic. 
I identified areas of potential personal bias prior to data collection. My role in the 
data collection and analysis was to serve as a key instrument to collect, organize, and 
analyze data to capture the meaning of the topic under study as described by the 
participants. To help mitigate bias, I maintained self-awareness during the interviewing 
process. Contacting individuals with whom I do not have a professional relationship 
helped me proactively manage any potential conflicts of interest. The completion of the 
Protecting Human Research Participants course provided by the National Institute of 
Health (NIH), and the documentation of the data collection and data analysis process 
prior to commencing the data collection, helped mitigate personal bias during data 
collection.  
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I transcribed each interview word by word into a transcript after completion and 
used primarily Excel spreadsheets supported with the use of NVivo software to sort and 
analyze the data. The Excel spreadsheets and NVivo software helped in the data analysis 
process in developing codes and themes. When I conduct future research studies that 
would involve interviews, I will forward the recordings for transcription to a professional 
service and will use software analysis tool as a primary tool supported with Excel 
spreadsheets to analyze and sort the data and develop code and themes. 
The findings from this research study expanded my knowledge in the area of 
marketing branded prescription medicines. The key discovery was the level of 
uncertainty that organizational leaders face when managing marketing and product life 
cycle programs from the moment of product introduction to the market to patent 
expiration. The findings from this research study could be utilized in my career.  
Conclusion 
The study makes several significant contributions to the existing literature on 
development and implementation of marketing strategies and programs during various 
stages of product life cycle specific to branded prescription medicines market within the 
pharmaceutical industry in the United States. Guided by the general systems theory and 
the evolutionary systems theory, the purpose of this qualitative case study was to 
determine the best practices among marketing managers within pharmaceutical 
companies on how to pursue marketing strategies during various stages of product life 
cycle. The data gathered in this study was multidimensional and included semistructured, 
interviews and secondary data sources. I collected the data through interviews and 
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secondary data sources to understand the strategies and processes necessary for improved 
product life cycle management, and the challenges and factors influencing the decision-
making processes within marketing.  
The semistructured interviews included responses from three managers within a 
marketing department at a pharmaceutical company in central Ohio of the United States. I 
conducted member checking follow-up interviews to ensure trustworthiness of the 
interview responses. The review of secondary data included company documents and 
government databases. I triangulated the data collected through interviews and member 
checking and compared the interview data to company documents, government 
databases, and the literature. 
The themes that emerged from the data allowed for recommendations for 
innovations and learning, resource allocation models of marketing mix instruments 
during various stages of product life cycles, factors influencing the decision-making 
processes, and promoting best practices in the area of marketing. I grouped the research 
findings into four main emergent themes: (a) marketing as a function, (b) product life 
cycle phases, (c) factors influencing the decision-making processes, and (d) strategic 
activities in executing business strategies. All emergent themes and subthemes 
contributed significantly to answering the overarching research question. 
The first main theme (a) marketing as a function was broken down to the 
following subtheme elements: product, branding, product life cycle programs, price, 
competition and market, sales, promotion, and new product launches. The second main 
theme (b) product life cycle phases could be divided into two categories: premarket 
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phase, and postmarket phase or commercialization. Premarket life cycle phases that 
emerged from the data were: discovery, phase I of development, phase II of development, 
and phase III of development. Postmarket phases that emerged from the data are: 
introduction phase, growth phase, maturity phase, and decline phase. The third main 
theme (c) factors influencing the decision-making processes included the following 
subthemes: (i) factors associated with market share, revenue generation, and profitability, 
(ii) challenges and factors influencing the current models of product portfolio mix, and 
(iii) key success factors to fight competition. The fourth main theme (iv) strategic 
activities in executing business strategies was broken down to the following two 
subthemes: strategic activities in executing business strategies, and alignment of 
marketing programs with corporate and business strategies. 
If marketing management and product life cycle management are beneficial to 
organizations, this study’s value is the contribution to the identification and resolution of 
issues that companies face when developing and implementing marketing strategies and 
programs during various stages of product life cycle within the branded prescription 
medicines market segment. The study may contribute to the understanding of the 
marketing strategies and processes organizational leaders used to manage the resource 
allocation of marketing mix instruments during various stages of product life cycle to 
extend the life of the molecule, successfully deliver products to the marketplace, and 
maintain market competitiveness. Organizational leaders should evaluate their 
organizations’ business strategies and align their resources and marketing plans before 
making a decision on a strategy. This study’s results may also have implications for 
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positive social change, such as assisting organizational leaders to better understand the 
challenges and business practices in implementing marketing strategies during various 
stages of product life cycle to successfully deliver products in the marketplace, improve 
patients’ health and their access to medication, and improve financial performance and 
spending within the communities. 
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Appendix A: Email Invitation to Participants 
Dear  _____________________________, 
My name is Natasa Naneva. I am a doctoral candidate at Walden University. I invite you 
to participate in my research study.  
The purpose of my study is to explore the views and experiences of marketing/business 
professionals who develop and implement marketing strategies (product price, place, 
promotion) to target markets, related to the marketing efforts in the pharmaceutical 
industry in the United States. Your experience will be of huge interest to my study. I hope 
to receive three to five volunteers to participate in a single case study.  
If you are interested in participating, please review the attached informed consent before 
replying with your name and contact information. The first 5 volunteers will be accepted 
as potential participants. In order of receipt, I will extend an interview invitation 
beginning with the first to the fifth respondent until successfully completing the data 
collection process to support a single case study. I will reply to all volunteers notifying 
you of your initial status among volunteers. 
 
Thank you kindly in advance for your time and consideration. 
Please do not hesitate to contact me if you have any questions.  
 
 
Sincerely, 
Natasa Naneva 
Natasa Naneva 
Doctoral Candidate 
Doctorate of Business Administration: Marketing Management 
Walden University - College of Management and Technology  
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Appendix B: Qualitative Interview Questions 
Date: 
Location: 
Interviewee: 
 
Primary Research Topic under Study 
 
The primary research topic is “Marketing Strategies during Product Life Cycle in the 
Pharmaceutical Industry” in the United States.  
 
A qualitative case study will be posed through interviews to explore the lived experiences 
of the participants regarding marketing solutions in the pharmaceutical industry, in the 
United States.  
 
Primary Research Goal 
 
The primary research goal is to explore and understand the marketing strategic aspects 
and identify the factors that are most strongly associated with the revenue generation and 
market shares in the pharmaceutical industry, in the United States. 
 
Questions: 
 
1. How do you pursue marketing (product, price, place, and promotion) 
during various stages of the product life cycle? 
2. Briefly describe the premarket and postmarket strategies in terms of (a) 
marketing mix: product, price, place, and promotion, (b) sales goals, (c) 
customers, (d) competition/market, (e) targeted market shares, and (f)  
marketing goal, for each of the following stages: launch strategy, first year 
post-launch, and post first year of product launch. 
3. How do these decisions relate to the company’s revenue generation, 
market share, and profitability?  
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4. What factors (variables) are most strongly associated with revenue 
generation, market shares, and profitability? 
5. What factors influence the decision-making process? 
6. What factors influence the company’s product portfolio management? 
7. What are the marketing implications and the challenges in the current 
models of the company’s product portfolio management?  
8. What are the strategic activities that are essential in executing business 
strategies? 
9. How does your company align the strategic marketing programs with the 
corporate strategies, and business strategies?  
10. What are the key success factors for a pharmaceutical drug manufacturer 
(generic drug manufacturer or brand drug manufacturer) in order to fight 
competition, and the challenges within the industry? 
Wrap Up Questions 
1. What additional information would you like to add to the interview? 
 
2. What are your suggestions for my research topic? 
 
3. Who else do you think I should interview? 
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Appendix C: Interview Protocol 
Introduce myself to the participant.  
Thank the participant for voluntary participation in the study. 
Briefly describe the purpose of the study. 
Briefly describe the interview process. 
Go over the consent form, discuss confidentiality and ethical issues, and answer 
participant’s questions regarding participation in the study. 
Ask for permission to turn on the audio recording device and start recording after 
obtaining permission. 
Introduce the participant with generic code, such as INT1, INT2, and so on, to conceal 
his/her identity. 
Begin the interview with question #1 and follow through question #10. 
Continue the interview with the additional wrap up questions. 
Take notes during the interview.  
Check for verbal cues (such as changes in voice, or intonations) and nonverbal cues (such 
as body language) during the interview.  
Inform the participant that I will summarize the answers for each question in a form of 
synopsis and email a copy for verification.  
Discuss member checking with the participant: 
Close the interview by thanking the participant for the cooperation and contribution to the 
study. 
